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Research Summary 
  
Acute otitis media (AOM) is an inflammation of the middle ear commonly found in children 
with symptoms of rapid onset (less than 48 hours) of ear pain, acute inflammation, and middle ear 
effusion (e.g. air fluid level, bulging) [1]. AOM is often self-limiting. In general, 60% of AOM cases will 
have clinical symptom improvement in the first 24 hours and 80% of cases in 72 hours without 
antibiotic treatment [2,3]. However, antibiotics are frequently prescribed regardless of the fact they 
do not relieve pain symptoms in most cases [3-5]. We conducted a survey study using clinical 
scenarios that demonstrated up to 88% of 352 physicians in Jakarta, Depok, and Bekasi (Indonesia) 
would prescribe antibiotics for mild AOM. However evidence shows that only one-third of cases 
benefit from antibiotics, generally the more severe, such as AOM with moderate-to-severe local or 
systemic symptoms, young children (< 2 years) with bilateral AOM, and AOM with tympanic 
membrane perforation [6]. In addition, frequent use of antibiotics leads to increased risk 
of unfavourable side effects (e.g. diarrhea, vomiting, rash) and antibiotic resistance, a serious threat 
to health globally [3,7].   
Proposed alternatives or additions to antibiotics include various herbal preparations, decongestants, 
and corticosteroids [8,9]. However, the evidence for these is too weak to recommend for clinical 
practice. The anti-inflammatory effect of corticosteroids suggests it could be a viable treatment 
alternative for AOM. Our survey study demonstrated that 44% of ENT specialists would prescribe 
corticosteroids for children with AOM. We also conducted a systematic review of randomised 
placebo-controlled trials (RCTs) of steroids for AOM. Although only two small trials [10-12], indicated 
corticosteroids could be useful in this condition, our confidence in the results is low, due to small 
sample size and very low to low quality evidence. Therefore, we propose an adequately powered 
parallel, double-blind, stratified, randomised, placebo-controlled pragmatic trial of corticosteroids 
for acute otitis media in children (OPAL study), to address this uncertainty.    
Prior to this, we will conduct a pilot study. This study will mimic the main study in terms of its 
process and procedures, but on a smaller scale. However, due to budget constraints, we will conduct 
a pilot study as a pragmatic, randomised, open-label, single-blind study, without using a placebo. 
The objectives of our pilot study are to: (1) assess the overall process and procedures of the main 
study; (2) verify a sample size calculation for main study; and (3) conduct a mechanistic explanatory 
study using tympanometry. We will include 60 children with AOM, who then, based on their AOM 
severity, will be stratified as mild or severe AOM, and randomly allocated to an intervention group 
(prednisolone) or control group (without prednisolone). An appointed nurse who performs the 
randomisation, patient, as well as the parents will be aware of treatment allocation, however both 
physicians and audiologists will remain unaware of the allocation at least until the data collection at 
Day-3. We will assess the following outcomes: (1) recruitment rate: (2) the success of the study 
procedures; (3) ability to measure planned outcomes in the main study; (4) the compliance to study 
and study drug; and (5) the verification of sample size calculation for main study. In the mechanistic 
study using tympanometry, we will assess: (1) the change in middle ear effusion at various time 
points; (2) the duration of middle ear effusion; and (3) the correlation between ear pain and other 
symptoms with the changes in middle ear effusion at various time points.  
If corticosteroids prove effective in relieving pain or other relevant symptoms in children, and are 
safe, they could become a useful alternative to antibiotics in mild cases of AOM, and an addition to 
antibiotics in severe cases. The treatment is relatively cheap, easy to dispense and administer. It can 
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also reduce antibiotic use, particularly in mild cases of AOM. This could lead to a reduction in 
antibiotic resistance, thus saving precious antibiotics for severe diseases where rapid response to 
antibiotics is critical.  
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The Protocol  
  
See Appendix 1. Protocol of Oral Prednisolone for Acute otitis media in chiLdren: a pilot 
pragmatic, randomised, open-label, single-blind controlled study (OPAL study).  
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Case Report Forms (CRFs)  
  
To see CRF01 to CRF11 and FORM01 to FORM10, please refer to Appendix 2. Case report forms.  
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Setting Up The Study Site   
 
Prior to the trial, the research team will set up the site for the trial. We will provide a starting kit 
along with an inventory checklist. The appointed nurse who works at the site will receive the starting 
kit. The starting kit contains:   
1. Office stationery set (e.g. pen, highlighters, scissor, glue stick, stapler)  
2. File binders:  
a. Confidential study document binder:  
i. FORM01: Study registration log book 
ii. CRF01: Completed consent form 
iii. CRF02: Completed study registration form 
iv. CRF08: Completed randomisation form 
b. Case report form binder:  
i. CRF01: Participant information sheet and consent form (will be separated to 
confidential study binder at the end of the initial visit) 
ii. CRF02: Study registration form  (will be separated to confidential study 
binder at the end of the initial visit) 
iii. CRF03: Eligibility form 
iv. CRF04: Baseline information form 
v. CRF05: Outcome form 
vi. CRF06: Symptom diary 
vii. CRF07: Prescription of study medication 
viii. CRF08: Randomisation form (will be separated to confidential study binder 
at the end of the initial visit) 
ix. CRF09: Follow-up visit card 
x. CRF10: Serious adverse event reporting form 
xi. CRF11: Feedback form  
xii. FORM07: Guideline of antibiotics for acute otitis media in children 
xiii. FORM08: Prednisolone dose for OPAL study 
xiv. FORM09: Instruction of prednisolone use for parents 
xv. FORM10: Lupred pharmaceutical brochure 
c. Study medication storage binder for the pharmacists:  
i. FORM02: Study medication stock form 
ii. Form03: Study medication dispensing form 
d. Completed case report form and non-participating subject binder: 
i. FORM05: Recapitulation of completed case report form 
ii. FORM06: Recapitulation of non-participating subject form (e.g. not-eligible, 
not-consented individual forms) 
e. Study medication return binder:  
i. FORM04: Study medication return form 
3. Medicine in a transparent storage container:  
a. Prednisolone tablets (Lupred® 5)  
b. Sirplus, a sweetener syrup 
c. FORM10: Pharmaceutical Lupred brochure 
Manual of Operations of the OPAL Study. Version 1.1. Date 21 November 2017 
Page 8 of 36 
 
4. Study souvenirs: 
a. Initial visit (Day-0): Lunch box 
b. Visit-1 (Day-3): Water bottle  
c. Visit-2 (Day-7): Toys 
d. Visit-3 (Day-30): Mini towel 
e. Visit-4 (Day-90): Bag 
5. Transportation cost reimbursement @$15   
6. Inventory checklist form  
The research team will visit and monitor the site at the end of the first week to check the 
completeness of study documentation (e.g. study document binders, case report forms), study 
medication stock and other supporting tools. The next monitoring visit will be conducted once every 
one or two weeks, depending on the recruitment flow of each site.   
 
Study medication delivery and storage  
A research member will visit the site once every one or two weeks to deliver the study 
medication. When receiving the study medication, the pharmacist will record the quantity, the batch 
number of study medication, and the date of medicines received on FORM02: Study medication 
stock form (see Appendix 2).  
The study medication will be stored at the pharmacy, in a cool dry place, protected from direct 
sunlight, where the temperature stays below 30°C, separately from other medication.   We will 
provide FORM10: Lupred pharmaceutical brochure. The pharmacist will provide the brochure to the 
parents, along with the study medication and the instruction of its use. 
Rooms and other equipment for the study 
In order to conduct the trial, we need several rooms and equipment which will be used for various 
activities, as follows:  
1. Rooms:  
a. Nurse station:  
i. Identify the symptoms of acute otitis media using FORM01: Study 
recruitment log book. 
ii. Performing a general examination to measure body weight, height, 
temperature, and blood pressure. 
b. Consultation room:  
i. Delivering the information regarding the trial and obtain consent from 
the parents using CRF01: Participant information sheet and consent 
form. 
ii. Identifying the eligibility for the study and stratify the eligible children 
based on the severity of acute otitis media  using CRF03: Eligibility 
form. 
iii. Obtaining baseline history information usimg CRF04: Baseline 
information form. 
iv. Identifying symptoms and signs of acute otitis media, including the 
severity of symptoms (using VAS and AOM-SOS), complication of acute 
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otitis media, medicine which have been taken prior the visit using 
CRF05: Outcome form. 
v. Assessing the condition of nose, throat, as well as the ears using 
otoscope (if feasible)   
vi. Explaining and tutor the parents in completing CRF06: Symptom 
diary. 
vii. Assessing, interpreting, and recording the tympanometry results  
viii. Preparing the CRF07: Prescription of study medication (see Appendix 
10) for every study participant with doses according to their ages. The 
guideline for prednisolone dose is available in FORM08: Prednisolone 
dose for OPAL study and at the top of CRF07. Prescription of study 
medication 
ix. Prescribing other medications, such as antibiotics for children with 
severe AOM based on physician’s clinical preference or based on 
FORM07: Guideline of antibiotics for AOM in children and 
symptomatic medications, if necessary  
c. Audiology room/corner:  
i. Conducting a tympanometry examination.  
d. Private room for randomisation process:  
i. Performing and recording the randomisation of intervention allocation 
using CRF08: Randomisation form  
ii. Dispensing the prescription of study medication for study 
participants who are allocated to intervention (prednisolone) group.   
iii. Reconfirming the parent’s understanding and ability in completing 
CRF06: Symptom diary  
iv. Educating the parents on the use of prednisolone, identification of 
potential side effects, and provide the information regarding 24-
hour emergency call centre. The nurse will provide FORM09: 
Instructions of prednisolone use for parents  
v. Requesting the parent to complete CRF02: Study registration  
vi. Completing CRF09: Follow-up visit card with scheduled visits in the 
next three months  
vii. Providing the study souvenir and transport cost reimbursement to 
each study participant 
viii. Collecting and checking all the study documents, storing them 
according their binder, and secure the binders in a locked filing 
cabinet:   
1. The confidential study document binder (compilation with other 
study participant documents):   
a. FORM01: Study registration log book.  
b. CRF01: Completed consent form  
c. CRF02: Completed study registration form.  
c. CRF08: Completed randomisation form. 
2. The case report form binder (no name on each form and only 
identified by an ID registration):  
a. CRF03: Eligibility form 
b. CRF04: Baseline history form  
Manual of Operations of the OPAL Study. Version 1.1. Date 21 November 2017 
Page 10 of 36 
 
c. CRF05: Outcome form  
e. CRF10: Serious adverse events reporting form   
f. CRF11: Feedback form  
2. Equipment:   
a. Weight scale 
b. Measuring tape  
c. Thermometer  
d. Paediatric tensimeter  
e. Head lamp  
f. Tongue depressor  
g. Rhinoscope 
h. Otoscope   
i. Tympanometry 
j. Copy machine/scanner 
k. Office stationery  
l. Smart phone with internet connection 
m. Telephone 
n. Filing cabinet 
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Step-by-step Procedure  
The nurse station  
Objective(s)  
1. Initially identify of children with acute otitis media  
2. Perform general examination (weight, height, body temperature, blood pressure)  
3. Provide CRF01: Participant information sheet and consent form and CRF02. Study 
registration form for the parents 
4. Prepare the study binders and case report forms  
Tool(s)  
1. Weight scale  
2. Measuring tape  
3. Thermometer 
4. Paediatric tensimeter  
5. FORM01. Study recruitment log book  
6. Case report form binder  
7. Registration ID labels 
8. OPAL study stickers  
Personnel  
1. Attending nurse.  
  
Procedures  
1. When the medical record arrives, the attending nurse will identify whether the patient has 
AOM symptoms using three screening questions in FORM01: Study recruitment log book 
(see Figure 1), as follows:  
a. Has your child experienced ear pain in the past 48 hours?  
b. Has your child been tugging or rubbing her/his ear(s) and been more irritable or 
fussy or crying more than usual over the past 48 hours?  
c. Has your child been experiencing ear discharge in the past 48 hours?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1. FORM01: Study recruitment log book. 
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2. If the parent responds ‘YES’ to one of these three questions, the attending nurse will then 
perform general examination (i.e. body weight and height, temperature, blood pressure) 
and record the results on FORM01. Study recruitment log book. The nurse will also prepare 
the case report forms which are compiled in one binder (case report form binder), as 
follows:   
a. CRF01: Participant information sheet and consent form.  
b. CRF02: Study registration form 
c. CRF03: Eligibility form.  
c. CRF04: Baseline information form.  
d. CRF05: Outcomes form.  
e. CRF06: Symptom diary.  
f. CRF07: Study medication prescription.  
g. CRF08: Randomisation form  
h. CRF09: Follow-up visit card 
l. CRF10: Serious adverse events reporting form 
m. CRF11:  Feedback form  
m. FORM07: Guideline of antibiotics for acute otitis media in children 
i. FORM08: Prednisolone dose for OPAL study 
i. FORM09: Instruction of prednisolone use for parents  
j. FORM10: Lupred pharmaceutical brochure 
3. If possible, the nurse will provide CRF01: Participant information sheet and consent form 
and CRF02: Study registration form for the parents so they can read the information sheet 
and complete the registration form while they are waiting for consultation. 
4. The nurse will then report this patient to a physician as a potential study participant along 
with FORM01: Study recruitment log book and the case report form binder with a specific 
registration ID label attached on every form in the binder.  The form and binder will be 
inserted in the medical record of that particular patient. Therefore, the physician will notify 
this patient as a potential study participant for OPAL study 
 
The consultation room  
Study consent, recruitment, and stratification 
Objective(s)  
1. Identify the eligibility of potential children to be included in the trial  
2. Provide sufficient information regarding the research, including the overall process 
and potential effects caused by the study   
3. Obtain the consent from eligible patients and their parents to participate or not 
to participate in the study  
4. Stratify the eligible patients based on their AOM severities 
Tool(s)  
1. FORM01: Study recruitment log book  
2. Case report form binder: 
a. CRF01: Participant information sheet and consent form  
b. CRF02: Study registration form 
c. CRF03: Eligibility form  
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3. Non-participating subject form binder: 
a. FORM06: Recapitulation form of non-participating subject form. 
 
Personnel  
1. Participating clinicians  
Procedures  
1. The attending nurse will notify the physician that the patient has AOM symptoms and 
provide the physician with FORM01: Study recruitment log book and Case report form 
binder. 
2. The physician will re-confirm the eligibility of the patient using inclusion and 
exclusion criteria on the CRF03: Eligibility form (see Appendix 1. Protocol, section ‘Eligibility 
criteria’, page 15-16). If the parent has responded ‘YES’ to all inclusion criteria and ‘NO’ 
to all exclusion criteria, then the patient is eligible for the study. However, if the parent has 
responded at least one ‘NO’ to the inclusion criteria or one ‘YES’ to the exclusion criteria, 
then the patient is not eligible for the study (see Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. After it has been confirmed that the child is eligible for the trial, then the 
physician will deliver the information regarding the trial and obtain the consent for the trial 
using CRF01: Participant information sheet and consent form (see Appendix.1 Protocol, 
section ‘Consent’, page 26-27). The physician will give the opportunity for the parents to 
Figure 2. CRF03: The eligibility form – The inclusion and exclusion criteria. 
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read the information sheet and raise questions, and will provide further information if 
necessary.  
4. After the physician identifies the eligibility and obtains the consent for the study, the 
physician will then stratify the study participant based on the severity of the AOM symptoms 
according to the following criteria on CRF03: Eligibility form (see Appendix.1 Protocol, 
section ‘Participant enrolment’, page 19-20). :  
a. Moderate to severe symptoms, locally or systemically (e.g. moderate to severe ear pain, 
fever ≥ 39°C, complications)  
b. Aged <2 years with bilateral acute otitis media  
c. AOM with perforation of tympanic membrane(s)  
d. If visible, otoscopic finding shows moderate to severe bulging and/or yellowish purulent 
tympanic membrane(s)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. If the study participant has at least one ‘YES’ on the criteria of a to c, then the patient will 
be allocated to ‘SEVERE AOM’ group. If the patient has all ‘NO’ for a to c criteria, then the 
patient will be allocated to ‘MILD AOM’ group. The fourth criterion (otoscopic finding) is an 
optional criterion because of the difficulty in identifying the tympanic membranes in small 
children. However, if it is visible, the physician will tick the circle corresponding to the 
otoscopic finding  
6. For children who are stratified to ‘SEVERE AOM’ group, the physician will prescribe 
antibiotics according to their clinical preferences. However, we will provide FORM07: 
Guideline of antibiotics for acute otitis media in children. 
7. The physician will then complete FORM01: Study recruitment log book by providing 
information regarding:   
a. Whether the patient participated in the study 
b. Reasons (i.e. not eligible, did not give consent, was not approached) for those who 
did not participate in the study  
8. The nurse will  complete the column ‘The randomisation ID for those who went to the study’ 
after the child has been randomised to either intervention or control group.  
9. The physician will separate the case report form of children who are not eligible or do not 
give consent. Their eligibility forms will be removed from their case report binders and will 
be stored in the Non-participating subject form binder, after they ensure that all forms 
Figure 3. CRF03: The eligibility form – The consent and stratification based on severity. 
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have the registration ID label on the top right of each form. This will be recorded on 
FORM06: Recapitulation of non-participating subject form. 
Collecting baseline data and examination   
Objective(s)  
1. Obtain relevant information to acute otitis media   
2. Identify of AOM complications, severity of AOM symptoms, and history of medication 
3. Perform ear, nose, and throat examination, as well as interpret the tympanometry 
examination result 
4. Teach the parents of study participant to complete the symptom diary  
Tool(s)  
1. Head lamp  
2. Tongue depressor   
3. Rhinoscope   
4. Otoscope 
5. Tympanometry   
6. Case report form binder: 
a. CRF04: Baseline information form 
b. CRF05: Outcomes form   
c. CRF06: Symptom diary  
d. CRF07: Study medication prescription  
e. FORM07: Guideline of antibiotics for acute otitis media in children  
f. FORM08: Prednisolone dose for OPAL study 
Personnel  
1. Participating physicians  
2. Audiologist 
Procedures  
1. The physician will obtain further baseline information using the CRF04: Baseline information 
form, such as the breastfeeding history, day-care attendance, vaccination history. 
2. The physician will then obtain more detailed information relevant to acute otitis media using 
CRF05: Outcome form, such as symptoms and complications of acute otitis media: ear 
discharge, intense pain in and behind the ear, swelling behind the ear, or facial asymmetry  
3. The physician will copy the result of general examination from FORM01: Study recruitment 
log book  (i.e. body weight, height, temperature, blood pressure) measured by 
the attending nurse.  
4. The physician will identify the condition of nose and throat and record the results by ticking 
the circles corresponding to the findings. (see Figure 4) 
5. The physician will perform an otoscopic examination and record the result by ticking the 
circles corresponding to the findings: normal, erythema, air-fluid level, complete 
effusion, opacification and mild bulging, moderate to severe bulging, bulla, and/or 
perforation (see Figure 4 and Figure 5). 
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6. The physician will then identify and record any medications that have been taken before the 
baseline visit prescribed by other physicians or purchased over-the-counter (e.g. antibiotics, 
analgesics, decongestants). The physician will also record the name and dose of medications 
prescribed for the study participants.   
7. The physician will identify the severity of the ear pain using visual analogue scale (VAS) (see 
Appendix 1. Protocol, section ‘Data collection methods’, page 22-23). The VAS is a 100-mm 
horizontal line. The left end of the line represents ‘no pain’ and the right end of the line 
represents ‘pain as bad as it could possibly be’. The physician will ask the parent to place a 
vertical line across the horizontal line that corresponding to the severity of ear pain during 
Normal  Hyperaemic  
(without 
opacification) 
Hyperaemic with air-
fluid level (without 
opacification) 
Hyperaemic with 
complete effusion 
(without 
opacification) 
Opacification and 
mild bulging 
Opacification,  
complete effusion, 
and mild bulging 
Hyperaemic, 
complete effusion, 
and moderate-to-
severe bulging 
Bullae Tympanic 
membrane 
perforation 
Figure 4. CRF05: The outcome form – General, ear, nose, throat, and otoscopic 
examination. 
Figure 5. The otoscopic characteristics of acute otitis media. 
Manual of Operations of the OPAL Study. Version 1.1. Date 21 November 2017 
Page 17 of 36 
 
the past 24 hours. This will also be included in CRF06. Symptom diary; therefore at the same 
time, the physician will teach the parent to complete this scale in the diary, so the 
parents will be able to complete this at home (see Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
8. The physician will then identify the severity of other relevant-symptoms of acute otitis 
media using acute otitis media severity (AOM-SOS) (see Appendix 1. Protocol, section ‘Data 
collection methods’, page 23-24). This consists of seven questions identifying several 
symptoms as follows: has the child (1) been tugging/rubbing the ear(s)?; (2) been crying?; (3) 
been more irritable or fussy?; (4) been having more difficulty sleeping; (5) been less playful 
or active?; (6) been eating less than usual?; and (7) been having fever or feeling warm to 
touch over the past 12 hours?. These questions are very important for young children, 
particularly those who cannot express their symptoms (non-verbal children). The parent 
will tick the circle corresponding to the child’s symptoms. This will also be included in the 
CRF06: Symptom diary; therefore, the physician will teach the parent to complete this 
questionnaire in the diary, so they will be able to complete this at home (see Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. The physician then will provide CRF06: Symptom diary to the parent. The symptom diary 
consists of three mini booklets:  
a. The first mini booklet: The parent must complete the booklet after the baseline visit 
to Day-3. The appointed nurse will collect this mini booklet at Visit-1 (Day-3)  
b. The second mini booklet: The parent must complete the booklet at Day-4 to Day-7. 
The appointed nurse will collect this mini booklet at Visit-2 (Day-7)  
Figure 6. CRF05: Outcome form – Visual analogue scale (VAS). 
Figure 7. CRF05: Outcome form – Acute otitis media using acute otitis media severity (AOM-SOS). 
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c. The third mini booklet: The parent must complete the booklet at Day-8 to Day-14. 
The research team will collect this mini booklet at Day-14 during the home visit   
10. The physician will then send the study participant to the audiology room for tympanometry 
examination after ensuring the ear canals are free from obstructing ear wax. Prior to this, 
the physician will explain the purpose and the procedure of tympanometry examination to 
the parents 
11. After the tympanometry examination, the study participant and the parent will return to the 
consultation room with the tympanometry result. The physician will analyse and interpret 
the tympanometry findings by completing the curve type of the tympanogram.  
12. Before the study participant leaves the consultation room to meet the nurse who will 
conduct a randomisation, the physician will prepare CRF07: Prescription of 
study medication (see Figure 8) and put it back in the case report form binder. The 
prednisolone dose can be accessed in FORM08: Predisolone dose for OPAL study and at the 
top of CRF07: Precription of study medication. This prescription will be dispensed by the 
appointed nurse to children who are allocated in the intervention group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13. The physician will also prescribe antibiotics for study participants with severe AOM based on 
the physician’s clinical preference. We will provide FORM07: Guideline of antibiotics for 
AOM in children for their reference. The physician may prescribe symptomatic medication. 
We will ask them not to prescribe steroids 
14. The physician will advise the parent to closely observe the study participant for 48 hours for 
persistence or the worsening of the symptoms (i.e. ear pain, fever) and potential 
complications (i.e. ear discharge, swollen on the back of the ear). If the parents identify any 
condition above, they should bring the study participant back to the hospital at any time for 
re-assessment and the initiation of antibiotic treatment 
15. At the following visits (Day-3), the physician will identify any side effects such as abdominal 
pain, vomiting, diarrhea, anxiety. The physician will also identify whether the parent should 
Figure 8. CRF07: Prescription of study medication. 
Manual of Operations of the OPAL Study. Version 1.1. Date 21 November 2017 
Page 19 of 36 
 
seek any medical help due to the side effects (e.g. go to other physicians, go the emergency 
department) and whether the parent should continue or stop the medication   
16. The physician will record the additional medication or treatment or examination that is given 
due to the side effects or whether the study participant requires a hospitalisation.  
 
Tympanometry test   
Objective(s)  
1. Measure the condition in the middle ear  
Tool(s)  
1. Tympanometer  
2. Otoscope   
3. Case report form binder: 
a. CRF05. Outcome form   
4. Glue stick  
5. Copy machine or scanner  
Personnel  
1. Audiologist or trained nurse  
Procedures  
1. The audiologist will explain the procedure of tympanometry examination  
2. The audiologist will ask the parent to hold the child’s head firmly. Then the audiologist will 
identify the condition of ear canal using an otoscope to identify any ear wax and estimate 
the size of the ear cuffs. After connecting the ear cuffs to a probe tip, the audiologist 
will slowly insert the probe tip into the ear canal until the graphs appear on the screen. This 
procedure will be repeated on the other side of the ear. After the graphs indicate sufficient 
results (e.g. no air leak, no block), the result is then ready to be printed.  
3. The audiologist will document the tympanometry results on CRF05: Outcome form – 
Tympanometry examination (see Figure 9), as follows: (1) ear canal volume; (2) compliance; 
(3) static acoustic admittance; (4) middle ear pressure for both ears. Several  
tympanogram machines use terminology ‘compliance’ for ‘statistic acoustic 
admittance’, therefore we provide both components in this section to avoid confusion. 
The physician will analyse and determine the type of tympanogram curve after this 
examination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. CRF05: Outcome form – Tympanometry examination. 
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4. The audiologist will attach the study registration ID label and write the date of examination 
on the printed tympanometry result paper, copy (using the copy machine or scanner), 
and attach the copied tympanometry result on the ‘Tympanometry examination’ section.  
5. After the examination, the audiologist will send the study participant and the parent back to 
the consultation room. The physician then will analyse and interpret the tympanometry 
findings and conclude the consultation in his/her usual way.  
 
Randomisation   
Objective(s)  
1. Randomly allocate the children to receive either prednisolone (intervention group) or none 
(control group)  
Tool(s)  
1. Smart phone or computer with internet connection for accessing the randomisation 
website  
2. Telephone to call a randomisation call-centre 
3. Case report form binder: 
a. CRF01: Participant information sheet and consent form 
b. CRF02: Study registration form 
c. CRF03: Eligibibility form 
d. CRF06: Symptom diary 
e. CRF07: Prescription of study medication 
f. CRF08: Randomisation form 
g. CRF09: Follow-up visit card 
h. FORM08: Prednisolone dose for OPAL study 
i. FORM09: Instruction of prednisolone use for parents 
j. FORM10: Lupred pharmaceutical brochure 
4. Confidential study document binder: 
a. Completed FORM01. Study recruitment log book 
b. Completed CRF01. Completed consent form 
c. Completed CRF02. Completed study registration form 
d. Completed CRF08. Completed randomisation form 
5. Completed case report form and non-participating subject binder: 
a. Non-participating subject form (e.g. not-eligible, not-consented individual forms) 
6. Study souvenirs 
7. Transport cost reimbursement envelope 
Personnel  
1. Appointed nurse  
Procedures  
1. The appointed nurse will complete CRF0: Randomisation form to randomise the 
intervention allocation for each patient (see Figure 10). The appointed nurse requires 
FORM01: Study recruitment log book; CRF01: Consent form; and CRF02: Eligibility form to 
be able to answer several questions and confirm the answers, as follows: 
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a. Part 1 – Eligibility criteria: all ‘YES’ for all inclusion criteria and all ‘NO’ for all 
exclusion criteria. The nurse will check the eligibility of the study participant using 
FORM01: Study recruitment log book and CRF03: Eligibility form  
b. Part 2 – Consent to the study: consent to the study has been given. The nurse will 
check the consent to the study using CRF01: Consent form and CRF03: Eligibilty 
form 
c. Part 3 – Randomisation information: Parents’ mobile numbers, the severity of AOM 
(The nurse will check the severity using CRF03: Eligibilty form), and patient’s date of 
birth and age. 
d. Part 4 – Randomisation result: randomisation ID, intervention allocation 
(prednisolone or no prednisolone / control group), and prednisolone dosage for 
patient who is allocated to prednisolone group. The nurse will use FORM08: 
Prednisolone dose for OPAL study as a guidance for the prednisolone dose. The 
dosages of prednisolone will be determined based on age, as follows: 
i. Children aged 6 months to < 2 years will receive 10 mg per day (or 2 tablets 
per day) for 5 days  
ii. Children aged 2 years to < 6 years will receive 20 mg per day (or 4 tablets 
per day) for 5 days 
iii. Children aged 6 years to 12 years will receive 30 mg per day (or 6 tablets per 
day) for 5 days 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. The nurse will use Part 1 to Part 3 to obtain the randomisation result in Part 4 section. This 
can be accessed within two ways, as follows: 
a. Randomisation website: 
i. The appointed nurse will receive an invitation email from MASCOT.org.au. This 
email will notify the nurse regarding the name of the study, which is OPAL STUDY, 
and the name of institution (e.g. Cipto Mangunkusumo Hospital, etc.). Prior to the 
study, we obtained a list of email addresses of potential appointed nurses during the 
training session. For practice, we sent the invitation email from MASCOT.org.au with 
Figure 10. CRF08: Randomisation form. 
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the title of study of PRACTISE STUDY. The nurses were able to use this link to 
practice as much as they like until they are competent to use this tool. 
ii. At the end of the email, there is a link to the MASCOT study randomization system 
website (see Figure 11).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii. After clicking the link, the attending nurse will automatically open the login page of 
the MASCOT study randomization system website. The first page will confirm the 
name and institution. If the information  is correct, the nurse will click ‘Begin’ button 
(see Figure 12). 
 
 
 
 
 
 
 
 
 
 
 
  
 After that, the page will ask the nurse to insert the Registration ID of the study 
participant (see Figure 13). The nurse will use the ID based on the Registration ID 
label attached on the top right of case report forms and the binder.  
 
 
 
 
 
 
 
 
 
Figure 11. The MASCOT study randomization system – Invitation email for MASCOT study 
randomization system. 
Figure 12. The MASCOT study randomization system – The enroler confirmation page. 
Figure 13. The MASCOT study randomization system – The study 
registration ID page 
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iv. The next page presents several questions regarding the eligibility criteria (inclusion 
and exclusion criteria) and whether the consent the study has been given, as follows: 
1. All ‘YES’ for all inclusion criteria 
2. All ‘NO’ for all inclusion criteria 
3. Has consent been given 
The nurse will then click ‘Select’  ‘Yes’ to all questions to be able to proceed to 
the next step. To proceed, the nurse will click ‘Check Eligibility’ button at the left 
bottom of the page (see Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v. The next page will show whether the study participant is allocated to prednisolone 
or control (no prednisolone) group. The attending nurse will insert the date of birth 
using an available calendar or put the month (mm) / date (dd) / year (yyyy) 
manually. The nurse will check the date of birth on the available calendar. The page 
will automatically convert this information to age of that particular patient (please 
recheck the age). The nurse will select the severity of AOM based on the information 
in CRF03. Randomisation form, as a ‘Mild AOM’ or ‘Severe AOM’ accordingly. To 
proceed, the nurse will then select ‘Submit Answers’ button. The nurse must ensure 
that the submitted answers are correct as there will be no opportunity to correct 
the answers after they have been submitted (see Figure 15). 
 
 
 
 
 
 
 
Figure 14. The MASCOT study randomization system – The eligibility page. 
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vi. If the patient is allocated to the prednisolone group, then the page will require 
information of the dose of prednisolone:  
1. Children aged 6 months to < 2 years will receive 10 mg per day (or 2 tablets per 
day) for 5 days  
2. Children aged 2 years to < 6 years will receive 20 mg per day (or 4 tablets per 
day) for 5 days 
3. Children aged 6 years to 12 years will receive 30 mg per day (or 6 tablets per 
day) for 5 days 
The nurse must ensure that the prednisolone has been prescribed according to the 
dose on CRF07. Prescription of OPAL study. This must be prepared by the physician 
before the randomisation process. The nurse can also check the dose using FORM08. 
Prednisolone dose of OPAL study. The nurse will then select the dose accordingly. 
The nurse will select ‘Submit’ button (see Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. The MASCOT study randomization system – The date of birth and 
AOM severity page. 
Figure 16. The MASCOT study randomization system – The prednisolone dose. 
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vii. The next page will provide the randomisation results (see Figure 17), as follows: 
1. Treatment group: the prednisolone or control (no prednisolone) group 
2. Dosage of prednisolone for patient who is allocated to the prednisolone group. 
This information will not be available for patient who was allocated to the 
control group. 
3. Registration ID. This will confirm the Registration ID that the nurse has 
submitted at the start of the randomisation process 
4. Randomisation ID. This is a new specific ID for patient that has been 
randomised. 
5. Study. This will confirm the name of the study, which is ‘OPAL STUDY’. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii. The nurse will copy the randomisation result to CRF08: Randomisation form. This 
form will then be separated from the case report form binder to the confidential 
study document binder. This information will be concealed from the physicians and 
audiologists 
ix. If the nurse is using a computer that is connected to the printer, then the nurse can 
directly print the randomisation result page. However, if using smart phone, then the 
nurse can download the page to be recalled and printed later. The nurse can click 
‘Add Another’ button if there is another patient to be randomised. 
b. By phone: 
i. The attending nurse can contact the principal investigator (+62 8111 012 185) or the 
research assistant (+82 812 8799 0123) who will access the MASCOT study 
randomization system website.  
ii. The attending nurse has to complete CRF08: Randomisation form and report all 
information from this form to the research assistant by phone, as follows: 
1. Name of the appointed nurse and the institution 
2. Registration ID 
Figure 17. The MASCOT study randomization system – The randomisation result page for 
the prednisolone and control groups. 
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3. All ‘YES’ for all inclusion criteria 
4. All ‘NO’ for all inclusion criteria 
5. Has consent been given? 
6. Date of birth and age of the patient 
7. Dose of the prednisolone (please confirm with FORM08: Prednisolone dose 
for OPAL study and CRF07: Prescription of study medication) 
8. Severity of AOM 
iii. The research assistant will require five minutes to access the randomisation system 
website and provide the randomisation allocation results back to the nurse. 
iv. The research assistant will call the attending nurse and provide the information, as 
follows: 
1. Randomisation ID 
2. Treatment group: prednisolone or control (no prednisolone) group 
3. Dosage of prednisolone for patient who is allocated to the prednisolone 
group. This information will not be available for patient who was allocated to 
the control group. 
v. This information will be recorded at the bottom column of CRF08: Randomisation 
form. This form will then be separated from the case report form binder to the 
confidential study document binder. This information will be concealed from the 
physicians and audiologists.  
3. For patients who are allocated to the prednisolone group, the nurse will dispense CRF07: 
Prescription of study medication to the parent(s). The nurse will provide information 
regarding the use of prednisolone, as follows: 
a. Taking the medication all at once, in the morning before 9 am after breakfast, 
everyday, for five days as  
b. Mixing the medication with sweetener syrup that has been provided by the study 
c. Mixing the medication with milk, juice, jam, or jelly 
d. Giving back one dose of medication if the child vomits less than 30 minutes after 
taking the medication. However, if the child vomits after 30 minutes, then the 
parent should not give another dose.  
The nurse will also provide FORM09: Instruction of prednisolone use for parents 
4. For every patient, the nurse will confirm whether the parent(s) have already had CRF06: 
Symptom diary and understood how to complete it. 
5. The nurse will provide CRF09: Follow-up visit card for each patient. The nurse will write 
scheduled dates for follow-up visits, based on the initial visit. 
6. The nurse will ask the parent(s) to complete CRF02: Study registration form, if it has not 
been completed. 
7. The nurse will remind the parent(s) to observe the patient and come to the hospital for 
follow-up visit after 48 hours (day-3) or if the study participant’s condition worsens at any 
time or does not show clinical improvement within 48 hours. The nurse will inform the 
parent(s) that the parent(s) can contact the 24-hour call centre for any questions or 
assisstances at anytime. 
8. The nurse will also ensure the study participant and the parent(s) will not inform their 
physician and audiologist regarding the intervention they received in the trial (prednisolone 
or without prednisolone) until at least the outcome measurement or data collection at Day-
3.  
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9. The nurse will give Rp. 150.000,- (approx. $15) cash for transportation 
cost reimbursement in an envelope to the parent(s).  
10. The nurse will provide study souvenirs to the patient in each visit, as follows: 
a. Initial visit: Lunch box 
b. First visit (Day-3): Water bottle  
c. Second visit (Day-7): Toys 
d. Third visit (Day-30): Mini towel 
e. Fourth visit (Day-90): Study bag 
11. Before sending the patient home, the nurse will check the completeness of all study 
documents from the binders: 
a. Case report form: 
i. CRF01: Consent form 
ii. CF02: Study registration form 
iii. CRF03: Eligibility form 
iv. CRF04: Baseline information form 
v. CRF05: Outcome form 
vi. CRF08: Randomisation form 
vii. CRF10: Serious adverse events reporting form 
viii. CRF11: Feedback form 
b. Confidential study document binder: 
i. FORM01: Study recruitment log book, including copy the randomisation ID 
to the form, and reasons if patient has not been recruited to the study. 
12. The nurse will apply a sticker on the patient medical record as an identification that the 
patient is in the OPAL study (see Figure 18), as well as on the page of consultation page in 
the medical record (see Figure 19). 
 
 
 
 
 
  
 
 
 
 
 
 
 
13. When the process is over, the patient has left the room, and all documents are well 
completed, the nurse will then separate the forms into the binders: 
a. Case report form: 
i. CRF03. Eligibility form 
ii. CRF04. Baseline information form 
iii. CRF05. Outcome form 
iv. CRF10. Serious adverse events reporting form 
v. CRF11. Feedback form 
b. Confidential study document binder: 
Figure 19. The OPAL study identification sticker 
for the medical record page. 
Figure 18. The OPAL study identification sticker 
for the cover of medical record. 
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i. FORM01. Study recruitment log book 
ii. CRF01. Consent form 
iii. CRF02. Study registration form 
iv. CRF08. Randomisation form 
c. Completed case report form and non-participating subject binder: 
i. FORM06. Non-participating subject form (e.g. not-eligible, not-consented 
individual forms).  
14. The nurse will then secure all documents and binders in the locked cabinets. 
 
 
Preparing and dispensing the study medication   
Objective(s)  
1. Prepare the prednisolone tablets in form of powder  
2. Dispense the study medication along with the instruction for its use  
3. Record the dispensing using the FORM03: Study medication dispensing form   
Tool(s)  
1. CRF07: Prescription of study medication  
2. Prednisolone tablets  
3. Sweetener syrup 
4. FORM03: Study medication dispensing form 
5. FORM10: Lupred pharmaceutical brochure 
Personnel  
1. Pharmacist  
Procedures  
1. The pharmacist will receive CRF07: Prescription of study medication from the parents 
and prepare the study medication according to the prescribed dose. Prior to this, the 
pharmacist will recheck the dose using the prednisolone dose guideline attached on the 
top of the prescription.  
2. The pharmacist will then prepare the prednisolone by crushing the prednisolone tablets, 
mixing them with sweeteners, and packing them in five daily paper-packs.  
3. The pharmacist will dispense the study medication with the instruction, as follows:  
a. give the medicine in the morning, after breakfast and in the morning (before 9 
am), everyday for five days 
b.  mix the medicine with sweetener syrup of a ratio of 1:3 
c. give the medicine with a glass of water, milk, or juice, or mix it with a small 
amount of soft food such as jam, or yoghurt 
d. give the medication all at once 
e. if the child vomits in less than 30 minutes after taking the study medication, 
then the parent should give another dose.  
The pharmacist will also provide FORM10. Lupred pharmaceutical brochure for the  
parents 
4. The pharmacist will complete FORM03: Study medication dispensing form by recording 
the registration ID, the study medication dose, and date dispensed for the study 
medication  
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Returning the study medication   
Objective(s)  
1. Identify the adherence to the study medication by collecting the left-over medication  
1. Record the study medication return using FORM04. Study medication return form  
Tool(s)  
2. FORM04. Study medication return form  
Personnel  
1. The appointed nurse  
Procedures  
1. At Day-7, the appointed nurse will collect the left-over study medication, including the 
paper-wrap, and record this on FORM04: Study medication return form (see Figure 20). 
 
  
  
  
  
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. FORM04: Study medication return form (for nurse).  
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Follow-up Visits   
 
Each study participant will have additional four follow-up visits after the baseline visit (Visit-0), as 
follows (see Appendix 1. Protocol, section ‘Participant timeline’, page 19):  
1. First visit (Visit-1) on day-3 (48 hours after the baseline visit)  
2. Second visit (Visit-2) on day-7 after the completion of 5-day cycle of study medication   
3. Third visit (Visit-3) on day-30 or month-1  
4. Fourth visit (Visit-4) on day-90 or month-3  
Using the information of parents’ mobile phone numbers provided on CRF02: Study registration 
form, a research assistant will send a daily text message as a reminder: (1) to remind the parents to 
give the prednisolone (for study participant in the prednisolone group) every morning for five days, 
(2) to visit the hospital at Day-3 and Day-7, and (3) to complete the SYMPTOM DIARY for two 
weeks. For the third and fourth visits, the research coordinator will send reminder text messages 
one week and one day before the follow-up dates (see Appendix 1. Protocol, section ‘Adherence 
monitoring’, page 17).  
First follow-up visit (Day–3)  
The study participant and the parent(s) will have the first visit after 48 hours observation or on the 
third day after the baseline visit. If they miss the follow-up visit at Day-3, they can still come until the 
next two days (Day-4 to Day-5) after the scheduled date.    
The study participant will come to the nurse station. The attending nurse will:  
1. Identify the patient as a study participant by the OPAL study sticker on the front page of 
medical record. 
2. Measure and record the weight, height, body temperature, and blood pressure  
3. Report and send the study participant to the appointed nurse. 
  
The appointed nurse will:  
1. Use the registration ID label on the OPAL study sticker to find that particular case report 
form binder from the filing cabinet.  
2. Check the completeness of the case report forms in the binder 
3. Obtain information from the parents regarding the symptom of AOM, any complications (i.e. 
mastoiditis, perforation of tympanic membrane, and the adherence on the study medication 
use, as well as identify side effects, and complications of acute otitis media) from the first 
mini-booklet of the symptom diary.   
4. Check the completeness and collect the first mini booklet of CRF06: Symptom diary. The 
nurse will  confirm the symptoms, complication, or any side effects reported in the symptom 
diary. The nurse will place the first mini booklet of symptom diary back to the case report 
form binder. The nurse will remind the parent to continue completing the second mini 
booklet of symptom diary. the parent should complete the symptom diary in the next 
morning before administering any medicine to their children.  
5. Check whether the study participant still has a sufficient number of study medication for the 
next two days.   
6. Report the study participant to any participating physician on duty that day, along with the 
case report from binder.  
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7. After the study participant finish the consultation and data collection with the participating 
physician, the study participant again will meet the appointed nurse. The appointed nurse 
will check the completeness of all study documents in the case report form binder. 
8. record the visit date on CRF09: Follow-up visit card 
9. remind the parent to take the study medication regularly, complete the second mini booklet 
of the symptom diary, and to come  for the next follow-up visit (Visit-2) at the Day 7. 
10. hand over a study souvenir (lunch box) and transport cost reimbursement envelope for each 
study participant. 
  
The participating physician will: 
1. Identify any complications of AOM and perform ENT, otoscopic, and tympanometry 
examination. 
2. Identify the severity of AOM symptoms using VAS and AOM-SOS on CRF05: Outcome form. 
3. assess whether there is a sufficient improvement of symptoms over the past 48 hours. If 
there is no improvement or worsening of the symptoms of acute otitis media, based on the 
clinical judgement, the physician may prescribe antibiotics for the study participant in the 
mild AOM group or change the antibiotics for the study participant in the severe group. This 
will be recorded in CRF05: Outcome form.  
4. Identify any side effects. If it is necessary to determine the treatment for the side effects, 
the physician can retrieve the information from the nurse whether the study participant was 
allocated to prednisolone or control group. However, this must be done after the physician 
complete assessing and recording all outcome data in CRF05: Outcome form. 
5. prescribe the study medication accordingly, if the study participant require more 
medication. 
6. send the participant back to the appointed nurse. 
 
Second follow-up visit (Day–7)  
The process is similar to Visit–1. If the study participants and the parents miss the follow-up visit at 
Day-7, they can still come until the next two days (Day-8 to Day-9) after the scheduled date.  The 
study participant will come to the nurse station, where the attending nurse will identify a patient as 
a study participant by the OPAL study sticker on the front page of the medical record. The nurse will 
measure the weight, height, body temperature, and blood pressure of the study participant. The 
nurse will then report this to the appointed nurse. Using the registration ID number attached on the 
OPAL study sticker on the front page of the medical record, the attending nurse will collect that 
particular subject’s case report form binder. 
The appointed nurse will:  
1. Identify any adverse effects or complications since the last visit  
2. Check the completeness and collect the second mini booklet of CRF06: Symptom diary  
3. Remind the parents to complete the third mini booklet of CRF06: Symptom diary on the 
next morning until Day-14. The nurse will inform the parents that at Day-14, a research 
staff will visit their home to collect the diary. The research staff will also obtain feedback 
from the parents regarding their experience and obstacles during the past 14 days of the 
study, using CRF11: Feedback form. 
4. Collect the left-over study medication from those in the prednisolone group. This will be 
recorded in FORM04: Study medication return form. The appointed nurse will complete 
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the study registration ID, returning date, and numbers of left-over study medication. She 
can add some comment regarding the use of prednisolone if necessary.   
5. Report the study participant to any participating physician on duty that day, along with 
the case report from binder.  
6. After the study participant finish the consultation and data collection with the 
participating physician, the study participant again will meet the appointed nurse. The 
appointed nurse will check the completeness of all study documents in the Case report 
form binder. 
7. record the visit date on CRF09: Follow-up visit card 
8. remind the parent to come  for the next follow-up visit (Visit-3) at the Day 30. 
9. hand over a study souvenir (toys) and transport cost reimbursement envelope for each 
study participant. 
 
 The participating physician will: 
1. Identify any complications of AOM and perform ENT, otoscopic, and tympanometry 
examination. 
2. Identify the severity of AOM symptoms using VAS and AOM-SOS on CRF05: Outcome form. 
3. Identify any side effects. If it is necessary to determine the treatment for the side effects, 
the physician can retrieve the information from the nurse whether the study participant was 
allocated to prednisolone or control group.  
4. Send the study participant back to the appointed nurse. 
 
Third follow-up visit (Day–30)  
At the third visit, the patient will come on Day–30. If the study participant misses the scheduled 
follow-up visit, then the study participant can come on any other day up to one week after the 
scheduled date. Similar to previous visits, the nurse will identify the study participant using the OPAL 
study sticker attached on the front page of the medical record and perform a general examination. 
The attending nurse will report this subject to the appointed nurse. The appointed nurse will collect 
and prepare the case report form binder, and bring the study participant with the binder to the 
participating physician on duty.  
The physician will identify whether in the past one month, the study participant experiences a new 
episode of ear pain or any other symptoms related to acute otitis media. The physician will also 
conduct a nose and throat examination, as well as an ear examination using otoscope. This 
information will be recorded in CRF05: Outcome form. The study participant will then undergo a 
tympanometry examination and will go back to the consultation room for the assessment of the 
tympanometry result. At the end of the visit, the physician will hand over the completed study 
documents in the case report form binder back to the appointed nurse where she will check the 
completeness of the forms and store it back in the locked filing cabinet.   
 
Fourth follow-up visit (Day–90)  
The process is similar to Visit–3. At the end of the visit, the physician will hand over the completed 
study documents in the case report form binder to the appointed nurse where the nurse will then 
check the completeness of the forms. The appointed nurse will collect al the study documents form 
the case report form binder and clip them together, and separate the document to a plastic sleeve in 
the completed case report form and non-participating subject binder. The nurse will then record 
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the randomisation ID, date enrolled to the study, whether the study participant come to all follow-
up visits, and date of completion of the study.  
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Assessing Adverse Events   
The appointed nurse will be the first person who identifies adverse events on the first visit at Day-
3 (48 hours after the baseline visit). The adverse events will be identified by obtaining information of 
any unfavourable effects after taking the study medication in forms of: (1) interview and (2) the 
assessment of the completed first mini-booklet of the symptom diary (see Appendix 1. Protocol, 
section ‘Harms’, page 25-26).   
The nurse will report any adverse events to the physician without acknowledging the study 
intervention that the patient has received. However, if it necessary to determine the treatment for 
the adverse events, the physician may have the information of intervention allocation. The physician 
will check other medications that have been prescribed (e.g. antibiotics, decongestants, mucolytic) 
at the baseline visit and obtain more detailed information regarding the adverse events to identify 
its correlation with trial drug or other concomitant drugs. The physician will then record this on 
CRF05: Outcome form.  
The physician will record severe adverse event(S) on CRF10: Serious adverse events reporting form 
and inform this to the chief investigator (CI). The physician will report any adverse events that cause 
the modification or discontinuation on study medication to the CI. The decision to discontinue study 
medication will be determined by the physician based on the clinical judgment and the CI based on 
perspective of good clinical practice (GCP). If the patient requires other tests and/ treatments, the 
physician will provide these services. All the costs will be reimbursed by the study. However, this 
must be reported and recorded on CRF05: Outcome form.  
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Feedback Form  
As this study is a pilot study, we will obtain information from all individuals involved in the study (i.e. 
participating physicians, appointed nurses, audiologists, pharmacists, study participants, and the 
parents) to identify their experience and obstacles that they encountered during the study.   
For the participating physicians, audiologists, the appointed nurses, and pharmacists, we will obtain 
their feedback using CRF11: Feedback form in an interview session. We will interview them after 
they have enrolled at least five children into the study.  
We will obtain the feedback from the parents at Day-14 during the home visit. The home visit will be 
conducted to collect the third mini-booklet of the symptom diary, where we will also interview the 
parents to obtain  the feedback using CRF11: Feedback form.  
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Closing Out The Study  
When closing out the study, the research team will check several documents to validate the 
compatibility and the completeness of the data:   
1. FORM01: Study recruitment log book, will be checked for its compatibility with CRF01: 
Consent form; CRF03: Eligibility form; and CRF08: Randomisation form in the case 
report form binder of each study participant. 
2. The completeness and the date of follow-up visit in CRF05: Outcome form, will 
be checked for its compatibility with the visit dates on CRF06: Symptom diary and 
CRF09: Follow-up visit card. 
3. The number of CRF11: Feedback form will be checked for its compatibility with the 
number of participating physicians, audiologists, appointed nurses, pharmacies, and the 
parents who are involved in the study  
 
In regards to study medication, the research team will check the numbers of unused medication at 
the pharmacy and the left-over medicine on the parents, and compare the numbers with FORM03: 
Study medication dispensing form; FORM04: Study medication return form; and the number of 
used paper-packs accordingly.  
In regards to administrative work, the research team will:  
1. Collect the left-over envelopes for the reimbursement of patients’ transportation cost and 
check the compatibility with the numbers of follow-up visits recorded in CRF09: Follow-up 
visit card. 
2. Confirm the hospital cashier regarding the study-related payment (e.g. registration fee, 
tympanometry examination, any additional test or treatment due to adverse events) 
according approved Memorandum of Agreement (MoU) with the numbers of follow-up visits 
recorded in CRF09: Follow-up visit card and CRF05: Outcome form for any additional tests 
or treatments for side effects.  
3. Confirm the inventory list with the starting kit container. 
At the end of study, as part of the dissemination of the study results, the research team will:  
1. Provide a study summary that will include the examination results of individual study 
participants and the overall result of the study to each participant.  
2.  Provide a report document of the study to the Bond University’s Human Research Ethics 
Committee, the Research Committee Ethics Faculty of Medicine Universitas Indonesia 
(FMUI) – Dr. Cipto Mangunkusumo Hospital (CMH), and all participating hospitals.  
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Trial registration 
Registry name: http://www.ANZCTR.org.au/ACTRN12618000049279.aspx 
The World Health Organisation Trial Registration Data set 
Primary Registry and Trial Identifying Number ACTRN12618000049279 
Date of Registration in Primary Registry 16 January 2018 
Secondary Identifying Numbers - 
Source(s) of Monetary or Material Support Self-funded research 
Primary Sponsor Respati W. Ranakusuma, MD, ORL 
Secondary Sponsor(s) None 
Contact for Public Queries Respati W. Ranakusuma, MD, ORL 
Centre for Research in Evidence-Based Practice  
Faculty of Health Sciences and Medicine Bond University, QLD, Australia 
14 University Drive, Robina 4226, Queensland 
Phone number: +61424957129 (Australia) / +6228111012185 (Indonesia) 
Email: rranakus@bond.edu.au 
Contact for Scientific Queries Respati W. Ranakusuma, MD, ORL 
Email: rranakus@bond.edu.au  
Phone number: +61424957129 (Australia) / +6228111012185 (Indonesia) 
Centre for Research in Evidence-Based Practice Faculty of Health Sciences 
and Medicine Bond University, QLD, Australia 
14 University Drive, Robina 4226, Queensland 
Email: OPAL.study@bond.edu.au  
Phone number: (+61) 7 559 51588 
Public Title Oral prednisolone for acute middle ear infection in children 
Scientific Title Oral prednisolone for acute otitis media in children: a pilot pragmatic 
randomised open-label single-blind study (OPAL study) 
Countries of recruitment Indonesia 
Health Condition(s) or Problem(s) Studied Acute otitis media in children 
Intervention(s) Intervention Name:  
• Active intervention: Prednisolone tablet  
• Active comparator: None  
Intervention Description:  
• Prednisolone tablet with doses based on range of age for five days:  
o 6 months – <2 years: 10 mg/day 
o  2 – <6 years: 20 mg/day 
o  6 – 12 years: 30 mg/day 
• None   
 
Key Inclusion and Exclusion Criteria Ages eligible for study: 6 months to 12 years 
Sexes eligible for study: both males and females 
Accepts healthy volunteers: no 
Inclusion criteria:  
• children (6 months – 12 years) with acute otitis media, defined as a 
current onset within 48 hours of ear-related symptoms (e.g. ear pain, ear 
tugging/rubbing or irritability) and if possible to assess, otoscopic 
findings of acute inflammation (e.g. erythema) and middle ear effusion 
(e.g. bulging, air-fluid level) 
 
Exclusion criteria:  
• children with major and severe medical conditions (e.g. heart failure, 
kidney failure) 
• immunocompromised children (e.g. HIV, children receiving cancer 
treatment) 
• children with congenital malformations and/or syndromes (e.g. cleft 
palate, Down’s syndrome) 
• children with high risk of risk of strongyloidiasis infection 
• children with ear ventilation tube(s) 
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• children who had exposed to persons with varicella (chicken pox) or 
active Zoster infection in the past 3 weeks without any prior varicella 
immunisation or infection 
• children who have taken systemic (i.e. oral, injection) or topical steroids 
in the preceding four weeks  
• children who have taken antibiotics in the preceding two weeks; a 
• children who are hypersensitive to prednisolone or prednisone, or other 
corticosteroids. 
 
Study Type Type of study: interventional 
Method of allocation: stratified, randomised 
Masking: open-label, single-blind (outcome assessor) 
Assignment: parallel 
Purpose: Efficacy  
Phase III 
 
Date of first enrolment 01 January 2018 
Target sample size 60 children 
Recruitment status Pending (not started): participants are not yet being recruited or enrolled 
at any site 
 
Outcome(s) (1) Outcome Name: Recruitment rates  
Metric/method of measurement: Informed consent form and case 
report forms (CRFs) 
The timepoint(s) of interest: Baseline visit (visit-0)  
(2) Outcome Name: The success of the study procedures 
Metric/method of measurement: CRFs (i.e. eligibility and 
randomisation form, outcomes form) 
The timepoint(s) of interest: Baseline visit (visit-0)  
(3) Outcome Name: Ability to measure planned outcomes in main study 
Metric/method of measurement: CRFs (i.e. eligibility and 
randomisation form, outcomes form) and symptom diary (e.g. Visual 
Analogue Scale/VAS and Acute Otitis Media – Severity of Symptoms 
Scale/AOM-SOS), and feedback form 
The timepoint(s) of interest: Baseline visit, visit-1 (day-3 to-5), visit-2 
(day-7 to -9), day3, visit-3 (day-3 to -40), and visit-4 (day-90 to -100) 
(4) Outcome Name: Compliance to study and study drug 
Metric/method of measurement: CRF (i.e. outcomes form), the 
symptom diary, and number of left-over drug 
The timepoint(s) of interest: Visit-1 (day-3 to-5), visit-2 (day-7 to -9), 
day3, visit-3 (day-3 to -40), and visit-4 (day-90 to -100) 
(5) Outcome Name: The verification of sample size calculation for main 
study 
Metric/method of measurement: CRFs (i.e. eligibility and 
randomisation form)  
The timepoint(s) of interest: Baseline visit (visit-0)  
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Protocol version 
Protocol version No. Date issued 
Protocol OPAL Study Version 1.0.0 (V1.0.0) 27 July 2017 
Protocol OPAL Study Version 1.1.0 (V1.1.0) 17 October 2017 
 
Protocol Amendment Number:  AM1.0 
Amendment history: 
Amendment No. Protocol version 
no. 
Date issued Author(s) of 
changes 
Detail of changes made 
Amendment No. 1.0 Protocol V1.1.0 17 October 2017 Respati W 
Ranakusuma 
1. The modification of the 
form of trial drug 
We planned to use 
prednisolone liquid. Due to 
administrative issues 
where the proposed 
pharmaceutical 
manufacturer was unable 
to share confidential 
documents that were 
required for importing the 
trial drug to Indonesia, we 
therefore will use 
prednisolone tablet for this 
trial. The pharmacist will 
crush the prednisolone 
tablets and mix it with 
sweetener. The crushed 
tablet will be packed in 
daily paper-package. The 
parents will mix the 
crushed tablet with juice or 
honey. This method is 
commonly practiced in 
Indonesia, particularly for 
paediatric patients. 
2. The duration of the trial 
drug use 
We planned to give 
prednisolone for seven 
days. Although 7-day 
duration of corticosteroid 
use is considered as a 
short-term use, we will 
reduce its duration to five 
days to minimise the 
potential harms caused by 
corticosteroids. 
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Funding 
This research is supported by self-funding of the principal investigator (Dr. Respati W. Ranakusuma, 
ORL).  
We will purchase the trial drug, prednisolone tablets, from PT Pratapa Nirmala, Tangerang, 
Indonesia. This pharmaceutical manufacturer is not linked to this study and does not have authority 
over any procedural implementation, scientific process, or decision in the study.  
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Name Affiliation Role of protocol contributors 
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ENT surgeon, PhD candidate 
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• Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University 
14 University Drive, Robina QLD 4226 
Australia 
• Clinical Epidemiology and Evidence-
Based Medicine Unit, Dr. Cipto 
Mangunkusumo Hospital – Faculty of 
Medicine Universitas Indonesia 
Jl. Diponegoro 71 Jakarta 10430 
Indonesia 
Initiated the study design and 
methodology; developed the protocol 
including case report forms (CRFs), 
informed consent, and symptom diary 
Dr. Amanda McCullough, PhD, PGCHET, 
BSc (Hons) 
Epidemiologist, expert in acute 
respiratory infections and antibiotic 
resistance 
Telp: +61 7 559 55204 
Fax: N/A 
Email: amccullo@bond.edu.au  
Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University, 14 
University Drive, Robina QLD 4226 
Australia 
Initiated the study design from the 
clinical epidemiologic perspective; 
refined the protocol including case 
report forms (CRFs), informed consents, 
and symptom diary 
Associate Professor Elaine Beller, BSc, 
MAppStat 
Clinical trialist, biostatistician 
Telp: +61 7 559 55523 
Fax: N/A 
Email: ebeller@bond.edu.au 
Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University, 14 
University Drive, Robina QLD 4226 
Australia 
Initiated the study design and 
methodology from the clinical trialist 
and biostatistician perspectives; refined 
the protocol including case report forms 
(CRFs), informed consents, and 
symptom diary 
Professor Christopher Del Mar, 
FAFPHM, MBBChir, MA, MD, FRACGP, 
BSc 
Epidemiologist, evidence-based 
practitioner, expert in acute respiratory 
infection and antibiotic resistance 
Telp: +61 7 559 52504 
Fax: N/A 
Email: cdelmar@bond.edu.au  
Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University, 14 
University Drive, Robina QLD 4226 
Australia 
Initiated the study design from the 
clinical perspective; refined the protocol 
including case report forms (CRFs), 
informed consents, and symptom diary 
Professor Dr. Sudigdo Sastroasmoro, 
PhD, Paed 
Paediatrician, epidemiologist, evidence-
based practitioner 
Telp: +62 21 316 1760 
Fax: N/A 
Email: sudigdo1947@gmail.com 
• Clinical Epidemiology and Evidence-
Based Medicine Unit, Dr. Cipto 
Mangunkusumo Hospital – Faculty of 
Medicine Universitas Indonesia 
Jl. Diponegoro 71 Jakarta 10430 
Indonesia 
• Department of Child Health Faculty of 
Medicine Unit, Universitas Indonesia – 
Dr. Cipto Mangunkusumo Hospital 
DIponegoro 71 Jakarta 10430 
Indonesia 
Provided advice in paediatric 
perspectives, supervising the trial in 
Jakarta 
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Contact information of trial sponsor or funder(s) 
Name Contact information Role of study sponsor and funders  
Dr. Respati W. Ranakusuma, ORL 
 
• Centre for Research in Evidence-Based 
Practice (CREBP) Faculty of Health 
Sciences and Medicine, Bond University 
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• Clinical Epidemiology and Evidence-
Based Medicine Unit, Dr. Cipto 
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Contact information of research team and others overseeing the trial 
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Dr. Eka Dian Safitri, ORL 
ENT surgeon 
Telp: +62 21 316 1760 
Fax:  N/A 
Email: ekadian.safitri@ceebm.org   
 
Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
(1) involved in the development of 
tympanometry study; (2) providing 
training related to using and 
interpreting tympanometry to 
physicians, nurses, and 
tympanometry technicians  
Dr. Yupitri Pitoyo, ORL 
ENT surgeon 
Telp: +62 21 316 1760 
Fax:  N/A 
Email: yupitri.pitoyo@ceebm.org 
 
Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
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healthcare centres including the 
physicians and nurses 
Dr. Arie Sulistyowati, MSc, Paed. 
Paediatrician, epidemiologist 
Telp: +62 21 316 1760 
Fax:  N/A 
Email: arie.sulistyowati@ceebm.org 
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Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
Providing advice and expertise in 
terms of paediatric patients  
Widyaningsih, MPH 
Public Health, qualitative study expert 
Telp: +62 21 316 1760 
Fax:  N/A 
Email: widyaningsih.ade@ceebm.org  
 
Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr. Cipto Mangunkusumo 
Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
 
(1) submitting a research ethics 
application to the Indonesian Medical 
Research Ethics Committee; (2) 
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including the physicians and nurses 
Research Coordinator 
Dr. Respati W. Ranakusuma, ORL 
ENT surgeon, PhD candidate 
Telp: +62 8111 012 185 
Fax:  N/A 
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Hospital – Faculty of Medicine Universitas 
Indonesia 
Jl. Diponegoro 71 Jakarta 10430 – Indonesia 
 
C0-investigators  
Dr. Tri Juda Airlangga H, ORL 
ENT surgeon 
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Department of Ear, Nose, and Throat Head 
and Neck Surgery 
Dr. Cipto Mangunkusumo Hospital – Faculty 
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(1) Recruiting patients  
(2) Coordinating patient recruitment 
among other clinicians in the 
hospital 
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ENT surgeon 
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hospital 
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CHAPTER 1 – INTRODUCTION 
 
1.1 Background and rationale 
1.1.1 Background  
Antibiotic resistance, a major global threat, impacts more than two million people with illness and 
accounts for 23 thousand deaths annually in the United States [1]. One of the key drivers of the 
development of antibiotic resistance is antibiotic prescribing [2].  Antibiotics are mostly prescribed 
for common diseases, such as acute respiratory infections (ARIs) [3]. One of the ARIs commonly 
found in paediatric population with high antibiotic prescribing is acute otitis media [4,5]. In East 
Jakarta, Indonesia, the prevalence of AOM in children (< 18 years) was 5.4% [6]. In contrast, in 
Australia, there were an average of 35 new AOM cases reported by general practitioners per year 
(April 2010 – March 2015) [7].  
Acute otitis media (AOM) is characterised by rapid onset of symptoms (e.g. earache, ear 
tugging/rubbing, irritability), middle ear effusion (e.g. bulging, immobile tympanic membrane, air 
fluid level), and acute inflammation (e.g. erythema) [8]. Almost three quarters of children have an 
episode of AOM in their first five years of life, with the peak incidence at the age of six to 12 months 
[9,10]. Guidelines recommend close monitoring for 48 hours (expectant observation) along with 
adequate pain management for mild AOM (e.g. mild symptoms, fever < 39°C) [8]. Children with 
severe symptoms, young age (< 2 years) with bilateral AOM, and AOM with tympanic membrane 
perforation are more likely to benefit from antibiotic treatment [11]. A high rate of antibiotic 
prescription for AOM is evident. Eighty-nine per cent new AOM cases were managed by antibiotics 
in Australia during 2010 to 2015 [7]. In Indonesia, a survey study using clinical scenarios, 
demonstrated that up to 88% of physicians would prescribe antibiotics for mild case of AOM. 
Unclear clarification of antibiotic use in the Indonesian practice guideline for AOM in the primary 
care may contribute to this [12]. The option of using antibiotics also must be balanced against the 
risks, such as adverse effects (e.g. vomiting, diarrhoea, rash) and antibiotic resistance [13,14]. 
1.1.2 Rationale for the proposed study 
Prednisolone 
Reducing antibiotic use is crucial to lowering the risk of antibiotic resistance. One of the methods 
is to use an alternative treatment that does not involve antibiotics. The current alternative 
treatments (i.e. ear drops, herbal products, probiotics, zinc, decongestants) demonstrate 
insufficient evidence on their benefits for AOM [15,16]. It is important to understand the 
pathophysiology of AOM, which is an inflammatory process involving both cellular and chemical 
inflammatory mediators (i.e. cytokines, chemokines, mast cells, prostaglandins, leukotrienes) in 
the middle ear. These inflammatory mediators contribute in altering the vascular permeability, 
increasing mucous glycoprotein secretion, as well as stimulating the chemotaxis process, the 
activity of epithelial secretion and other mediators [17]. An intervention suppressing this 
inflammatory process, could have an important role in the resolution of AOM. Corticosteroids 
suppress the inflammation process by inhibiting the mediators and cytokines characteristic of AOM, 
the recruitment of leukocytes and monocyte-macrophages into affected areas, and the synthesis 
and/or release of numerous inflammatory mediators and cytokine, and also reducing vascular 
permeability [18].  
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Corticosteroids are produced in the adrenal cortex. Cortisol (glucocorticoids), one of the most 
common corticosteroids, is responsible for anti-inflammatory effects. The production of 
glucocorticoids is controlled by hypothalamus, pituitary, and adrenal (HPA) axis. Corticosteroid 
treatment may affect the production of natural corticosteroid by suppressing the HPA axis [19,20]. 
We have identified prednisolone is commonly used and safe in the treatment of inflammatory and 
autoimmune diseases in children. Prednisolone, a synthetic intermediate-acting glucocorticoid 
with a biological half-life of 12 to 36 hours, is commonly used in the treatment of inflammatory and 
autoimmune diseases in children. Although prednisolone has a lesser anti-inflammatory potency 
compared to other common corticosteroids (i.e. methylprednisolone, dexamethasone), but it has 
lesser growth effect which is one of the concerning issues in the disease management in paediatric 
population [19].  
We will give prednisolone at a dose of 1 mg/kg to 2 mg/kg body weight based on age category, 
once daily for five days. As there is a wide therapeutic dose window for prednisolone, this will 
enable us to operationalise the dose as 10 mg/day for children aged six months less than two years; 
20 mg/day for children aged two to five years; and 30 mg/day for children aged six to 12 years, 
simplifying both randomisation and dosage instructions. The current treatment for AOM does not 
include corticosteroids in the guidelines. Therefore, we determined the dose and duration of 
prednisolone based on the doses regularly used in the paediatric otitis media trials and regular 
dose for other inflammatory and infection diseases in children based on the international and 
national practice guidelines, such as bronchial asthma, juvenile rheumatoid arthritis, and acute 
bacterial meningitis [21-25]. The duration of corticosteroid use in otitis media trials varies between 
three to seven days [18, 26-28]. An animal study [29] using mice infected with Streptococcus 
pneumoniae and non-typeable H. influenzae (NTHi) bacteria demonstrated that most of AOM-
related cytokines peaks at three to six hours after the infections (interleukin-6/IL-6, interleukin-1 
alpha/IL-1α, tumor necrosis factor alpha/TNF-α) an at six hours to three days (interleukin-10/IL-10). 
In general, these cytokines will be progressively reduced between the fourth to sixth day of 
infection and the acute otitis media will be resolved after the sixth day [29]. Therefore, we will give 
the prednisolone for five days in order to boost the natural resolution mechanism in AOM cases 
and to minimize the potential harms of corticosteroid use even though 7-day duration is still 
regarded as short-term use.  
A single daily dose is preferable over divided doses to prevent the hypothalamic-pituitary-adrenal 
(HPA) axis suppression. Prednisolone should be given in a single dose at 6 to 8 am in the morning 
to mimic the normal diurnal rhythm of cortisol production [19,20] and because it is also more 
convenient for children and parents in the study to just take a trial drug once a day.  
Potential harms  
Despite the favourable effect of corticosteroids for inflammation, there are still several potential 
adverse effects related to its short-term use. A systematic review identified side effects of short-
course of corticosteroids (less than two weeks) in children, such as gastrointestinal disturbances 
(i.e. vomiting, gastritis, nausea), behavioural changes (i.e. mood swings, nervousness), HPA axis 
suppression, increased blood pressure, hyperglycaemia, weight gain, and decreased bone 
mineralisation [30]. Even though there were more children experiencing these side effects 
compared to placebo, the included studies used a diverse of corticosteroids’ types and duration, 
as well as the results were uncertain and include both important beneficial and harmful effects of 
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corticosteroid. Vomiting and behavioural disturbances (i.e. anxiety, aggressive behaviour) are the 
common side effects [30].  
Regarding vomiting, there were three studies comparing prednisolone to placebo or control (other 
type of corticosteroids). A good quality RCT [31] included children aged 10 to 60 months with virus-
induced wheezing who received a single dose of inhaled albuterol. These children then were 
randomly allocated to either prednisolone (10 mg oral prednisolone for children aged 2 years and 
younger; 20 mg for aged >2 years) group (n=343) or placebo (n=344). No significant differences on 
clinical outcomes (e.g. time to hospital discharge) or adverse effects between two groups were 
detected. There was one child from prednisolone group who vomited that required the 
discontinuation of the prednisolone [odds ratio (OR) 3.02 (95% confidence interval (CI) 0.12 to 74.33; 
p-value=0.50; number needed to harm (NNTH; number of children who are treated with 
prednisolone that will result in one additional event of side effects) = 34 children)] [31]. One study 
[32] on children aged one to 17 years with acute asthma presenting to the emergency department 
(ED). The children received a dose of inhaled albuterol and either a single dose of oral prednisone 
2 mg/kg (n=41) or placebo (n=40). There was no a significant difference in the incidence of vomiting 
after taking the prednisone between the prednisone group (n=3; 7.3%) and the placebo group (n=1; 
2.5%) [OR 3.08 (95% CI 0.31 to 30.92; p-value=0.34; NNH=21)] [32]. The same author with similar 
inclusion criteria [33] demonstrated a significant difference on the incidence of vomiting between 
children who received single dose prednisone 2 mg/kg/day (n=10/66) and nebulised 
dexamethasone 1.5 mg/kg (n=0/62), however the confidence interval was very wide that included 
a high number of NNTH (if we treat more than 50 children with prednisone, then we will expect 
one additional event of vomiting) [OR 23.23 (95% CI 1.33 to 405.54; p-value=0.03; NNH=7)] [33].  
Regarding behavioural changes, one RCT [34] randomly allocated children aged two to 16 years 
with acute exacerbation of mild persistent asthma to receive either oral prednisone/prednisolone 
high dose (2 mg/kg/day) or low dose (1 mg/kg/day) for five days. There were significant differences 
in observed adverse events between high-dose and low-dose groups in regard to anxiety (9/43 vs 
2/43, respectively) [OR 5.43 (95% CI 1.10 to 26.83; p-value=0.04; NNTH=7)] and aggressive behaviour 
(9/43 vs 0/43) [OR 23.96 (95% CI 1.35 to 426.33; p-value=0.03; NNTH=5)]. The wide of intervals 
demonstrated a wide variance in the number of children needed to treat to expect one additional 
adverse event. There were no significant differences in other unfavourable effects (i.e. facial 
fullness and erythema, abdominal pain, diarrhea, euphoria, depression, and hyperactive) [34]. 
Another RCT [35] included children aged two to 15 years with acute exacerbation of asthma who 
were randomly allocated to receive oral prednisolone 1 mg/kg/day for three days (5-day group) vs 
same dose of prednisolone for three days (3-day group). There were no significant differences in 
regard to the incidence of rash and behavioural disturbance (e.g. angriness, aggressiveness, 
crankiness, irritability) between the two groups [35]. 
An RCT of the use of prednisolone for pediatric AOM reported no significant differences between 
children who received oral prednisolone 2 mg/kg/day for five days and placebo group who 
experienced moderate side effects (e.g. drowsiness, nervousness, diaper rash, dry mouth) [18]. 
This study also demonstrated that there was no correlation between the use of corticosteroid and 
the persistence or the emergence of viral infections [18]. Other potential side effects correlated 
with the use of corticosteroids are fluid retention and headache [18,30].  
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Based on these trials, we consider 5-day duration of prednisolone for this study is appropriate 
and safe for children.  
Clinical trial of corticosteroids for acute otitis media in children 
Evidence has demonstrated insufficient benefits and harms of corticosteroids. An RCT 
demonstrated that corticosteroid reduced the duration of ear discharge in AOM children with 
ventilation tubes [26]. Another RCT demonstrated a temporary resolution of middle ear effusion 
after five days of corticosteroid treatment [18]. In a systematic review of randomised placebo-
controlled trials (RCTs) of steroids for AOM, only two small trials [18,27,36] (very low to low quality) 
indicated corticosteroids could be useful in this condition. However, our confidence in the results 
is low, due to small sample size and very wide confidence intervals around the observed results. 
This insufficient evidence creates a research gap in the management of AOM, particularly in non-
severe cases, where antibiotics are not required.  Therefore, we propose an adequately powered 
clinical trial to address this uncertainty. 
We will conduct a large, parallel, pragmatic, multicentre, stratified, double-blind, randomised, 
placebo-controlled trial with the allocation ratio 1:1 to test the effectiveness of corticosteroids for 
760 children with AOM including 60 children for a tympanometric mechanistic sub-study and pilot 
study, described further in this protocol. As a comparator to prednisolone, we will use a placebo 
for the following advantages: (1) it is the most accurate test in assessing the efficacy of a treatment; 
(2) it will show the true additional benefits and/or harms of the prednisolone; and (3) it is crucial 
when the outcome is assessed using subjective measurements.  The primary objective and 
outcome of this proposed trial is to assess the effectiveness of corticosteroids as a monotherapy 
in children with mild AOM, and as an addition to antibiotics in children with severe AOM, on ear 
pain at three days after randomisation using visual analogue scale (VAS). The secondary outcomes 
include ear pain at other time points, total duration and severity of pain, adverse effects, 
complications of AOM (e.g. perforation of tympanic membrane, mastoiditis), and AOM recurrence.   
1.1.3 Rationale for pilot study 
Prior to our main study, we will conduct a pilot study, described in this protocol. This study will 
mimic the main study in terms of its process and procedures, but on a smaller scale. However, due 
to budget constraints, we will conduct a pilot study as a pragmatic, randomised, open-label, single-
blind study. We will blind outcome assessors (i.e. physicians and tympanometry technicians), so 
they will not aware of the allocation of the intervention. 
The main study will involve many participating physicians and healthcare facilities across Jakarta, 
Bekasi, and Depok, most of whom have not been involved in a clinical trial before, will have a long 
follow-up period up to three months, and will utilise a symptom diary and a specific translated 
instrument to assess the severity of symptoms (acute otitis media – severity of symptom scale or 
AOM-SOS) which is not widely recognised by physicians in Indonesia.  Therefore, this pilot study is 
crucial to test the feasibility of the main study, including the characteristics of our main study 
design, all the study processes and procedures (e.g. the recruitment, stratification, randomisation, 
outcome measurement), and other operational strategies in our proposed main study.  
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1.2 Objectives 
The first objective of our pilot study is to assess the overall process and procedures of the main 
study, as follows: (1) the recruitment criteria; (2) stratification and randomisation processes; (3) 
outcome measures using validated and customised tools (e.g. visual analogue scale/VAS, Acute 
Otitis Media – Severity of Symptoms Scale/AOM-SOS, case report forms/CRFs, symptom diary); (4) 
identification of any potential practical and operational issues that may appear in the main study 
which will require re-structuration of the planned methods and procedures after commencing this 
pilot study; and (5) verification of sample size calculation for main study. 
Our second objective is to conduct a mechanistic explanatory study using tympanometry. It aims 
to assess the efficacy of corticosteroids in improving the resolution of middle ear effusion in AOM. 
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CHAPTER 2 – METHODS 
 
2.1 Trial design 
This study is a pilot of a parallel, pragmatic, stratified, randomised, open-label, single-blind 
controlled trial of corticosteroids, as monotherapy for mild AOM, and in addition to individually 
prescribed antibiotics for severe AOM. In the main study, we will stratify eligible children based on 
the clinical specialty (primary care or secondary/tertiary care) and severity of AOM (mild or severe). 
However, for this pilot study, we only include ear-nose-throat-specialists (ENTs) who work at 
tertiary centres for the convenience of the implementation of the mechanistic sub-study as 
tympanometry is only available at the hospitals (tertiary centres). Therefore, we will stratify the 
children based on their AOM severity and then will randomly allocate to corticosteroid 
(prednisolone) or control (usual care without prednisolone) (Figure 1) with the allocation ratio of 
1:1. Because it is a n open-label study, the parents/caregivers and an appointed nurse who will 
perform the randomisation will be aware of treatment allocation, whilst the clinicians and 
tympanometry technicians will remain unaware of the treatment. 
2.2 Participants, interventions, and outcomes 
2.2.1 Study setting 
Prior to this study, we conducted a feasibility study to survey the current management of AOM in 
children in three cities in Indonesia and to identify the willingness of physicians to participate in 
our proposed clinical trial of corticosteroids for AOM in children. Based on clinical scenarios, there 
were sufficient number of physicians who would prescribe corticosteroids for AOM. There were 
171 physicians from 87 primary/secondary to tertiary centres (public and private) in DKI Jakarta, 
Depok, and Bekasi who were willing to participate in our proposed main study. However, we will 
only pilot this study at seven public and private hospitals in Jakarta and Bekasi: (1) Dr Cipto 
Mangunkusumo Hospital; (2) Persahabatan Hospital; (3) Gatot Subroto Army Hospital; (4) Antam 
Medika Hospital; (5) Cempaka Putih Islamic Hospital; (6) Proklamasi ENT Hospital; and (7) Hermina 
Bekasi Hospital. 
2.2.2 Eligibility criteria 
2.2.2.1 Inclusion criteria 
We will include 60 children aged six months to 12 years old with AOM, defined as current onset (48 
to 72 hours) of AOM-relevant symptoms (e.g. earache, ear tugging/rubbing or irritability in non-
verbal children). If it is feasible, otoscopic findings of middle ear effusion (e.g. bulged tympanic 
membrane, limited or absent mobility of the tympanic membrane, air fluid level, ear discharge) and 
acute inflammation (e.g. erythema) will confirm the diagnosis.  
2.2.2.2 Exclusion criteria 
We will exclude children: 
1. with major and severe medical conditions (e.g. heart diseases, kidney failure) 
2. who are immunocompromised (e.g. HIV, children receiving cancer treatment) 
3. with congenital malformations and/or syndromes (e.g. cleft palate, Down’s syndrome) 
4. with ear ventilation tube(s) 
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5. exposed to persons with varicella (chicken pox) or active Zoster infection in the past three 
weeks without prior varicella immunisation or infection 
6. who have high risk of strongyloidiasis infections with symptoms and signs of unexplained 
eosinophilia, skin reaction due to larvae penetration into the skin (e.g. inflammation, 
oedema, petechiae, severe pruritus), particularly on the feet regions, pulmonary (e.g. dry 
cough, throat irritation, dyspnoea, wheezing, haemoptysis, repeated episodes of fever and 
mild pneumonitis), or gastrointestinal symptoms (e.g. upper abdominal pain, diarrhea, 
anorexia, nausea, epigastric pain, malabsorption, and vomiting)  
7. who have taken systemic (i.e. oral, injection) or topical steroids in the preceeding four 
weeks  
8. who have taken antibiotics in the preceeding two weeks 
9. who are hypersensitive to prednisolone or prednisone, or other corticosteroids  
2.2.3 Interventions 
Children in the mild AOM group will be randomly allocated to receive either a single dose of 
prednisolone tablets daily for five days as an addition to expectant observation or expectant 
observation alone (without prednisolone). At the baseline visit, the participating physicians will 
inform the parents/caregivers to closely observe the children for 48 hours without immediate 
antibiotic treatment. 
Children in the severe AOM group will be randomly allocated to receive either a single dose of 
prednisolone tablets daily for five days as an addition to antibiotics according to physicians’ 
preferences or antibiotic alone (without prednisolone). Antibiotic treatment is commonly 
prescribed for AOM with severe symptoms. The information regarding the antibiotics (e.g. 
antibiotic type, dose, duration) will be recorded in the case report forms (CRFs).  
2.2.3.1 Prednisolone and control group  
Prednisolone group 
Prednisolone tablets will be given in the intervention groups in both mild and severe groups. It is 
given at a dose of 1 mg/kg to 2 mg/kg body weight, once daily for five days.  The pharmacist will 
crush the tablets, mix them with sweeteners, and pack them in a daily paper-pack. It should be 
given in a single dose at 6 to 8 am in the morning to mimic the normal diurnal rhythm of cortisol 
production [19,20]. Participating physicians will advise the parents to give the prednisolone at 
about the same time each day as a daily routine for children which will also help parents to 
remember.  
Control group 
Due to budget constraints, we are not able to provide a matched placebo as prespecified for the 
main study. Therefore, we will not give placebo for children in the control group, either in the mild 
or severe group. Children in the control group of the mild AOM group will still receive expectant 
observation and those in the severe AOM group will receive antibiotics, and other concomitant 
treatment based on physicians’ preferences (if necessary). The only difference between the 
intervention and control group is solely whether they receive prednisolone (intervention group) 
or not (control group).  
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2.2.3.2 Criteria for trial drug discontinuation or modification 
When giving the prednisolone to a child, parent can mix the prednisolone powder with jelly or juice. 
If children vomit less than 30 minutes after having a dose of prednisolone, parents should give the 
same dose again. However, if they vomit again after 30 minutes, parents should not give another 
dose of prednisolone until the next dose on the next day. This should be noted in the symptom 
diary. If children keep vomiting after receiving prednisolone, parents should contact the research 
team. If the parents forget to give prednisolone to their children, they can give the missed dose as 
soon as they remember on the same day and they should also note this in the symptom diary. 
If there are any adverse events and adverse drug reactions which have been assessed by research 
team that would require the discontinuation of drug trial and further assessment and treatment, 
then the treatment will be discontinued for this particular case, however follow-up will continue, 
where possible. This will be reported in the CRFs. Serious adverse events will be reported to Bond 
University’s Human Research Ethics Committee (BUHREC) and the Research Committee Ethics 
Faculty of Medicine Universitas Indonesia (FMUI) – Dr. Cipto Mangunkusumo Hospital (CMH). 
2.2.3.3 Adherence monitoring  
Participating physicians will provide information regarding the administration of the prednisolone. 
The researcher will send a daily text-message reminder to all the parents in both prednisolone and 
control groups during the intervention period of five days to take the drug regularly and to 
complete the symptom diary daily. The text-message will also remind all the parents to visit the 
clinic after the 48-hour expectant observation or visit-1 (day-3), visit-2 (day-7), visit-3 (day-30), and 
visit-4 (day-90) for re-assessment. At each visit-1 and visit-2, the parents will return the first and 
second mini-booklets of symptom diary and the left-over drug to the appointed nurse (at visit-2). 
The nurse will then check the symptom diaries and the left-over drug for the adherence in taking 
intervention drugs. We will visit the patients’ homes to collect the third mini booklet of symptom 
diary that will record the symptoms from day-7 to day-14 after the baseline visit. 
2.2.3.4 Concomitant care and interventions 
Physicians may give symptomatic medicine (i.e. ibuprofen, acetaminophen, decongestant, 
mucolytic) according to their usual practice and these will be recorded in the CRFs and symptom 
diary. Parents will record the use of these medicine in the symptom diary. The decision on 
concomitant medication will be made without knowledge of allocation to the prednisolone or 
control group. 
2.2.4 Outcomes 
2.2.4.1. The pilot study outcomes 
Recruitment rate 
Recruitment rate is defined as the proportion of consultations with potentially eligible children 
who provide their consent to be included in the study. As this is recognised as a crucial aspect of 
conducting a clinical trial and may cause study discontinuation due to low recruitment [37], we will 
assess this in our pilot study. We will identify the rates and challenges during the recruitment 
process and determine the best strategy for the main study to overcome these challenges and 
obstacles.  
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The success of the study procedures 
The success of the study procedures includes the following: (1) obtaining informed consent from 
the patients and their parents; (2) the recruitment based prespecified eligibility criteria, including 
the use of otoscope to diagnose AOM if feasible; and (3) the stratification and randomisation 
process, including stratifying eligible children based on the severity and obtaining the allocation 
result whether the children will be allocated to the prednisolone or control group.  
Ability to measure planned outcomes in the main study 
We will assess the ability to measure planned outcomes in main study, which are: (1) the proportion 
of children with pain reduced by at least the minimum clinically important amount, at day-3 after 
randomisation. This will be assessed using a VAS recorded in the patient symptom diary; (2) the 
severity of pain and other AOM-relevant symptoms at various time points using VAS, AOM-SOS, 
and the symptom diary; (3) duration to AOM resolution; (4) adverse effects, defined using standard 
clinical trials criteria, recorded in the diary, and reported to the central office and ethics committee 
as required.; (5) complications of AOM (e.g. perforation of tympanic membrane(s), mastoiditis); 
and (6) AOM recurrence, defined as a new episode of AOM at one to three months after 
randomisation. We will report these narratively due to a limited sample size and insufficient formal 
power calculation for this pilot study to be able to detect actual effects of corticosteroids to 
improve clinical outcomes in AOM. 
The compliance to study and study drug 
The compliance to study and study drug is defined as a proportion of children who regularly take 
the study drug (assessed using the symptom diary and any left-over drug) and come to follow-up 
visits per protocol. Participants will be followed-up closely by clinicians and research staff. Children 
will return for a visit at day-3 after randomisation, ensuring collection of the primary outcome.  
The verification of sample size calculation for main study 
Based on our size calculation, we plan to enrol 760 children in the main study. We estimate that 
there will be 35% of the total sample of children with AOM in the severe group (i.e. children with 
severe symptoms, fever ≥ 39°C, children aged < 2 years with bilateral AOM, AOM with perforation 
of tympanic membrane). Therefore, within this pilot study, we can assess the accuracy of this 
assumption. Also, we will check another assumption of the sample size calculation, which was the 
proportion in the control group with the resolution of pain at three days, which was 42.5%. 
2.2.4.2. The mechanistic or tympanometry sub-study outcomes 
Primary outcomes 
The change in middle ear effusion (MEE) at various time points 
We will assess the change in the MEE at the following time points: baseline visit, visit-1 (day-3), visit-
2 (day-7), visit-3 (day-30), and visit-4 (day-90). We will measure MEE using static acoustic 
admittance, defined as “the amount of energy absorbed by the tympanic membrane and middle 
ear, measured in mmho or mL” [38]. We will also measure the difference of this results between 
the intervention and control group. 
Secondary outcomes 
Duration of MEE  
We will also assess the duration to the resolution of MEE using tympanometry. 
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The correlation between ear pain and other symptoms with the changes in MEE at various time 
points 
We will identify the correlation between ear pain and other symptoms (i.e. ear tugging, irritability, 
crying, lack of sleep, lack of appetite, less of playfulness, fever) with the changes in MEE at various 
time points. 
2.2.5 Participant timeline 
Table 1 illustrates the timeline for visits and follow-ups. We will measure the outcomes at various 
time points: (1) visit-1 after the 48-hour observation (day-3); (2) visit-2 (day-7); (3) visit-3 (day-30); 
and (4) visit-4 (day-90). Patients will visit the hospital at visit-1 and visit-2, whilst the last two visits 
will be a home-visit. However, children in the mechanistic sub-study have to visit the hospitals at 
those follow-up visits. To improve the compliance of the study, the research personnel will send a 
daily text-message reminder to all the parents in the study during treatment period to take the 
drug, complete the symptom diary, and visit the clinic after the 48-hour expectant observation and 
other time points. At visit-2, parents will return the symptom diary and any left-over drug.   
Table 1. Follow-up timeline 
 STUDY PERIOD 
 
Enrolment  
Allocation 
Post-allocation Close-out 
TIMEPOINT 
0 
(Day-0) 
t1  
(Day-3) 
Interventi
on ends 
(Day-5) 
t2* 
(Day-7) 
t3* 
(Day-30) 
t4* 
(Day-90) 
ENROLMENT:       
Eligibility screen X     
Informed consent  X     
Allocation X     
INTERVENTIONS:       
[Intervention A] Prednisolone (5 days)       
[Intervention B] Control (5 days)       
ASSESSMENTS:       
Baseline examination (weight, height, 
BP, body temperature) 
X X X X* X* 
Severity of pain and duration using VAS X X X   
Overall symptoms and its duration using 
AOM-SOS 
X X X   
Adherence to trial drug X X X   
Adverse effects X X X   
Otoscopic examination X X X X* X* 
Tympanometry examination X+ X+ X+ X+ X+ 
Complication X X X   
Recurrence of AOM    X* X* 
BP=blood pressure; VAS=visual analogue scale; AOM-SOS: acute otitis media-severity of symptoms scale 
*The follow-up will be carried out by home-visit and phone, but those in the mechanistic sub-study will have their follow-
up visits to the clinics; +These time-point assessments will be applied only for children in the mechanistic sub-study 
Participant enrolment 
In the main study, we will stratify eligible children by the clinical specialty (primary care or 
secondary/tertiary care) and severity of AOM (mild or severe). However, we only include ear-nose-
throat-specialists (ENTs) who work at tertiary care in this pilot study. Therefore, we will stratify the 
children based on their AOM severity and then will randomly allocate these eligible children to 
receive either a single dose prednisolone for five days or without, as an addition to expectant 
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observation in the mild AOM group or as an addition to antibiotics according to physicians’ 
preferences (e.g. antibiotic type, dose, duration) in the severe AOM group (see Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participating physicians will assess the eligibility of children who come to the hospital based on 
their symptoms and clinical features of AOM. The eligible children will then be stratified based on 
the severity of AOM to either mild or severe AOM group. This process will be assisted using an 
eligibility and randomisation form. The participating clinicians will then obtain a clinical history and 
perform a baseline examination, including general, otoscopic, and tympanometry examination. 
The results of these procedures will be recorded at the baseline history form and outcomes form. 
The tympanometry examination will be conducted by an audiologist or a tympanometry technician. 
The physician will assess and analyse the tympanometry findings and record the results in the 
outcome form. After these procedures, the children will be sent to the appointed nurse who will 
perform the randomisation and dispense the prescription for a study medication (prednisolone) if 
the patient is assigned to the intervention group.   
Is this child eligible for the study? 
Primary vs secondary/tertiary care 
Mild AOM Severe AOM 
 
Prednisolone + 
expectant  
observation 
 
Expectant  
observation alone 
 
 
Prednisolone + 
antibiotic 
Antibiotic  
alone 
 
 
S
tr
at
if
ic
at
io
n
 
R
an
d
o
m
is
at
io
n
 
Figure 1. Flow chart of the stratification and randomization of the study 
suspected AOM 
AND 
aged 6 months to 12 years old 
AND 
symptoms suggestive of AOM (e.g. ear tugging, irritability, pain) 
AND 
Available for follow-up visits 
AND/OR 
otoscopic examination shows bulging, middle ear level, and/or immobile tympanic membrane(s), if feasible 
 
With moderate to severe symptoms, locally or systemically 
(moderate to severe ear pain, fever ≥39°C, complications) 
OR 
aged <2 years with bilateral AOM 
OR 
both AOM and tympanic membrane perforation 
OR 
additional otoscopic finding: the appearance of moderate to severe bulging and/or 
opaque/yellowish/purulent tympanic membrane(s), if feasible 
E
li
g
ib
il
it
y 
YES NO 
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2.1.6 Sample size 
We did not determine a sample size for the pilot study. There are several suggestions in calculating 
the sample size for a pilot study (e.g. at least 55 participants or at least 9% of the sample size of the 
main study) [39]. Since we will need 60 children in the mechanistic sub-study, we will include 60 
children with AOM in our pilot study. The sample size of the mechanistic study was determined 
based on the main primary outcome, which is the mean value of static acoustic admittance or 
acoustic compliance in the tympanogram. In a previous study of children with middle ear effusion 
(MEE) who underwent tympanometry assessment and had a history of chronic or recurrent middle 
ear disease [40], the response within each subject group was normally distributed with standard 
deviation 0.3.  If the true difference in the experimental and control means is 0.3 units, we will need 
to study 22 experimental subjects and 22 control subjects to be able to reject the null hypothesis 
that the population means of the experimental and control groups are equal with probability 
(power) 0.9. The Type I error probability associated with this test of this null hypothesis is 0.05. 
With a 20% allowance for dropouts, the total sample size becomes 56 or we will include 60 children 
for this pilot study. 
Using the worst-scenario that of 50 physicians who work at seven appointed hospitals and have 
approximately 97 patients with AOM per week, we estimate that only 30% of the physicians will 
confirm their participation and 25% of the patients will give their consents to participate in our 
study.  We then estimate that it will require nine months to recruit 60 children with AOM in this 
pilot study, including the extra months for potential slow recruitment and last follow-up (three 
months after the baseline visit).   
2.1.7 Recruitment 
Recruitment of physicians 
Our feasibility survey study (April–August 2016) demonstrated there were 352 physicians (general 
practitioners, ear-nose-throat specialists, and paediatricians) who were willing to participate in our 
main study and they had 705 paediatric patients with AOM in the past seven days. For our pilot 
study, we identified 50 physicians from the most feasible seven hospitals located in DKI Jakarta 
who were willing to participate in our study and had approximately 97 paediatric patients with 
AOM in a week.  
Recruitment of participants 
After physicians deliver the patient information and obtain the consent from the eligible children, 
they will use the eligibility and randomisation form to assist them in stratifying the children based 
on their AOM severity. Physicians then will complete other CRFs, as the following: baseline history 
form and outcome form. Physician will assist the parents to complete the symptom diary.  The 
similarity on the forms and sequences of both outcome CRF and symptom diary will help parents 
to be able to fill those correctly.  
2.3 Assignment of interventions 
2.3.1 Allocation  
Sequence generation and implementation 
All children and their parents who are eligible and consented will be enrolled, and stratified based 
on their AOM severities or clinical features. The randomisation process will be performed by the 
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appointed nurse who will randomly allocate children to either prednisolone and expectant 
observation or control (expectant observation alone) in the mild group and either antibiotic with 
prednisolone or control (antibiotic alone) in the severe group. A permuted block randomisation 
sequence will be computer-generated by the Centre for Research in Evidence-Based Practice Bond 
University, Gold Coast, Australia. Random numbers will not be disclosed to the outcome assessors 
(i.e. participating clinicians and audiologists/tympanometry technicians), to ensure allocation 
concealment. Batches of intervention packages will be dispatched to participating centres from a 
central pharmacy facility at the Clinical Research Supporting Unit, Faculty of Medicine Universitas 
Indonesia (CRSU FMUI). 
Allocation concealment mechanism and implementation 
The information of the eligibility and stratification which is provided by the participating physicians 
will help the appointed nurses to obtain the information from the randomisation website, whether 
the children will be allocated to the prednisolone or control group, identified by the 2-digit patient 
ID numbers. During the consultation, the physician will prescribe study medication for every 
subject with the dose based on the patient age and insert the prescription in the CRF folder. The 
nurse who performs the randomisation will give the prescription to the subjects who are allocated 
to the intervention group (prednisolone group). The subject then will give the prescription to the 
pharmacy, where the pharmacist will prepare the prednisolone by crushing the tablets, mixing 
them with sweeteners, packing the prednisolone mixed powder in a daily individual paper-pack for 
five days, and dispense these to the subjects along with instructions for preparation.  The 
pharmacist will record the dispensing on the form provided by the study for this purpose.   
2.3.2 Blinding (masking) 
In this study, the appointed nurses and the children and their parents will know the allocation of 
the intervention. We will ensure that the participating physicians and the audiologists/ 
tympanometry technicians will be blinded to the intervention allocation during the study. 
Emergency unblinding 
The unblinding process should be done if there are serious adverse events and limited only to that 
particular participating physician.  
2.4 Data collection, management, and analysis 
2.4.1 Data collection methods 
We will assess the outcomes using CRFs, patient symptom diary, and feedback forms. The CRFs 
consist of eligibility-and-randomisation, baseline history, outcomes, serious adverse events (if 
applicable), and drug dispensing and returned forms. The outcome form will record the severity of 
pain and overall symptoms with their durations using VAS and AOM-SOS, as well as the resolution 
of AOM signs using otoscopic and tympanometry examinations (for the mechanistic study).   
We will identify the recruitment rate by assessing the proportion of children who provide their 
consents divided by the proportion of consultations with potentially eligible children during the 
trial. We will use the informed consent and a study recruitment log book to record the reason(s) 
why children were not randomised. 
We will assess the success of the study procedures using feedback forms. On the feedback form, 
patients and their parents and participating physicians will rate their understanding and challenges 
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they have during the implementation of study procedures (e.g. obtaining the randomised 2-digit 
patient ID numbers and their allocation of the treatment, completing the informed consent forms 
and CRFs) using grading scale ranged from one to five (1=very easy; 2= easy; 3=moderate/neutral; 
4=difficult; 5=very difficult). 
To assess the ability to measure planned outcomes in main study, we will also use a feedback form 
to identify the understanding, the challenges, the complexity of the outcome assessment tools 
utilised for this study (e.g. CRFs and patient symptom diary which includes VAS and AOM-SOS) 
from the perspective of the patients and their parents and the participating physicians. The CRFs 
and symptom diary will record the clinical history and symptoms (e.g. VAS, AOM-SOS), as well as 
physical examination (e.g. temperature, blood pressure, otoscopic examination if feasible). This 
information will be obtained from the perspectives of the patients and their parents and the 
clinicians.  
The VAS is acknowledged as a well-established and validated scale for assessing pain [41].  It has a 
100-mm horizontal scale with ‘no pain’ anchor at the left endpoint and ‘the most severe pain’ at 
the right endpoint of the scale. The patient will mark a vertical line along the horizontal line as the 
representation of their pain level. The scale will be determined by measuring the distance from the 
left endpoint (‘no pain’) to the marked line [42]. A 10-mm difference has been reported to indicate 
a clinically significant change [43,44]. The AOM-SOS is used to assess the severity of other AOM-
relevant symptoms daily. particularly in non-verbal children. Table 2 illustrates several AOM-related 
symptoms described as “no”, “a little”, and “a lot”. This scale was developed as an outcome 
reporting tool scoping symptom and activity limitation due to AOM in the proceeding 12 to 24 hours 
[45]. Shaikh et al. [45] used the mean of 4.2 points as a minimal important difference. We have 
translated the original English) version of AOM-SOS to Indonesian version of AOM through forward 
and backward translation process. 
Table 2. Acute otitis media severity of symptoms scale (AOM-SOS) [45] 
We are interest finding out how your child has been doing. For each question, please place a 
check mark in the box corresponding to your child’s symptoms. Please answer all questions 
 No A Little A Lot 
Over the past 12 h, has your child been tugging, rubbing, or     
     holding the ear(s) more than usual? 
   
Over the past 12 h, has your child been crying more than usual? 
    
Over the past 12 h, has your child been more irritable or fussy  
     than usual? 
   
Over the past 12 h, has your child been having more difficulty  
     sleeping than usual? 
   
Over the past 12 h, has your child been less playful or active  
     than usual? 
   
Over the past 12 h, has your child been eating less than usual? 
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Over the past 12 h, has your child been having fever or feeling  
     warm to touch? 
   
 
The compliance to the study and study drug will be identified by assessing the completion of CRFs 
and symptom diary, particularly on the attendance of patients and the parents on their scheduled 
follow-up visits, the completion of the trial drug based on the symptom diary and the left-over drug. 
We will identify the parents who have low literacy during the informed consent process.  For 
parents who have low literacy, we will visit their home one day after the initial visit to identify a 
person who lives nearby (e.g. family members, neighbours) that are able to assist the parents in 
completing the symptom diary, daily for two weeks. If there is noone can assist them, then the 
research personnel will assist them in completing the symptom diary by phone. If it is not feasible, 
we will visit their home daily to be able to assist them.  
To assess the verification of sample size calculation for main study, we will use the CRFs.  
To ensure that all the outcome data can be sufficiently collected and recorded properly according 
to prespecified plans, we will conduct an individual/institutional training for participating 
physicians prior the implementation of this pilot study. The training will include following sections: 
(1) introduction and summary of the study; (2) introduction of international clinical practice 
guidelines of AOM; (3) The diagnosis of AOM using otoscope and reporting the otoscopic results; 
(4) the introduction and dissemination of the principles of quality methodology clinical trial (e.g. 
eligibility, randomisation, blinding, outcome assessment) and good clinical practice (e.g. patient 
consents, confidentiality, data management); (5) practical steps of eligibility assessment, 
stratification, and randomisation; and (6) practical steps in completing study documentation (i.e. 
patient informed consents, CRFs, feedback forms, patient symptom diary). 
2.4.2 Data management 
The integrity and completion of data will be maintained through mechanisms such as consistency 
checks during data entry, and cross-checks between items after data entry. All the actions and 
modifications to data stored in the database will be documented and retrievable for viewing. 
Missing data or errors will be detected before final submission to the electronic database and will 
be recorded in a summary along with the descriptions for each missing and/or error data. The 
summary will then be notified to the co-investigators in that hospital for further investigation by 
checking and confirming the original forms or other resources for correction or completion for 
those with missing and/or erroneous data. The modification to original forms will be done by 
research personnel at that hospital and will be documented on paper and electronic versions. It 
will be annotated with the date, name, and signature of the person who is responsible for making 
modifications.  
The central data coordinator will check the validity and completeness of study data on a regular 
basis. All data in the central database will be protected with a regular complete back up system.  
2.4.3 Statistical methods 
For the recruitment rate, we report the outcome as the proportion of children in percentages (%). 
For the success of the study procedures and the ability to measure planned outcomes in main study, 
we will report the outcomes as the proportion of clinicians in percentages based on the grading 
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scale of their feedback reporting on prespecified outcome measure tools. For the compliance to 
study and study drug, we will report the outcomes as the proportion of children in percentages 
who attend the follow-up visits and complete the cycle of study drug.  
To assess the verification of sample size calculation for main study, we will report this outcome as 
the proportion of children in each stratum (mild and severe AOM group) and those with pain at 
Day-3 after randomisation in the control group.  
For the mechanistic sub-study, we will report continuous variables (i.e. the change in MEE at 
various time points (mean in days standard deviation), the duration of MEE) as a mean difference 
(MD) with 95% confidence intervals (CI) also the difference between two groups. We also will 
report the correlation between ear pain and other symptoms with the changes in MEE at various 
time points. 
2.5 Monitoring 
2.5.1 Data monitoring 
Data monitoring committee 
Since this is a short study, we do not need data monitoring committee for this pilot study. However, 
independent personnel from Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit, Dr 
Cipto Mangunkusumo Hospital (CMH) – Faculty of Medicine Universitas Indonesia (FMUI), who is 
not involved in this study, will assess the process and the quality of patient recruitment, data entry, 
and a compilation of research data in central database. Her feedback will be important to improve 
the implementation of our main study. 
Interim analysis 
Due to the small number of recruited patients to the trial and the duration of the trial will be lesser 
than one year, we will not perform an interim analysis.  
2.5.2 Harms 
An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily have 
to have a causal relationship with trial drug; whereas adverse effects or adverse drug reaction, is 
defined as all noxious and unintended responses to a trial drug related to any dose.  
At the Visit-2 (Day-3), the appointed nurse is the first person who will identify any adverse effects 
(AEs). These will be identified by history taking (e.g. interview) and the symptom diary. The parents 
will provide information in the symptom diary regarding the adverse effects and whether they seek 
any treatment or medical assistance to manage AEs. The nurse then will report the adverse effects 
to the physicians along with the information of the intervention group which the child was 
allocated to. This information will be provided after the physician assess and record the primary 
outcome (i.e. ear pain three days after the randomization) on the 'Outcome form'. This is important 
to keep the concealment. 
Adverse events and adverse drug reaction will be collected after they sign the written consents 
and being enrolled in the trial. All adverse events occurring after the enrolment into the study, 
during the additional treatment or hospitalization due to adverse events and/or ADR will be 
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recorded. A subject who experiences a serious adverse event (SAE), defined as any untoward 
medical occurrence at any dose that may result in-patient and/or prolonged hospitalization, 
persistent or significant disability, medically important events, life threatening events, and death, 
will receive sufficient treatment and will be recorded and reported to the Research Committee 
Ethics FMUI – CMH and the Bond University’s Human Research Ethics Committee (BUHREC). We 
will responsible for any additional examinations and/or treatment that are required to manage AEs. 
We will not report SAE occurring after the trial discontinuation, unless there is a temporal 
relationship between trial drugs or other protocol procedure to the events, as well as whether the 
event is unexpected or unexplained given the subject’s clinical course, previous medical conditions, 
and concomitant medications. All the SAE will be recorded in SAE form. 
2.5.3 Auditing 
For the main study, we will establish an audit committee from the CRSU FMUI and CEEBM Unit 
CMH-FMUI which is independent from the trial investigators and the funding body. However, this 
will not occur separately from monitoring for the pilot study. This independent committee will 
conduct monitoring of source paper and electronic documents in the website system, monitor the 
conduct of trial in multicentre sites, interviewing the investigators and coordinators, and check the 
storing, distribution, and the use of trial drugs. At the start of the trial, the committee will ensure 
that the research staff are capable in data entry and in using the website system. Observation and 
quality assessment of the whole trial will be ensured to be always in accordance with the protocol 
and International Conference Harmonization – Good Clinical Practice (ICH-GCP) standards.  
2.6  Ethics and dissemination 
2.6.1 Research ethics approval 
This study will be conducted according to the Declaration of Helsinki and ICH-GCP guidelines. We 
will seek ethics approval from: (1) the Bond University’s Human Research Ethics Committee 
(BUHREC) Bond University, Queensland, Australia; (2) the Medical Ethics Committee of the Faculty 
of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; 
(3) the Directorate-General for Politics and General Government – The Ministry of Internal Affairs 
Republic Indonesia; (4) the Health Agency for the Province of DKI Jakarta; and (5) local research 
committee at each participating hospital.  
2.6.2 Protocol amendments 
Any modifications to the protocol which may impact on the trial process (e.g. the modification of 
study objectives, study design, study population, sample sizes, the procedures, and significant 
administrative sectors), potential benefits and harms/safety of the patients will require a formal 
amendment to the protocol. This amendment will be notified and approved by the funding body 
and the Ethics committee prior to its implementation. Notification is also applied to the health 
authorities in accordance with local regulations. Minor modifications that may not impact on the 
trial process will also be notified and approved by the funding body and will be notified to The 
Ethics Committee. 
2.6.3 Consent  
The participating physician will provide patient information sheet and obtain informed consent 
from the parent(s) or legal guardian of patients, before conducting the recruitment and 
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randomisation process. In obtaining the consent, the investigators will inform the trial process 
including known and potential risks from the trial. As children are considered a vulnerable 
population, those aged younger than 12 years old are considered not competent to give research 
consent and the parent or their legal guardian will make the decision. The parent can also make 
decision for children aged 12 years, however there should be assent from children to participate in 
the research. For parents who are illiterate, we will identify the literacy level before we start the 
informed consent session and will ensure that the language used in the oral and written 
information about the trial, including the written informed consent form, should be 
understandable to the parents and justified to their literacy level. During the process, the 
participating physician will confirm the participant’s understanding of the process of the trial, 
including the risks and benefits. For particularly crucial topics, the participating physician will ask 
several questions related to that topic to ensure they are well-informed and understand. Gaining 
informed consent will be a major topic discussed during training sessions for staff. 
The person who delivers the consent (i.e. participating physician, research assistant) also will 
provide their signatures on the consent form, stating that they have provided information and 
opportunity for potential participants to understand and raise relevant questions according the 
trial. We will ensure that the consent process is free of coercion.  As the participation into the trial 
is voluntary, we will emphasise their rights to withdraw from the trial at any time without any 
consequences, particularly on the quality of their healthcare services. 
2.6.4 Confidentiality 
All information related to the trial will be stored securely at the study site and the research office. 
All participant information will be stored in locked file cabinets in areas with limited access. All data 
collection, including CRFs, test results, and administrative forms will be kept confidential by only 
using coded IDs as identifiers and will be stored separately from all forms and records that contain 
names or other identifiers (e.g. informed consents forms). All databases will be secured with 
limited access using password-protected access systems. All counselling sessions and general to 
specific examinations (e.g. ear, nose, throat examination, otoscopic and tympanometry 
examination) will be conducted in private rooms in the participating physicians’ clinics or hospital. 
All the involved research staffs such as physicians, nurses, and audiologists will be required to sign 
agreements to preserve the confidentiality of all participants.  
The confidentiality of every participant will be maintained and will not be distributed externally 
without the written permission of the participant, except as necessary for trial monitoring by 
national regulatory authorities related to the medical and research safety. 
2.6.5 Declaration of interests 
Respati W. Ranakusuma (RWR) has nothing to disclose.  
Amanda McCullough (AMC) has nothing to disclose. 
Elaine M. Beller (EMB) has nothing to disclose. 
Christopher Del Mar (CDM) has nothing to disclose. 
Eka Dian Safitri (EDS) has nothing to disclose. 
Yupitri Pitoyo (YPO)has nothing to disclose.  
Widyaningsih (WID) has nothing to disclose. 
Arie Sulistyowati (ARS) has nothing to disclose. 
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Sudigdo Sastroasmoro (SSO) has nothing to disclose. 
 
2.6.6   Access to data 
The Principal Investigator will be given access to the cleaned data sets. She will also have direct 
access to each sites’ data sets and by request. Project data sets will be secured using password. 
To ensure confidentiality, data dispersed to project team members will be blinded of any 
identifying participant information. 
2.6.7 Ancillary and post-trial care 
Short-term corticosteroids are very unlikely to have harm outside those we will be measuring. 
However, we will responsible for the adverse effects that occurring from the trial drug during the 
trial (immediate) and post-trial (ancillary care) related to trial drug. The compensation will include 
the treatment cost relevant with the trial drug, such as the consultation visit, additional 
examinations, and treatment (e.g. medicine, hospitalization cost). Due to other potential 
concurrent treatments within the drug trial, there will be robust review and analysis process to 
conclude the cause of adverse events. Participating physicians will explain the procedure for the 
management of adverse effects of trial drug during the process of consent approval before 
entering the trial. We will also include this information on the patient symptom diary, including the 
24-hour emergency call and list of recommended healthcare providers.  
2.6.8 Dissemination policy 
2.6.8.1 Trial results 
Trial results, either statistically significant or non-significant, and other components of the trial 
(literature review, survey study, pilot study, etc.) will be reported in a journal manuscript after 
being distributed to all the principal investigators to be reviewed. 
2.6.8.2 Authorship 
The authorships and contributions of this trial will be acknowledged on the protocol, manuscript, 
and the report. Before the publication in medical journal or paper presentation, the principal 
investigators (PIs) will provide written consent of their acknowledgment and contribution in the 
reported trial. 
• Respati W Ranakusuma contributes in: (1) designing and developing the protocol; (2) 
conducting the trial; and (3) interpreting and reporting the trial in the final trial report and 
manuscript for publication. 
• Amanda McCullough contributes in: (1) the protocol development (study design and 
methods); (2) interpreting the results; and (3) the writing process of the final trial report 
and manuscript for publication. 
• Elaine M Beller contributes in: (1) the protocol development (study design, methods, and 
statistics); (2) interpreting the results; and (3) the writing process of the final trial report 
and manuscript for publication. 
• Chris Del Mar contributes in: (1) the protocol development (study design, methods, and 
statistics), and (2) the writing process of the final trial report and manuscript for 
publication  
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• Sudigdo Sastroasmoro contributes in: (1) supervising the conduct of the trial in Indonesia; 
(2) interpreting the result; and (3) the writing process of the final trial report and 
manuscript for publication. 
• Eka Dian Safitri contributes in: (1) developing the mechanistic study using tympanometry; 
(2) providing training related to using and interpreting tympanometry to physicians, nurses, 
and tympanometry technicians; (3) interpreting the tympanometry findings; and (4) 
reviewing the final study report and manuscript for publication 
• Yupitri Pitoyo contributes in: (1) recruiting secondary and tertiary healthcare centres 
including the physicians and nurses; (2) interpreting the tympanometry findings; and (3) 
reviewing the final study report and manuscript for publication 
• Widyaningsih contributes in: (1) submitting a research ethics application to the Medical 
Research Ethics Committee in Indonesia; (2) submitting clinical trial permits to Indonesian 
institutions; (3) supporting the data collection and management; and (4) reviewing the 
final study report and manuscript for publication 
• Arie Sulistyowati contributes in: (1) providing advice and expertise in terms of paediatric 
patients; (2) supporting the data analysis; and (3) reviewing the final study report and 
manuscript for publication 
 
2.6.8.3 Reproducible research 
We will make the full protocol of this study to be publicly available to maintain its transparency and 
reproducibility. This full protocol will include detailed information regarding the study, particularly 
on study design and conduct that not are commonly include in the published protocol or 
information description in clinical trial registry. We will register the protocol into trial registry such 
as the Indonesia registry web portal (https://www.ina-registry.org/) and Australian New Zealand 
Clinical Trials Registry (http://www.anzctr.org.au/). We also will publish the results of this study in 
relevant medical journal as two separate papers as the following: (1) results of the pilot study and 
(2) results of the mechanistic sub-study. If necessary, we will include the anonymised participant-
level dataset in its appendix or online.  Unpublished outcomes will be reported in the full trial 
report that will be linked to the published study.  
APPENDICES 
Appendix 1. Flow chart of patient during the baseline and other visits 
Appendix 2. Patient information and consent form 
Appendix 3. Case report forms 
Appendix 4. Study recruitment log book 
Appendix 5. Patient symptom diary 
Appendix 6. Product (Lupred®) information summary 
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Appendix 1. Patient flow chart 
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recruitment log book, CRFs) to 
the physician 
 • Identification adverse effects 
and complications 
• Outcomes assessment using CRF 
and otoscope 
• Checking the symptom diary 
• Checking and interpreting the 
tympanometry findings 
• Checking the additional 
medication  
Physician 
• Checking the completion of study 
document 
• Identification adverse effects and 
complications 
• Checking the symptom diary 
• Checking the number of study 
medication, whether they will be 
available for the next two days 
• Completing the follow-up 
reminder card 
• Collecting the first mini-booklet of 
symptom diary and provide the 
second mini booklet at Visit-1 
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Other visits (Visit-1 to Visit-4) 
Attending Nurse 
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height, body temperature, and 
blood pressure  
• Preparing and handing over the 
case report form (CRFs) to the 
appointed nurse 
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PARTICIPANT INFORMATION SHEET AND CONSENT FORM 
 
Oral prednisolone for acute otitis media in children: a pilot pragmatic randomised open-label single-
blind controlled study (OPAL study) 
[Steroids for middle ear infection in children] 
 
Invitation 
You are invited to participate in a research study into the use of steroids (prednisolone) or an anti-inflammatory 
drug for middle ear infection in children.  
The study is being conducted by Dr.  Respati W. Ranakusuma, an otorhinolaryngologists and a researcher at the 
Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit Dr. Cipto Mangunkusumo Hospital–Faculty of 
Medicine Universitas Indonesia. This is part of an international collaborative study between CEEBM CMH-FMUI and 
the Centre for Research in Evidence-Based Practice (CREBP), Faculty of Health Sciences and Medicine Bond 
University, Queensland, Australia.  
Before you decide whether or not you wish to participate in this study, it is important for you to understand why 
the research is being done and what it will involve. Please take the time to read the following information carefully 
and discuss it with others if you wish. 
1. What is the purpose of this study? 
The purpose is to investigate whether steroids, as an alternative treatment, will reduce ear pain and other 
symptoms in children with acute or recent (less than 48 hours) middle ear infection. This study is part of a 
doctoral project at the CREBP Bond University, Queensland, Australia. As this is a pilot study, we also want to 
know your experience during the study. For example, the obstacles you found in giving the steroid to your 
child or completing the symptom diary daily.  
 
2. Why have my child and I been invited to participate in this study? 
Your child and you have been invited to participate in this study because your child age ranges between six 
months to 12 years and having symptoms and signs of acute middle ear infection, such as ear pain in the past 
48 hours, or holding or tugging her/his ear more frequently, more irritable, show lack of playfulness and/sleep 
in a young age (baby). If visible, from the ear examination, the ear drum(s) will show redness or yellowish, 
bulging, or discharge.  
 
3. What does participation in this study involve? 
If you agree to participate in this study, your physician will ask you more questions regarding the history of 
your child’s previous infection, allergy, and the severity of the symptoms (e.g. ear pain, fever, disruption of 
daily activities). As only your child and you as the parents know the best of how severe the symptoms are, we 
will ask you to show the severity of the symptoms using two tools. The first tool is called visual analogue scale. 
It is a 10-cm horizontal line, whereas the left end of the line represents ‘no pain’ and the right end represents 
‘the most painful’. We will ask you to draw a vertical line across this line at the point that represents how bad 
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the symptom that your child has been experiencing. The second tool is called acute otitis media – the severity 
of symptoms (AOM-SOS) that consisted of seven questions. You will be asked to choose one of the severity 
scales (‘no’, ‘a little’, or ‘a lot’) that corresponds to seven particular symptoms (i.e. tugging/rubbing the ears, 
crying more, more irritable, lack of sleep, playfulness, and appetite, and fever). Whilst you providing your best 
answers using these tools, your physician will also teach you to complete the symptom diary that consists 
similar questions that your physician has been obtained from you. This will help you in completing the 
symptom diary during the study which will help us to investigate the effect of the steroid in improving your 
child’ ear pain and other symptoms due to acute middle ear infection. After that, your attending nurse and 
physician will examine your child’s general status (i.e. body weight, height, body temperature, blood pressure) 
and ear-nose-throat status. From there, we will check the condition of your child’s middle ear using a tool 
called tympanogram. This is a painless procedure to detect whether there is a fluid in your child’s middle ear. 
From there, you will meet a nurse who will allocate your child whether she/he will receive the steroid 
(treatment group) or not receive the steroid (control group). Your child has 50% chance for being allocated to 
receive the steroid. We will do this process randomly where no one can predict in which group your child will 
be allocated to. This process will require 15 to 30 minutes because the nurse has to access this information 
from the website or calling the research team. If your child receives the steroid, she will give you a prescription 
for your study medication. You will give the prescription to the pharmacy at that hospital. The pharmacist will 
prepare your study medication by crushing the tablets, mixing it with sweeteners, and packing the study 
medication in a daily paper-package (you will receive five daily packages). The nurse will give an instruction to 
give a medication to your child every morning, once daily for 10 to 30 milligrams depends on your child’s age, 
for five days. She will tell you what to do if your child vomits after taking a drug or experiences any effects. 
She also will ask you to keep the confidentiality of the treatment that your child receives from your physician 
and audiologist. The whole process will require 60 to 120 minutes depends on the cooperativity of your child. 
We will ask you to come after two and seven days after your visit. On these visits, we will investigate whether 
the steroid will help reducing the ear pain and other relevant symptoms and whether it give unfavorable 
effects. During these visits, we will ask you to bring the symptom diary and the left-over drug so we can check 
your child’ condition. We also will ask you to come after one and three months to see whether during these 
time, your child experiences a new episode of acute middle ear infection. After these four additional visit after 
this visit, we consider that your child has completed the study.  
 
Any information obtained in connection with this research project that can identify you child and you will 
remain confidential. If you agree to participate in this study, you will be asked to sign the Participant Consent 
Form. 
 
4. What if I do not want to take part in this study, or if I want to withdraw later? 
Participation in this study is voluntary. It is completely up to you or both of you and your child if you child aged 
12 years, whether or not you participate. If you decide not to participate, it will not affect the treatment your 
child receive now or in the future. Whatever your decision, it will not affect your relationship with the staff 
caring for your child. However, it may not be possible to withdraw your data from the study results if these 
have already had your identifying details removed. 
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5. How is this study being paid for? 
The study is being for by Dr. Respati W. Ranakusuma, ORL which is supported by self-funded.  
 
6. Are there risks to my child in taking part in this study? 
The foreseeable risks in taking part in this study are the bitter taste of prednisolone tablets and some potential 
side effects of the steroids. Pharmacist will mix the crushed tablets with sweeteners and we will also provide 
honey to be mixed with the medication. The common potential side effects of steroids are nausea, vomiting, 
abdominal pain, nervousness, mood swings, headache, increased blood sugar and blood pressure, weight gain, 
etc. Growth disorder could be one of the side effects however it usually occurs on the longer use of the 
steroids. We cannot predict whether your child will have one of these effects or not at all.  
 
You may feel that the whole process of this study will take longer time compared to usual doctor visit due to 
collection of information and additional examination that will be conducted in this study. It may add some 
work for you to complete a symptom diary daily for the next 14 days. However, this is very important to be 
able to assess the day-by-day progress of your child with or without the steroids. Other potential 
inconveniences that your child and you may experience from this study are during the tympanometry 
examination and the follow-up visits (four additional visits are required in this study). Even though 
tympanometry is a painless procedure, we expect that your child will sit still for at least 10 minutes where 
she/he will hear a ringing sound and a pressure sensation during the process.   
 
7. What happens if my child suffers injury or complications as a result of the study? 
If you require treatment or suffer loss as a result of the negligence of any of the parties involved in the study, 
you may be entitled to compensation; the cost of your treatment would have to be paid out of such 
compensation. 
 
8. Will I benefit from the study? 
This study aims to further medical knowledge and may improve future treatment of acute middle ear infection 
(especially in mild cases where usually antibiotics are being prescribed), however, this study may not directly 
benefit you.  
 
9. Will taking part in this study cost me anything, and will I be paid? 
Participation in this study will not cost you anything, nor you will be paid. You will be reimbursed for reasonable 
travel expenses to the amount of $15. We also will cover the registration and consultation fees for the 
additional four follow-up visits to the hospital. 
 
10. How will my confidentiality be protected? 
Any identifiable information that is collected about your child in connection with this study will remain 
confidential and will be disclosed only with your permission, or except as required by law. Only the researchers 
named above will have access to your details and results that will be held securely at the CEEBM CMH – FMUI.  
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11. What happens with the results? 
If you give us your permission by signing the consent document, we plan to discuss/publish the results for the 
monitoring and safety purposes (by the Human Research Ethics Committee, data monitoring and auditing 
committee, if necessary) and for publication in peer-reviewed journals or presentation at conferences or other 
professional forums. In any publication, information will be provided in such a way that you cannot be 
identified.  
 
12. What should I do if I want to discuss this study further before I decide? 
When you have read this information, your physician as one of the researchers, will discuss it with you and any 
queries you may have. If you would like to know more at any stage, please do not hesitate to contact Dr. 
Respati W. Ranakusuma, ORL by phone on +62 8111 012 185.  
 
13. Who should I contact if I have concerns about the conduct of this study? 
This study has been approved by the Medical Ethics Committee FMUI and the Bond University’s Human 
Research Ethics Committee (BUHREC) Bond University, Queensland, Australia. Any person with concerns or 
complaints about the conduct of this study should contact Dr. Respati W. Ranakusuma on +62 8111 012 185, or 
email OPAL.study@bond.edu.au.  
 
The conduct of this study at (please circle the answer that representing your hospital) the Dr Cipto 
Mangunkusumo Hospital / Persahabatan Hospital / Gatot Subroto Army Hospital / Antam Medika Hospital / 
Cempaka Putih Islamic Hospital / Proklamasi ENT Hospital / Hermina Bekasi Hospital, has been authorised by 
the the Health Agency for the Province of DKI Jakarta and the Directorate-General for Politics and General 
Government – The Ministry of Internal Affairs Republic Indonesia.  
 
Thank you for taking the time to consider this study. If you wish to take part in, please sign the attached 
consent form. This information sheet is for you to keep 
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CONSENT FORM 
 
Oral prednisolone for acute otitis media in children: a pilot pragmatic, randomised, open-label, single-
blind study (OPAL study) 
[Steroids for middle ear infection in children] 
 
1. I, _________________________________________________________________________________ 
of ________________________________________________________________________________ 
agree to participate in the study described in the participant information statement set attached to this 
form. 
2. I acknowledge that I have read the participant information statement, which explains why my child has 
been selected, the aims of the study, and the nature and the possible risks of the investigation, and the 
statement has been explained to me to my satisfaction. 
3. Before signing this consent form, I have been given the opportunity of asking any questions relating to 
any possible physical and mental harm my child might suffer as a result of my child participation and I 
have received satisfactory answers. 
4. I understand that I can withdraw from the study at any time without prejudice to my relationship to my 
physician and the _______________________________________ Hospital. 
5. I agree that research data gathered from the results of the study may be published, provided that I 
cannot be identified. 
6. I understand that I have any questions relating to my participation in this research, I may contact Dr. 
Respati W. Ranakusuma, ORL on telephone +62 8111 012 185, who will be happy to answer them. 
7. I acknowledge receipt of a copy of this Consent Form and the Participation Information Statement. 
Complaints may be directed to the OPAL Study Support Office at the Clinical Epidemiology and Evidence-Based 
Medicine Unit, Dr Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia, Building H Dr Cipto 
Mangunkusumo Hospital, Diponegoro 71, Jakarta 10430, Indonesia (phone +62 21 316 1760, email 
OPAL.study@bond.edu.au). 
Signature of participant or the 
parent 
 
_____________________________ 
 
Name 
 
 
_____________________________ 
Date  
 
 
_____________________________ 
Signature of witness 
 
 
_____________________________ 
 
Name 
 
 
_____________________________ 
Date  
 
 
_____________________________ 
Signature of investigator 
 
_____________________________ 
 
Name 
 
_____________________________ 
Date  
 
_____________________________ 
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REVOCATION OF CONSENT 
 
Oral prednisolone for acute otitis media in children: a pilot pragmatic, randomised, open-label, single-
blind study (OPAL study) 
[Steroids for middle ear infection in children] 
 
 
I hereby wish to WITHDRAW my consent to participate in the study described above and understand that such 
withdrawal WILL NOT jeopardise any treatment or my relationship with the ___________________________ 
hospital or my medical attendants. 
 
 
Signature of participant or the 
parent 
 
_____________________________ 
 
Name 
 
 
_____________________________ 
Date  
 
 
_____________________________ 
 
The section for Revocation of Consent should be forwarded to Dr. Respati W. Ranakusuma, ORL at the Clinical 
Epidemiology and Evidence-Based Medicine Unit, Dr Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas 
Indonesia. 
 
 
 
 
 
 
 
For each question, please tick () your answer in the O or write you answer on ______ 
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                                                                                                                         REGISTRATION ID  
CRF02. STUDY REGISTRATION FORM 
PATIENT’S INFORMATION 
Patient’s name ___________________________________________________________ 
Place and date of birth __________________  ,  _______________________________________ 
Education O None                                     O Pre-school               O Elementary school       
O Middle junior school         
School attending hours O 1x / week                     from: _____  am/pm to _____ pm/pm 
O 2x / week                    from: _____  am/pm to _____ pm/pm 
O 3x / week                    from: _____  am/pm to _____ pm/pm 
O 4x / week                    from: _____  am/pm to _____ pm/pm  
O ≥ 5x / week                 from: _____  am/pm to _____ pm/pm                                      
Home address ___________________________________________________________ 
___________________________________________________________ 
___________________________________________________________ 
Home telephone number ___________________________________________________________ 
Home fax number ___________________________________________________________ 
Health service payment O self-payment                      O Private insurance         O Company insurance       
O Government health coverage (BPJS)                      O Other: __________       
Weight: ______ kg Height: _______ cm Temperature: _____ °C Blood pressure: ____________ mmHg 
PARENTS’ INFORMATION 
FATHER 
Father’s name ____________________________________________________________ 
Place and date of birth __________________ 
Education O None                        O Elementary school              O Middle junior school         
O High school         O Bachelor                          O Masters  
O Doctoral 
Occupation O None                        O Government employee     O Private employee         
For each question, please tick () your answer in the O or write you answer on ______ 
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O Entrepreneur      O Other: __________       
Home address O Same with patient’s address            
O Different address: __________________________________________ 
____________________________________________________________            
Home telephone number O Same with patient’s telephone number          
O Different number: __________________________________________ 
Mobile number ____________________________________________________________ 
Email address ______ ______________________________________________________ 
MOTHER 
Mother’s name ____________________________________________________________ 
Place and date of birth ____________________________________________________________ 
Education O None                        O Elementary school              O Middle junior school         
O High school         O Bachelor                          O Masters  
O Doctoral 
Occupation O None                        O Government employee     O Private employee         
O Entrepreneur      O Other: __________       
Home address O Same with patient’s address            
O Different address: __________________________________________ 
____________________________________________________________            
Home telephone number O Same with patient’s telephone number          
O Different number: __________________________________________ 
Mobile number ____________________________________________________________ 
Email address ____________________________________________________________ 
Date : |___|___| – |___|___| – 201 |___|                                                       Registration ID 
 
For each question, please tick (V) your answer in the circle 
Eligibility form. Version 1.1. Date 22 August 2017 
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 Doctor ID   : |___|___|___|                                          Hospital ID : |___|___|    
    
 
 
  
 
 
 
 
 
 
 
  
Is this child eligible for the trial? 
At least one ‘NO’ at the inclusion criteria, OR 
At least one ‘YES’ at the exclusion criteria 
Not eligible, then EXCLUDE 
All ‘YES’ at the inclusion criteria, AND 
All ‘NO’ at the exclusion criteria 
Eligible, then INCLUDE 
Do they have these following symptoms? 
Moderate to severe symptoms, locally or systemically (moderate to severe ear 
pain, fever ≥39°C, complications) OYes  ONo 
Aged younger than 2 years with bilateral acute otitis media OYes  ONo   
With perforation of tympanic membrane(s) OYes  ONo   
If visible, otoscopic finding shows moderate to severe bulging and/or yellowish 
purulent tympanic membrane(s) 
OYes  ONo  
At least one ‘YES’ 
All ‘NO’ MILD AOM SEVERE AOM 
INCLUSION CRITERIA 
Definite or suspected acute 
otitis media (AOM) 
OR 
 
Were you able to confirm 
otoscopically? 
                  OYes  ONo    
OYes  ONo     
            
 
 
 
Aged 6 months to 12 years OYes  ONo   
Available for follow-up visits OYes  ONo   
Obtaining the CONSENT NOT giving CONSENT EXCLUDE 
Giving CONSENT INCLUSION 
EXCLUSION CRITERIA 
Major medical conditions (e.g. heart failure, renal insufficiency, 
DM, peptic ulcers) OYes  ONo   
Immunocompromised (e.g. cancer treatment, HIV) OYes  ONo   
Congenital malformation/syndromes (e.g. cleft palate) OYes  ONo 
Ventilation tube(s) OYes  ONo   
Exposed to persons with varicella/active Zoster infection in the 
past 3 weeks with no prior history of varicella infection/ 
immunisation 
OYes  ONo  
Has taken oral/injection/topical steroids in the past 4 weeks OYes  ONo 
Has taken antibiotics in the past 2 weeks OYes  ONo   
Hypersensitive to prednisolone or other steroids OYes  ONo   
OYes ONo   With high risk of strongyloidiasis infection 
CRF03 – ELIGIBILITY FORM 
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 CRF04 – BASELINE INFORMATION FORM 
1     Did (do) you breastfeed your child?               O Yes                      O No 
       If ‘ YES’, until the age of                        O ≤ 2 months        O > 2 – 6 months       O > 6 months       
2 Does your child attend a day-care               O Yes                      O No 
How many days in a week?                    O ≤ 2 days               O > 2 days                                                                                                  
3     Have your child had a  pneumococcus vaccine (PCV)?                  O Yes         O No      O Do not know 
                                                                                                                           How many times: __________  times 
4     Have your child had an influenzae vaccine?                                    O Yes         O No      O Do not know 
                                                                                                                           How many times: __________  times 
5   How many episodes of recurrent acute respiratory infection (runny nose, cough, sore throat, fever) in the past 
year?                     O ≤ 3 episodes                             O > 3 episodes to 6 episodes                     O > 6 episodes 
6    Did your child have a history of 3 or more episodes of ear infection (ear pain, ear discharge, diarrhoea, or 
vomiting) during the past 12 months?                   O Yes                        O No 
7     At what age did the first episode of ear infection start? 
    O ≤ 6 months         O > 6 to 12 months      O >12 to 24 months     O > 2 to 5 years    O > 5 years 
8     Does your child have one of the following disorders:    
      O Bronchial asthma                                  
    O Allergic rhinitis                                 
    O Family history of atopic disorders   
    O None of above  
9     Number of children (including the patient) who live in the house                  ____________  children 
10   Number of persons who smoke at home                                                                ____________  person(s) 
                                                                                             Registration ID 
 
For each question, please tick () your answer on the circles or write you answer on ______ 
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CRF05 – OUTCOME FORM   
Baseline Visit (Day-0) : |___|___| – |___|___| – 20 |___|___| 
Complications (for Physician)              
1 Does your child experience discharge from the ear(s)?                                                                             O Yes   O No 
2 Does your child experience intense ear pain and pain behind the ear?                                O Yes   O No 
3 Does your child experience swelling/bulging/ or redness/tenderness of the ear(s)?               O Yes   O No                                                                                        
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?                  O Yes   O No                                                                                                       
General and ENT examination (for Nurse and Physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp. ________ °C 5.4 BP   _____ / _____ mmHg 
6 Nose        O Normal      O Oedema       O Hyperaemic      O Livid         O Serous discharge      O Mucoid discharge 
7 Tonsils    O Normal      O Hyperaemic   O Detritus           O Tonsil(s) T1   O Tonsil(s) T2           O Tonsil(s) T3-4                       
8 Pharynx  O Normal      O Hyperaemic   O Oedema         O Granules        O Post nasal drip (PND)        
9 Otoscopic examination 
   O Normal                 O Cerumen        O Erythema        O Air fluid level        O Complete effusion        O Opacification                  
  O Mild bulging       O Moderate to severe bulging (bulging rounded)       O Bulla                                   O Perforation 
10  Medicines that have been taken before the baseline visit  (please circle your dose measurement)                                                                
1. ______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
2. ______________________   Dose    :  _____mg perBW kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
3. ______________________   Dose    :  _____mg perBW kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
4. ______________________   Dose    :  _____mg perBW kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
5. ______________________   Dose    :  _____mg perBW kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
Medicines prescribed by physician (you) at the baseline visit   
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
1. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
2. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
3. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
4. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
5. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
Outcome: Symptoms (for patients and the parents. Physician will help them to complete these in the 
symptom diary)  
11 Please place a vertical line across the available horizontal line that best describes your or your child’s pain 
during the past 24 hours? 
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For each question, please tick () your answer on the circles or write you answer on ______ 
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12 We are interest finding out how your child has been doing. For each question, please place a checkmark (V) in 
the circle corresponding to your child’s symptoms. Please answer all questions. 
12.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s)   
         more than usual? 
O No     O A little     O A lot  
12.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot       
12.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot     
12.4  Over the past 12 h, has your child been having more difficulty sleeping than   
          usual? 
O No     O A little     O A lot         
12.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot      
12.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
12.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot      
13  Tympanometry examination (for Audiologist and interpreted by Physician) 
  O Cannot be performed. Reason: ___________________________________________________________________ 
  Tympanogram types (will be completed by physician)          [R]  Type  ______ / [L]  Type  ______       
  Ear canal vol (ECV)                  [R]  ________  mL   / [L]  ________  mL           
  Static acoustic admittance   [R] _______  mL      / [L] _______ mL             
  Compliance (SC)                      [R]  ________  mL   / [L]  ________  mL          
  Middle Ear Pressure or TPP  [R] _______  daPa  / [L] ______ daPa 
  Gradient or TW                         [R] _______  daPa  / [L] ______ daPa 
Put the copy of tympanometry copies here 
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For each question, please tick () your answer on the circles or write you answer on ______ 
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Follow-up Visit – 1 (Day – 3) : |___|___| – |___|___| – 20 |___|___| 
Complications (for Physician)              
1 Does your child experience discharge from the ear(s)?                                                                             O Yes   O No 
2 Does your child experience intense ear pain and pain behind the ear?                                O Yes   O No 
3 Does your child experience swelling/bulging/ or redness/tenderness of the ear(s)?               O Yes   O No                                                                                        
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?                  O Yes   O No                                                                                                       
General and ENT examination (for Nurse and Physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp. ________ °C 5.4 BP   _____ / _____ mmHg 
6 Nose        O Normal      O Oedema       O Hyperaemic      O Livid         O Serous discharge      O Mucoid discharge 
7 Tonsils    O Normal      O Hyperaemic   O Detritus           O Tonsil(s) T1   O Tonsil(s) T2           O Tonsil(s) T3-4                       
8 Pharynx  O Normal      O Hyperaemic   O Oedema         O Granules        O Post nasal drip (PND)        
9 Otoscopic examination 
   O Normal                 O Cerumen        O Erythema        O Air fluid level        O Complete effusion        O Opacification                  
  O Mild bulging       O Moderate to severe bulging (bulging rounded)       O Bulla                                   O Perforation 
10  Medicines prescribed by you (Physician) on today visit (please circle your dose measurement)                                                                                                                                                                           
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
1. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
2. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
3. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
4. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
5. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
11  Medicines NOT prescribed by you or from over-the-counter or others (e.g. other physician, drug store)  
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
1. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
2. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
3. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
4. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
5. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
Outcome: Symptoms (for Patients) 
12 Please place a vertical line across the available horizontal line that best describes your or your child’s pain 
during the past 24 hours? 
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For each question, please tick () your answer on the circles or write you answer on ______ 
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13. We are interest finding out how your child has been doing. For each question, please place a checkmark (V) in 
the circle corresponding to your child’s symptoms. Please answer all questions. 
13.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s)   
         more than usual? 
O No     O A little     O A lot  
13.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot       
13.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot     
13.4  Over the past 12 h, has your child been having more difficulty sleeping than   
          usual? 
O No     O A little     O A lot         
13.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot      
13.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
13.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot      
14 Side effects    
Does your child have these complaints after taking the medicine 
 14.1  Increased appetite O Yes     O No   14.8   Drowsiness  O Yes     O No   
 14.2  Increased urine amount O Yes     O No   14.9   Anxiety/distractibility/mood swing O Yes     O No   
 14.3  Weight gain O Yes     O No   14.10  Headache O Yes     O No   
 14.4   Gastritis/abdominal pain O Yes     O No   14.11  Skin rash or diaper rash O Yes     O No   
 14.5   Nausea O Yes     O No   14.12  Candidiasis O Yes     O No   
 14.6   Vomiting O Yes     O No   14.13  Dry mouth / throat irritation O Yes     O No   
 14.7   Diarrhea O Yes     O No   14.14  Sleep disturbance O Yes     O No   
 Others: ______________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No     Reason: _______________________________ 
_______________________________ Medicine 
prescribed: 
Has your child has been admitted 
to hospital? 
O Yes     O No          Reason: _______________________________ 
Medicine 
prescribed: 
_______________________________ 
Regarding the side effects, your 
action is/are (you may answer 
more than one): 
O Discontinuation of the study drug (prednisolone)     
O Continuation of the study drug 
O Discontinuation of other concomitant drugs as follows: 
1. _____________________                        3.     _____________________ 
2. _____________________                        4.    _____________________ 
The treatment you prescribed 
for the management of side 
effects 
1. _____________________; Dose  ___________;  Frequency  ______  / day                         
2. _____________________; Dose  ___________;  Frequency  ______  / day 
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day                        
Does this child require specific or 
additional tests or examination? 
O No     
O Yes. Please specify with the results: 
1. ___________________________________________________________ 
___________________________________________________________ 
2. ___________________________________________________________ 
___________________________________________________________ 
3. ___________________________________________________________ 
___________________________________________________________ 
                                                                                             Registration ID 
 
For each question, please tick () your answer on the circles or write you answer on ______ 
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Does this child require specific 
or additional treatment or 
medication 
O No     
O Yes. Please specify the treatment: 
1. _____________________; Dose  ___________;  Frequency  ______  / day                         
2. _____________________; Dose  ___________;  Frequency  ______  / day 
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day    
Does this child require a 
hospitalisation? 
O No     
O Yes. Please explain your reasons to hospitalise this child and the treatment   
      will be given 
      Reason: _________________________________________________________ 
                       _________________________________________________________ 
    The treatment:  
1. _____________________; Dose  ___________;  Frequency  ______  / day                         
2. _____________________; Dose  ___________;  Frequency  ______  / day 
3. _____________________; Dose  ___________;  Frequency  ______  / day 
4. _____________________; Dose  ___________;  Frequency  ______  / day    
15   Tympanometry examination (for Audiologist and interpreted by Physician) 
  O Cannot be performed. Reason: ___________________________________________________________________ 
  Tympanogram types (will be completed by physician)          [R]  Type  ______ / [L]  Type  ______       
  Ear canal vol (ECV)                  [R]  ________  mL   / [L]  ________  mL           
  Static acoustic admittance   [R] _______  mL      / [L] _______ mL             
  Compliance (SC)                      [R]  ________  mL   / [L]  ________  mL          
  Middle Ear Pressure or TPP  [R] _______  daPa  / [L] ______ daPa 
  Gradient or TW                         [R] _______  daPa  / [L] ______ daPa 
Put the copy of tympanometry copies here 
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Follow-up Visit – 2 (Day – 7) : |___|___| – |___|___| – 20 |___|___| 
Complications (for Physician) 
1 Does your child experience discharge from the ear(s)?                                                                             O Yes   O No 
2 Does your child experience intense ear pain and pain behind the ear?                                O Yes   O No 
3 Does your child experience swelling/bulging/ or redness/tenderness of the ear(s)?               O Yes   O No                                                                                        
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?                  O Yes   O No                                                                                                       
General and ENT examination (for Nurse and Physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp. ________ °C 5.4 BP   _____ / _____ mmHg 
6 Nose        O Normal      O Oedema       O Hyperaemic      O Livid         O Serous discharge      O Mucoid discharge 
7 Tonsils    O Normal      O Hyperaemic   O Detritus           O Tonsil(s) T1   O Tonsil(s) T2           O Tonsil(s) T3-4                       
8 Pharynx  O Normal      O Hyperaemic   O Oedema         O Granules        O Post nasal drip (PND)        
9 Otoscopic examination 
   O Normal                 O Cerumen        O Erythema        O Air fluid level        O Complete effusion        O Opacification                  
  O Mild bulging       O Moderate to severe bulging (bulging rounded)       O Bulla                                   O Perforation 
10  Medicines prescribed by you (Physician) today visit (please circle your dose measurement)                                                                                                                                                                           
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
1. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
2. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
3. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
4. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
5. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
11  Medicines NOT prescribed by you or from over-the-counter or others (e.g. other physician, drug store) 
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
6. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
7. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
8. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
9. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
10. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
Outcome: Symptoms (for Patients) 
12 Please place a vertical line across the available horizontal line that best describes your or your child’s pain 
during the past 24 hours? 
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For each question, please tick () your answer on the circles or write you answer on ______ 
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13  We are interest finding out how your child has been doing. For each question, please place a checkmark (V) in 
the circle corresponding to your child’s symptoms. Please answer all questions. 
13.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s)   
         more than usual? 
O No     O A little     O A lot  
13.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot       
13.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot     
13.4  Over the past 12 h, has your child been having more difficulty sleeping than   
          usual? 
O No     O A little     O A lot         
13.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot      
13.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
13.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot      
14 Side effects    
Does your child have these complaints after taking the medicine 
 14.1  Increased appetite O Yes     O No   14.8   Drowsiness  O Yes     O No   
 14.2  Increased urine amount O Yes     O No   14.9   Anxiety/distractibility/mood swing O Yes     O No   
 14.3  Weight gain O Yes     O No   14.10  Headache O Yes     O No   
 14.4   Gastritis/abdominal pain O Yes     O No   14.11  Skin rash or diaper rash O Yes     O No   
 14.5   Nausea O Yes     O No   14.12  Candidiasis O Yes     O No   
 14.6   Vomiting O Yes     O No   14.13  Dry mouth / throat irritation O Yes     O No   
 14.7   Diarrhea O Yes     O No   14.14  Sleep disturbance O Yes     O No   
 Others: ______________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No     Reason: _______________________________ 
_______________________________ Medicine 
prescribed: 
Has your child has been admitted 
to hospital? 
O Yes     O No          Reason: _______________________________ 
Medicine 
prescribed: 
_______________________________ 
Regarding the side effects, your 
action is/are (you may answer 
more than one): 
O Discontinuation of the study drug (prednisolone)     
O Continuation of the study drug 
O Discontinuation of other concomitant drugs as follows: 
1. _____________________                        3.     _____________________ 
2. _____________________                        4.    _____________________ 
Does this child require specific or 
additional tests or examination? 
O No     
O Yes. Please specify with the results: 
1. ___________________________________________________________ 
___________________________________________________________ 
2. ___________________________________________________________ 
___________________________________________________________ 
3. ___________________________________________________________ 
___________________________________________________________ 
Does this child require specific 
or additional treatment or 
medication 
O No     
O Yes. Please specify the treatment: 
5. _____________________; Dose  ___________;  Frequency  ______  / day                         
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6. _____________________; Dose  ___________;  Frequency  ______  / day 
7. _____________________; Dose  ___________;  Frequency  ______  / day 
8. _____________________; Dose  ___________;  Frequency  ______  / day    
Does this child require a 
hospitalisation? 
O No     
O Yes. Please explain your reasons to hospitalise this child and the treatment   
      will be given 
      Reason: _________________________________________________________ 
                       _________________________________________________________ 
    The treatment:  
5. _____________________; Dose  ___________;  Frequency  ______  / day                         
6. _____________________; Dose  ___________;  Frequency  ______  / day 
7. _____________________; Dose  ___________;  Frequency  ______  / day 
8. _____________________; Dose  ___________;  Frequency  ______  / day    
15   Tympanometry examination (for Audiologist and interpreted by Physician) 
  O Cannot be performed. Reason: ___________________________________________________________________ 
  Tympanogram types (will be completed by physician)          [R]  Type  ______ / [L]  Type  ______       
  Ear canal vol (ECV)                  [R]  ________  mL   / [L]  ________  mL           
  Static acoustic admittance   [R] _______  mL      / [L] _______ mL             
  Compliance (SC)                      [R]  ________  mL   / [L]  ________  mL          
  Middle Ear Pressure or TPP  [R] _______  daPa  / [L] ______ daPa 
  Gradient or TW                         [R] _______  daPa  / [L] ______ daPa 
Put the copy of tympanometry copies here 
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Follow-up Visit – 3 (Day – 30) : |___|___| – |___|___| – 20 |___|___| 
Outcome: Symptoms (for Patients) 
1 Within the past one month, does your child experience a new 
episode of ear pain with fever or runny nose, cough, or sore 
throat? Please write your answer and circle the most appropriate 
time  
 
O Yes            O No 
When?           ________  days / weeks ago  
How long?   ________  days / weeks  
2 Please place a vertical line across the available horizontal line that best describes your or your child’s pain 
during the past 24 hours? (if applicable) 
 
 
 
           
 
 
3.  We are interest finding out how your child has been doing. For each question, please place a checkmark (V) in 
the circle corresponding to your child’s symptoms. Please answer all questions (if applicable). 
3.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s)   
         more than usual? 
O No     O A little     O A lot  
3.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot       
3.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot     
3.4  Over the past 12 h, has your child been having more difficulty sleeping than   
          usual? 
O No     O A little     O A lot         
3.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot      
3.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
3.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot      
General and ENT examination (for Nurse and Physician)  
4.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp. ________ °C 5.4 BP   _____ / _____ mmHg 
5 Nose        O Normal      O Oedema       O Hyperaemic      O Livid         O Serous discharge      O Mucoid discharge 
6 Tonsils    O Normal      O Hyperaemic   O Detritus           O Tonsil(s) T1   O Tonsil(s) T2           O Tonsil(s) T3-4                       
7 Pharynx  O Normal      O Hyperaemic   O Oedema         O Granules        O Post nasal drip (PND)        
8 Otoscopic examination 
   O Normal                 O Cerumen        O Erythema        O Air fluid level        O Complete effusion        O Opacification                  
  O Mild bulging       O Moderate to severe bulging (bulging rounded)       O Bulla                                   O Perforation 
9   Tympanometry examination (for Audiologist and interpreted by Physician) 
  O Cannot be performed. Reason: ___________________________________________________________________ 
  Tympanogram types (will be completed by physician)          [R]  Type  ______ / [L]  Type  ______       
  Ear canal vol (ECV)                  [R]  ________  mL   / [L]  ________  mL           
  Static acoustic admittance   [R] _______  mL      / [L] _______ mL             
  Compliance (SC)                      [R]  ________  mL   / [L]  ________  mL          
  Middle Ear Pressure or TPP  [R] _______  daPa  / [L] ______ daPa 
  Gradient or TW                         [R] _______  daPa  / [L] ______ daPa 
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Follow-up Visit – 4 (Day – 90) : |___|___| – |___|___| – 20 |__|__| 
Outcome: Symptoms (for Patients) 
1 Within the past one month, does your child experience a new 
episode of ear pain with fever or runny nose, cough, or sore 
throat? Please write your answer and circle the most appropriate 
time  
O Yes            O No 
When?           ________  days / weeks ago  
How long?   ________  days / weeks 
2 Please place a vertical line across the available horizontal line that best describes your or your child’s pain 
during the past 24 hours? (if applicable) 
 
 
 
           
 
 
3  We are interest finding out how your child has been doing. For each question, please place a checkmark (V) in 
the circle corresponding to your child’s symptoms. Please answer all questions (if applicable). 
3.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s)   
         more than usual? 
O No     O A little     O A lot  
3.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot       
3.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot     
3.4  Over the past 12 h, has your child been having more difficulty sleeping than   
          usual? 
O No     O A little     O A lot         
3.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot      
3.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
3.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot      
General and ENT examination (for Nurse and Physician) 
4.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp. ________ °C 5.4 BP   _____ / _____ mmHg 
5 Nose        O Normal      O Oedema       O Hyperaemic      O Livid         O Serous discharge      O Mucoid discharge 
6 Tonsils    O Normal      O Hyperaemic   O Detritus           O Tonsil(s) T1   O Tonsil(s) T2           O Tonsil(s) T3-4                       
7 Pharynx  O Normal      O Hyperaemic   O Oedema         O Granules        O Post nasal drip (PND)        
8 Otoscopic examination 
   O Normal                 O Cerumen        O Erythema        O Air fluid level        O Complete effusion        O Opacification                  
  O Mild bulging       O Moderate to severe bulging (bulging rounded)       O Bulla                                   O Perforation 
9   Tympanometry examination (for Audiologist and interpreted by Physician) 
  O Cannot be performed. Reason: ___________________________________________________________________ 
  Tympanogram types (will be completed by physician)          [R]  Type  ______ / [L]  Type  ______       
  Ear canal vol (ECV)                  [R]  ________  mL   / [L]  ________  mL           
  Static acoustic admittance   [R] _______  mL      / [L] _______ mL             
  Compliance (SC)                      [R]  ________  mL   / [L]  ________  mL          
  Middle Ear Pressure or TPP  [R] _______  daPa  / [L] ______ daPa 
  Gradient or TW                         [R] _______  daPa  / [L] ______ daPa 
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Additional Visit : |___|___| – |___|___| – 20 |___|___| 
Complications (for Physician)              
1 Does your child experience discharge from the ear(s)?                                                                             O Yes   O No 
2 Does your child experience intense ear pain and pain behind the ear?                                O Yes   O No 
3 Does your child experience swelling/bulging/ or redness/tenderness of the ear(s)?               O Yes   O No                                                                                        
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?                  O Yes   O No                                                                                                       
General and ENT examination (for Nurse and Physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp. ________ °C 5.4 BP   _____ / _____ mmHg 
6 Nose        O Normal      O Oedema       O Hyperaemic      O Livid         O Serous discharge      O Mucoid discharge 
7 Tonsils    O Normal      O Hyperaemic   O Detritus           O Tonsil(s) T1   O Tonsil(s) T2           O Tonsil(s) T3-4                       
8 Pharynx  O Normal      O Hyperaemic   O Oedema         O Granules        O Post nasal drip (PND)        
9 Otoscopic examination 
   O Normal                 O Cerumen        O Erythema        O Air fluid level        O Complete effusion        O Opacification                  
  O Mild bulging       O Moderate to severe bulging (bulging rounded)       O Bulla                                   O Perforation 
10  Medicines prescribed by you (Physician) on today visit (please circle your dose measurement)                                                                                                                                                                           
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
6. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
7. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
8. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
9. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
10. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
11  Medicines NOT prescribed by you or from over-the-counter or others (e.g. other physician, drug store)  
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
11. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
12. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
13. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
14. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
15. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
Outcome: Symptoms (for Patients) 
13 Please place a vertical line across the available horizontal line that best describes your or your child’s pain 
during the past 24 hours? 
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13. We are interest finding out how your child has been doing. For each question, please place a checkmark (V) in 
the circle corresponding to your child’s symptoms. Please answer all questions. 
13.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s)   
         more than usual? 
O No     O A little     O A lot  
13.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot       
13.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot     
13.4  Over the past 12 h, has your child been having more difficulty sleeping than   
          usual? 
O No     O A little     O A lot         
13.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot      
13.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
13.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot      
14 Side effects    
Does your child have these complaints after taking the medicine 
 14.1  Increased appetite O Yes     O No   14.8   Drowsiness  O Yes     O No   
 14.2  Increased urine amount O Yes     O No   14.9   Anxiety/distractibility/mood swing O Yes     O No   
 14.3  Weight gain O Yes     O No   14.10  Headache O Yes     O No   
 14.4   Gastritis/abdominal pain O Yes     O No   14.11  Skin rash or diaper rash O Yes     O No   
 14.5   Nausea O Yes     O No   14.12  Candidiasis O Yes     O No   
 14.6   Vomiting O Yes     O No   14.13  Dry mouth / throat irritation O Yes     O No   
 14.7   Diarrhea O Yes     O No   14.14  Sleep disturbance O Yes     O No   
 Others: ______________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No     Reason: _______________________________ 
_______________________________ Medicine 
prescribed: 
Has your child has been admitted 
to hospital? 
O Yes     O No          Reason: _______________________________ 
Medicine 
prescribed: 
_______________________________ 
Regarding the side effects, your 
action is/are (you may answer 
more than one): 
O Discontinuation of the study drug (prednisolone)     
O Continuation of the study drug 
O Discontinuation of other concomitant drugs as follows: 
1. _____________________                        3.     _____________________ 
2. _____________________                        4.    _____________________ 
The treatment you prescribed 
for the management of side 
effects 
5. _____________________; Dose  ___________;  Frequency  ______  / day                         
6. _____________________; Dose  ___________;  Frequency  ______  / day 
7. _____________________; Dose  ___________;  Frequency  ______  / day 
8. _____________________; Dose  ___________;  Frequency  ______  / day                        
Does this child require specific or 
additional tests or examination? 
O No     
O Yes. Please specify with the results: 
4. ___________________________________________________________ 
___________________________________________________________ 
5. ___________________________________________________________ 
___________________________________________________________ 
6. ___________________________________________________________ 
___________________________________________________________ 
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Does this child require specific 
or additional treatment or 
medication 
O No     
O Yes. Please specify the treatment: 
9. _____________________; Dose  ___________;  Frequency  ______  / day                         
10. _____________________; Dose  ___________;  Frequency  ______  / day 
11. _____________________; Dose  ___________;  Frequency  ______  / day 
12. _____________________; Dose  ___________;  Frequency  ______  / day    
Does this child require a 
hospitalisation? 
O No     
O Yes. Please explain your reasons to hospitalise this child and the treatment   
      will be given 
      Reason: _________________________________________________________ 
                       _________________________________________________________ 
    The treatment:  
9. _____________________; Dose  ___________;  Frequency  ______  / day                         
10. _____________________; Dose  ___________;  Frequency  ______  / day 
11. _____________________; Dose  ___________;  Frequency  ______  / day 
12. _____________________; Dose  ___________;  Frequency  ______  / day    
15   Tympanometry examination (for Audiologist and interpreted by Physician) 
  O Cannot be performed. Reason: ___________________________________________________________________ 
  Tympanogram types (will be completed by physician)          [R]  Type  ______ / [L]  Type  ______       
  Ear canal vol (ECV)                  [R]  ________  mL   / [L]  ________  mL           
  Static acoustic admittance   [R] _______  mL      / [L] _______ mL             
  Compliance (SC)                      [R]  ________  mL   / [L]  ________  mL          
  Middle Ear Pressure or TPP  [R] _______  daPa  / [L] ______ daPa 
  Gradient or TW                         [R] _______  daPa  / [L] ______ daPa 
Put the copy of tympanometry copies here 
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Additional Visit : |___|___| – |___|___| – 20 |___|___| 
Complications (for Physician)              
1 Does your child experience discharge from the ear(s)?                                                                             O Yes   O No 
2 Does your child experience intense ear pain and pain behind the ear?                                O Yes   O No 
3 Does your child experience swelling/bulging/ or redness/tenderness of the ear(s)?               O Yes   O No                                                                                        
4 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?                  O Yes   O No                                                                                                       
General and ENT examination (for Nurse and Physician) 
5.1 Weight _____  kg 5.2  Height _______ cm 5.3  Temp. ________ °C 5.4 BP   _____ / _____ mmHg 
6 Nose        O Normal      O Oedema       O Hyperaemic      O Livid         O Serous discharge      O Mucoid discharge 
7 Tonsils    O Normal      O Hyperaemic   O Detritus           O Tonsil(s) T1   O Tonsil(s) T2           O Tonsil(s) T3-4                       
8 Pharynx  O Normal      O Hyperaemic   O Oedema         O Granules        O Post nasal drip (PND)        
9 Otoscopic examination 
   O Normal                 O Cerumen        O Erythema        O Air fluid level        O Complete effusion        O Opacification                  
  O Mild bulging       O Moderate to severe bulging (bulging rounded)       O Bulla                                   O Perforation 
10  Medicines prescribed by you (Physician) on today visit (please circle your dose measurement)                                                                                                                                                                           
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
1. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
2. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
3. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
4. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
5. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
11  Medicines NOT prescribed by you or from over-the-counter or others (e.g. other physician, drug store) 
Antibiotic  
Dose    :  _______mg / BW kg          Frequency   :    _______ / day for  _______ days 
Other medicine(s) 
1. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
2. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
3. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
4. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
5. _______________________   Dose    :  _____mg perBw kg / Teaspoon / Tablespoon ;  Frequency   :    ____ / day 
Outcome: Symptoms (for Patients) 
12 Please place a vertical line across the available horizontal line that best describes your or your child’s pain 
during the past 24 hours? 
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13  We are interest finding out how your child has been doing. For each question, please place a checkmark (V) in 
the circle corresponding to your child’s symptoms. Please answer all questions. 
13.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s)   
         more than usual? 
O No     O A little     O A lot  
13.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot       
13.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot     
13.4  Over the past 12 h, has your child been having more difficulty sleeping than   
          usual? 
O No     O A little     O A lot         
13.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot      
13.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
13.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot      
14 Side effects    
 14.1  Increased appetite O Yes     O No   14.8   Drowsiness  O Yes     O No   
 14.2  Increased urine amount O Yes     O No   14.9   Anxiety/distractibility/mood swing O Yes     O No   
 14.3  Weight gain O Yes     O No   14.10  Headache O Yes     O No   
 14.4   Gastritis/abdominal pain O Yes     O No   14.11  Skin rash or diaper rash O Yes     O No   
 14.5   Nausea O Yes     O No   14.12  Candidiasis O Yes     O No   
 14.6   Vomiting O Yes     O No   14.13  Dry mouth / throat irritation O Yes     O No   
 14.7   Diarrhea O Yes     O No   14.14  Sleep disturbance O Yes     O No   
 Others: ______________________________________________________________________________________ 
Did you bring your child to doctor 
(clinic or outpatient)?  
O Yes     O No     Reason: _______________________________ 
_______________________________ Medicine 
prescribed: 
Has your child has been admitted 
to hospital? 
O Yes     O No          Reason: _______________________________ 
Medicine 
prescribed: 
_______________________________ 
Regarding the side effects, your 
action is/are (you may answer 
more than one): 
O Discontinuation of the study drug (prednisolone)     
O Continuation of the study drug 
O Discontinuation of other concomitant drugs as follows: 
1. _____________________                        3.     _____________________ 
2. _____________________                        4.    _____________________ 
The treatment you prescribed 
for the management of side 
effects 
9. _____________________; Dose  ___________;  Frequency  ______  / day                         
10. _____________________; Dose  ___________;  Frequency  ______  / day 
11. _____________________; Dose  ___________;  Frequency  ______  / day 
12. _____________________; Dose  ___________;  Frequency  ______  / day                        
Does this child require specific or 
additional tests or examination? 
O No     
O Yes. Please specify with the results: 
7. ___________________________________________________________ 
___________________________________________________________ 
8. ___________________________________________________________ 
___________________________________________________________ 
9. ___________________________________________________________ 
___________________________________________________________ 
Does this child require specific O No     
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or additional treatment or 
medication 
O Yes. Please specify the treatment: 
13. _____________________; Dose  ___________;  Frequency  ______  / day                         
14. _____________________; Dose  ___________;  Frequency  ______  / day 
15. _____________________; Dose  ___________;  Frequency  ______  / day 
16. _____________________; Dose  ___________;  Frequency  ______  / day    
Does this child require a 
hospitalisation? 
O No     
O Yes. Please explain your reasons to hospitalise this child and the treatment   
      will be given 
      Reason: _________________________________________________________ 
                       _________________________________________________________ 
    The treatment:  
13. _____________________; Dose  ___________;  Frequency  ______  / day                         
14. _____________________; Dose  ___________;  Frequency  ______  / day 
15. _____________________; Dose  ___________;  Frequency  ______  / day 
16. _____________________; Dose  ___________;  Frequency  ______  / day    
15   Tympanometry examination (for Audiologist and interpreted by Physician) 
  O Cannot be performed. Reason: ___________________________________________________________________ 
  Tympanogram types (will be completed by physician)          [R]  Type  ______ / [L]  Type  ______       
  Ear canal vol (ECV)                  [R]  ________  mL   / [L]  ________  mL           
  Static acoustic admittance   [R] _______  mL      / [L] _______ mL             
  Compliance (SC)                      [R]  ________  mL   / [L]  ________  mL          
  Middle Ear Pressure or TPP  [R] _______  daPa  / [L] ______ daPa 
  Gradient or TW                         [R] _______  daPa  / [L] ______ daPa 
Put the copy of tympanometry copies here 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pilot pragmatic, randomised, open-label, single-blind, controlled study (OPAL Study) 
Prescription of OPAL study medication. Version 1.0. Date 5 September 2017 
 
Date ________________________ 
CRF07. Prescription for OPAL study medication 
 
 
 
 
 
Registration ID   :  
Name    : ___________________________ 
Age    : _________________ months / year(s) [write and circle your answer]   
Study medication dose : _________  mg per day =  _________  tablets per day 
 
 
 
R/ OPAL study medication tablet    ……..  
     Sach lact          add 
     m.f. pulveres dtd     No. V 
     ∫ 1 dd 1 pc (before 9 am) 
 
 
 
 
 
  
(sign here) 
Prednisolone doses: 
• Aged 6 months to < 2 years old    = 10 mg per day 
• Aged 2 years to < 6 years old         = 20 mg per day 
• Aged 6 years to 12 years old           = 30 mg per day 
 
                                                                                                                    REGISTRATION ID 
For each question, please tick () the circle corresponding to your answers or write you answer 
Randomisation Form. Version 1.1. Date 17 October 2017 
Page 1 of 1 
 
Nurse ID : |___|___|___|  Site ID : |___|___|___|    Date : |___|___| – |___|___| – 201 |___|   
CR08 – RANDOMISATION FORM 
Eligibility criteria (cross-check with ‘FORM01. study registration log book’, and ‘CRF03. Eligibility form’ 
in the ‘Case Report Form Binder’ of this subject).  
All YES for all inclusion criteria  O  Yes O  No 
All NO for all exclusion criteria O  Yes O  No 
Consent to the study questions (cross-check with ‘CRF01. Informed consent’ in the ‘Case Report Form 
Binder’ of this subject).  
Has consent given? O  Yes O  No 
RANDOMISATION 
Father’s mobile phone number  
Mother’s mobile phone number  
Severity of AOM O  Mild AOM O  Severe AOM 
Subject’s date of birth Date  Month  Year  AGE  Month/year 
RANDOMISATION RESULT 
Randomisation ID  
This subject is allocated to O Prednisolone group O Control group (no prednisolone) 
Prednisolone dosage (if the subject 
is allocated to prednisolone group) 
O 10 mg/day O 20 mg/day O 30 mg/day 
Nurse’s signature  
 
Nurse’s name  
 
 
Date  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Follow-up Visit Card 
Name                    :  ___________________________ 
Address  :  ___________________________ 
      ___________________________ 
Dad/Mom’s phone no : ______________________ 
Clinical Epidemiology and Evidence-Based Medicine (CEEBM) Unit 
Dr Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia  
Centre for Research in Evidence-Based Practice 
Faculty of Health Sciences and Medicine, Bond University, Australia 
  
 Initial visit 
date 
Scheduled 
visit dates 
Actual visit 
dates 
Notes 
Initial visit  
(Day–0) 
 
 
 
 
 
 
 
 
Visit – 1   
(Day – 3) 
  
 
 
 
 
 
Visit – 2   
(Day – 7) 
 
 
 
 
 
 
Visit – 3   
(Month – 1) 
 
 
 
 
 
 
Visit – 4  
(Month – 4) 
 
 
 
 
 
 
Follow-up Visit Schedule 
Please always bring this card to every 
your follow-up visit to the Hospital 
 Phone numbers of Hospitals 
and Call-centre OPAL Study 
Dr. Cipto Mangunkusumo Hospital 
Jl. Diponegoro No.71, Central Jakarta 
Operator : 1500135 
Persahabatan Hospital 
Jl. Persahabatan Raya No.1, East Jakarta 
Operator : 021 489 1708 Ext. 285 
ENT Clinic : Ext. 230 
Paediatric Clinic : Ext. 283 
Emergency Instalation : Ext. 499 
Gatot Soebroto Army Hospital 
Jl. Dr Abdul Rahman Saleh No.24, Senen, Central Jakarta  
Operator : 021 344 1008, 021 384 0702 
ENT Clinic : Ext. 2057 
Paediatric Clinic : Ext. 2535 
Emergency Instalation : Ext. 2121 
Jakarta Islamic Hospital Cempaka Putih 
Jl. Cempaka Putih Tengah I No. 1, Central Jakarta 
Operator : 021 425 0451, 021 428 01567 Ext. 0 
Outpatient Registration : Ext. 2 
Emergency Instalation : Ext. 1  
Proklamasi ENT Hospital 
Jl. Proklamasi No.43, Central Jakarta 
Operator : 021 390 0002, 021 392 4891 Ext. 0, 101, 227, 229 
ENT Clinic : Ext. 100, 236 244 
Emergency Instalation : Ext. 235 
Antam Medika Hospital Pulogadung 
Jl. Raya Pemuda No. 1A, Pulogadung, East Jakarta 
Operator : 021 806 14 888 
ENT Clinic : Ext. 1027 
Paediatric Clinic : Ext. 1019 
Emergency Instalation : Ext. 1045 
24-Call Centre OPAL Study 
Dr. Respati W. Ranakusuma, Sp.THT-KL : 08111 012 185 
                                                                                                                  REGISTRATION ID                                                                                                                 
Serious adverse events reporting form. Version.1.0. Date 22 August 2017 
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SUBJECT INFORMATION 
Weight (kg)  |____|____| , |____|____| kg 
List any relevant tests, 
laboratory data, history, 
including pre-existing 
medical conditions 
  
  
 
 
Any concomitant 
medication  
  
  
ADVERSE EVENT 
Report type          Initial report         Follow-up         Final 
Reason for reporting          Requires or prolongs hospitalization  
         Permanently disabling or incapacitating 
        Overdose 
        Other (please specify) 
      Congenital anomaly  
      Life threatening 
      Death 
      Date of death 
      Cause of death 
SUSPECTED DRUG 
Name of suspected drug  Generic name  
Dose details  Name of manufacturer  
Date of occurrence |____|____| - |____|____| - |____|____|____|____| (date – month – year) 
Duration of event |____|____| month(s)  |____|____| day(s) 
Starting date of 
medication 
|____|____| - |____|____| - |____|____|____|____| (date – month – year) 
Route of administration   Indication  
Discontinuation of drug 
because of event 
         No          Yes Dated (date / month / year) :  
 
If stopped/lowered dose, did the event resolve after this?          Yes          No          N/A 
If reintroduced did the event reappear?           Yes          No          N/A 
Outcomes         Recovered 
        Change in SAE 
        Recovered with sequelae 
        Patient died 
        Continuing 
        Unknown 
Severity         Mild         Moderate         Severe 
Action taken with study 
drug 
        None 
        Dose temporarily reduced       
        Dose reduced 
        Discontinued temporarily  
        Discontinued 
Other action*         None         Treated with medication         Other 
CRF10. SERIOUS ADVERSE EVENTS REPORTING FORM 
                                                                                                                  REGISTRATION ID                                                                                                                 
Serious adverse events reporting form. Version.1.0. Date 22 August 2017 
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Withdrawn from the trial 
due to SAE 
        No         Yes  
REPORTER INFORMATION 
Signature of reporter  
 
Date of signing |____|____| - |____|____| - |____|____|____|____| (date – month – year) 
Full name  
                                                                                          Registration ID 
 
For each question, please tick () your answer in the box or write you answer on ___ 
Feedback form. Version.1.1. Date 23 Augusts 2017 
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CRF11 – FEEDBACK FORM (for Physician only) 
 
 Questions Please place a checkmark (√) inthe box corresponding to  
your answer 
In
fo
rm
at
io
n
 S
h
e
e
t 
an
d
  
C
o
n
se
n
t 
Fo
rm
 
How do you rate the process 
of providing patient 
information and informed 
consent to your patient? 
 
 
Very easy 
 
 
Easy  
 
 
Neutral 
 
 
Difficult 
 
 
Very difficult 
If your answer ‘difficult’ or 
‘very difficult’, please place a 
checkmark (V) in the box 
corresponding to or write 
you reason(s). You may 
choose more than one 
         It was too difficult to explain this to my patient/parent 
         Time consuming 
         There was too much information to explain          
         I was not sure that my patient understood 
         Others  :  ____________________________________________ 
          ____________________________________________________ 
         ____________________________________________________ 
O
to
so
co
p
ic
 E
x
am
in
at
io
n
 
How do rate the process of 
conducting an otoscopic 
examination to your 
patient? 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very difficult 
If your answer ‘difficult’ or 
‘very difficult’, please place a 
checkmark (V) in the box 
corresponding to or write 
you reason(s). You may 
choose more than one 
         Patient was not cooperative 
         The ear canal was too narrow 
         Insufficient tool (e.g. the otoscope cylidner was too large)    
         Ear wax and it was too difficult to extract 
         The symptoms are definitely celar showing AOM 
         Others :  _____________________________________________ 
          ____________________________________________________ 
         ____________________________________________________ 
V
is
u
al
 A
n
al
o
g
u
e
 S
ca
le
 (
V
A
S
) 
How do you rate the process 
of providing related 
information and assisting 
your patient/parent to 
complete the visual 
analogue scale (VAS)? 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very difficult 
If your answer ‘difficult’ or 
‘very difficult’, please place a 
checkmark (V) in the box 
corresponding to or write 
you reason(s). You may 
choose more than one 
         It was too difficult to explain this to my patient/parent 
         Time consuming 
         I was not sure that my patient/parent understood 
         My patient/parent seem not confidence with the answer 
         Others  :  ____________________________________________ 
         ____________________________________________________ 
         ____________________________________________________ 
A
cu
te
 O
ti
ti
s 
M
e
d
ia
 –
 
S
e
ve
ri
ty
 o
f 
S
ym
p
to
m
 
S
ca
le
 
How do you rate the process 
of providing related 
information and assisting 
your patient/parent to 
complete the acute otitis 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very difficult 
                                                                                          Registration ID 
 
For each question, please tick () your answer in the box or write you answer on ___ 
Feedback form. Version.1.1. Date 23 Augusts 2017 
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media – severity of 
symptom scale (AOM–SOS)? 
If your answer ‘difficult’ or 
‘very difficult’, please place a 
checkmark (V) in the box 
corresponding to or write 
you reason(s). You may 
choose more than one  
         It was too difficult to explain this to my patient/parent 
         Time consuming 
         I was not sure that my patient/parent understood 
         There were several questions that difficult to explain or not   
         suitable for my patient/parent: question no. ___ ; ___ ; ___ ;  
         Others :  ____________________________________________ 
         ____________________________________________________ 
         ____________________________________________________ 
S
ym
p
to
m
 D
ia
ry
 
How do you rate the process 
of providing related 
information and assisting 
your patient/parent to 
complete the Patient/parent 
Diary?  
 
 
Very easy 
 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very difficult 
If your answer ‘difficult’ or 
‘very difficult’, please place a 
checkmark (V) in the box 
corresponding to or write 
you reason(s). You may 
choose more than one 
         It was too difficult to explain this to my patient/parent 
         Time consuming 
         I was not sure that my patient/parent understood 
         The sequence of the questions was too confusing   
         Questions in the symptom diary are too many 
         Others :   ____________________________________________ 
         ____________________________________________________ 
         ____________________________________________________ 
C
as
e
 R
e
p
o
rt
 F
o
rm
s 
How do you rate the process 
in completing the case 
report forms (CRFs)? 
 
 
Very easy 
 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very difficult 
If your answer ‘difficult’ or 
‘very difficult’, please place a 
checkmark (V) in the box 
corresponding to or write 
you reason(s). You may 
choose more than one  
         Time consuming 
         Too much unnecessary information was required 
         The sequence of the questions was too confusing 
         Several questions in the CRF were difficult to understand 
        Others   :  ____________________________________________ 
         ____________________________________________________ 
         ____________________________________________________ 
S
cr
e
e
n
in
g
 a
n
d
 S
tr
at
if
ic
at
io
n
 
P
ro
ce
ss
 
How do you rate the 
recruitment process, 
particularly in classifying the 
children based on their 
eligibility and stratification 
process to mild or severe 
AOM groups? 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very difficult 
If your answer ‘difficult’ or 
‘very difficult’, please place a 
checkmark (V) in the box 
corresponding to or write 
         The CRF03. Eligibility form is too complicated 
         The form was not helping me to screen and stratify my  
      patient/ parent               
         Despite I was guided by the form, I was still found the   
         process was still confusing, particularly in terms of deciding  
  
  
  
  
                                                                                          Registration ID 
 
For each question, please tick () your answer in the box or write you answer on ___ 
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you reason(s). You may 
choose more than one  
         which group my patient/parent should go to (i.e. mild vs  
         severe acute otitis media) 
         Others  :  ____________________________________________ 
         ____________________________________________________ 
         ____________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                          Registration ID 
 
For each question, please tick () your answer in the box or write you answer on ___ 
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FEEDBACK FORM (for Nurses who conducts randomisation only) 
 
 Questions  Please place a checkmark (√) inthe box corresponding to  
your answer 
R
an
d
o
m
is
at
io
n
 P
ro
ce
ss
 
How do you rate the 
randomisation process, in terms 
of obtaining the study ID and 
the allocation of the 
intervention (prednisolone 
group or control group)  
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very 
difficult 
If your answer ‘difficult’ or ‘very 
difficult’, please place a 
checkmark (V) in the box 
corresponding to or write you 
reason(s). You may choose 
more than one. 
         The CRF08. Randomisation form is too complicated 
         The randomisation process was too confusing  
         It was difficult to access the randomisation centre (randomi- 
         sation website or by phone) to obtain the study ID and the  
         allocation of the intervention  
         It was difficult to explain to the patients that they were     
         allocated to groups which reveice prednisolone or not 
         Others   ____________________________________________ 
         ___________________________________________________ 
         ___________________________________________________ 
D
is
p
e
n
si
n
g
 t
h
e
 S
tu
d
y 
M
e
d
ic
at
io
n
 
P
re
sc
ri
p
ti
o
n
 
How do rate the process of 
dispensing the study 
medication prescription and 
keep the intervention allocation 
concealed from their Physician 
and Audiologists? 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very 
difficult 
If your answer ‘difficult’ or ‘very 
difficult’, please place a 
checkmark (V) in the box 
corresponding to or write you 
reason(s). You may choose 
more than one  
         This process was too time consuming  
         I encountered difficulties when I was providing relevant   
         information on the intervention they received  
         It was difficult to ask my patients/parents to keep the  
         information of intervention allocation confidential 
         Others:  ____________________________________________ 
         ___________________________________________________ 
         ___________________________________________________ 
T
h
e
 c
o
m
p
il
at
io
n
 a
n
d
 t
h
e
 
S
to
ra
g
e
 o
f 
C
as
e
 r
e
p
o
rt
 F
o
rm
s 
How do rate the process of the 
compilation and the storage of 
study documents and binders? 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very 
difficult 
If your answer ‘difficult’ or ‘very 
difficult’, please place a 
checkmark (V) in the box 
corresponding to or write you 
reason(s). You may choose 
more than one  
 
         This process was too confusing 
         This process was too time consuming 
         It was difficult to find case report forms in the binder  
         The checklist of case report forms was not helping 
         Others:  ____________________________________________ 
         ___________________________________________________ 
         ___________________________________________________ 
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For each question, please tick () your answer in the box or write you answer on ___ 
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FEEDBACK FORM (for Audiologist/Trained Staff only) 
 
 Questions Please place a checkmark (√) inthe box corresponding to  
your answer 
T
ym
p
an
o
m
tr
y 
E
x
am
in
at
io
n
 a
n
d
 t
h
e
 C
o
m
p
e
ti
o
n
 o
f 
T
ym
p
an
o
m
e
tr
y 
S
e
ct
io
n
 in
 t
h
e
 C
as
e
 r
e
p
o
rt
 F
o
rm
 
How do you rate the process of 
tympanometry examination 
and completing the 
tympanometry section in CRF? 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very 
difficult 
If your answer ‘difficult’ or ‘very 
difficult’, please place a 
checkmark (V) in the box 
corresponding to or write you 
reason(s). You may choose 
more than one. 
         The patients’ parents seem did not understand teh reason this   
         examination being performed 
         It was difficult to conduct this examination to my patients  
         The ‘Tympanometry section’ in CRF05. Outcome form is  
         confusing. The provided examination components are   
         unfamiliar or different  
         It was difficult to find the ‘Tympanometry section’ in the  
         CRF05. Outcome form  
         It was difficult to print out the copy of tympanometry result 
         There were few components of this examination not provided  
         in the form 
         Others:  ____________________________________________ 
         ___________________________________________________ 
         ___________________________________________________ 
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For each question, please tick () your answer in the box or write you answer on ___ 
Feedback form. Version.1.1. Date 23 Augusts 2017 
Page 6 of 8 
 
 
FEEDBACK FORM (for Pharmacists only) 
 
 Questions Please place a checkmark (√) inthe box corresponding to  
your answer 
P
re
p
ar
at
io
n
 a
n
d
 D
is
p
e
n
si
n
g
 t
e
h
 
S
tu
d
y 
M
e
d
ic
at
io
n
 
How do rate the preparation 
and dispensing process of the 
study medication? 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very 
difficult 
If your answer ‘difficult’ or ‘very 
difficult’, please place a 
checkmark (V) in the box 
corresponding to or write you 
reason(s). You may choose more 
than one. 
         The instruction in CRF07. Prescription was confusing 
         The preparation of the study medication was too time-  
         consuming  
         I encountered difficulties when providing the information  
         about the study medication to my patients  
         Others:  ____________________________________________ 
         ___________________________________________________ 
         ___________________________________________________ 
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For each question, please tick () your answer in the box or write you answer on ___ 
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FEEDBACK FORM (for Parents only) 
 
Questions Please place a checkmark (√) inthe box corresponding to  
your answer 
How do you rate the process in completing the pain scale below? 
 
 
 
 
 
 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very 
difficult 
If your answer ‘difficult’ or ‘very difficult’, please 
place a checkmark (V) in the box corresponding 
to or write you reason(s). You may choose more 
than one. 
         I did not understand how to complte this scale  
          I need more information from my doctor   
          The provided instruction in the form was unclear 
 My doctor could not provide additional    
 information that I need  
         Others :  ______________________________________ 
         ______________________________________________ 
         ______________________________________________ 
How do you rate the process in completing the AOM-relevant symptom questionnaire below? 
 
 
  
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very 
difficult 
Apabila jawaban Anda ‘Difficult’ atau ‘Very 
difficult’, mohon berikan tanda centang di kotak 
yang sesuai atau berikan alasan Anda. Anda 
dipersilahkan untuk memilih lebih dari satu 
jawaban. 
          It was difficult to understand the question(s)  
          The options of answers were confusing  
          The provided instruction in the form was unclear  
          The question(s) was not suitable for my child,  
          therefore I did not know how to answer the  
          question(s): question no ____ ; ____ : ____ 
         I do not know how to complete the questionnaire  
  
  
                                                                                          Registration ID 
 
For each question, please tick () your answer in the box or write you answer on ___ 
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         Others :  ______________________________________  
         ______________________________________________ 
         ______________________________________________ 
How do you rate the process in completing 
the overall symptom diary? 
 
 
Very easy 
 
 
Easy 
 
 
Neutral 
 
 
Difficult 
 
 
Very 
difficult 
If your answer ‘difficult’ or ‘very difficult’, please 
place a checkmark (V) in the box corresponding 
to or write you reason(s). You may choose more 
than one. 
          I did not understand how to complete this diary   
          I need more information from my doctor in how to  
          complete this diary 
         Instuctions provided in the diary are unclear  
         Time consuming   
          Too many questions that I did not think they were  
          relevant with my child’s condition     
          The sequence of the questions was too confusing  
         Others :  _____________________________________ 
         _____________________________________________ 
         _____________________________________________ 
  
 
 
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine (CEEBM) Unit Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral prednisolone for acute otitis media in children: a pilot, pragmatic, randomised, open-label, single-blind study (OPAL Study) 
 
 
Study medication stock form. Version 1.1. Date 17 October 2017 
Page 1 of 1 
 
                         Pharmacist ID  : |___|___|___|___|                                                 Hospital ID   : |___|___|___|  
   
FORM02 – STUDY MEDICATION STOCK FORM 
Date received No. of 
tablets 
Batch 
number 
Name who 
received the 
medication 
Signature Date checked No. of 
tablets 
Batch 
number 
Name who 
checked the 
medication 
Signature Notes 
           
           
           
           
           
           
           
           
           
           
           
           
           
           
           
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine (CEEBM) Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral prednisolone for acute otitis media in children: a pilot pragmatic, randomised, open-label, single-blind, controlled study (OPAL Study) 
 
 
Study medication dispensing form.  Version.1.2. Date 14 November 2017 
 
      Pharmacy ID            : |___|___|___|___|    Hospital ID   : |___|___|___|
  
  
 
FORM03 – STUDY MEDICATION DISPENSING FORM (FOR PHARMACY) 
Randomisation/ 
Registration ID 
Date dispensed Dose (mg/day) Number of 
doses (day) 
Initial dose (5 days) 
or additional dose 
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine (CEEBM) Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral prednisolone for acute otitis media in children: a pilot pragmatic, randomised, open-label, single-blind, controlled study (OPAL Study) 
 
 
 
 
Study medication return form. Versioni.1.2. Date 14 November 2017 
 
      Nurse ID           : |___|___|___|___|       Hospital ID   : |___|___|___|  
 
FORM04 – STUDY MEDICATION RETUN FORM (FOR NURSE) 
Randomisation/ 
Registration ID 
Date returned Number of  
left-over drug  
Reason for return 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine (CEEBM) Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
 Prednisolone for acute otitis media in children: a pilot pragmatic, randomised, open-label, single-blind study (OPAL Study) 
Completed case report form. Version.1.0. Date 30 August 2017 
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FORM05 – COMPLETED CASE REPORT FORM (FOR NURSE WHO PERFORM A RANDOMISATION) 
Nurse ID : 
 
Protocol title:  Oral prednisolone for acute otitis media in children:  a pilot 
pragmatic, randomised, open-label single-blind study (OPAL study) 
Hospital ID : 
No Randomisation ID  Date enrolled to 
the study 
Date of Visit-1* 
(Day-3)  
 
Date of Visit-2* 
(Day-7) 
 
Date of Visit-3*  
(Day-30) 
Date of Visit-4*  
(Day-90) 
Date of 
completion of 
the study 
*Please write the checkmark (V) if the study participant come to each visit 
        
        
        
        
        
        
        
        
        
        
        
        
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine (CEEBM) Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
 Prednisolone for acute otitis media in children: a pilot pragmatic, randomised, open-label, single-blind study (OPAL Study) 
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FORM06 -  RECAPITULATION OF NON-PARTICIPATING SUBJECT FORM (FOR NURSE WHO PERFORM A RANDOMISATION) 
Nurse ID : 
 
Protocol title:  Oral prednisolone for acute otitis media in children:  a pilot pragmatic, 
randomised, open-label single-blind study (OPAL study) 
Hospital ID : 
No Registration ID Date subject 
offered into the 
study 
Date subject not 
participate in the 
study 
Reasons 
Please write the checkmark (V) if the study participant come to each visit 
Not eligible Refuse to 
participate in 
the study 
Others 
       
       
       
       
       
       
       
       
       
       
       
       
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pilot pragmati, randomised, open-label, single-blind, controlled study (OPAL Study) 
Guideline of antibiotics for acute otitis media. Version.1.0. Date 31 August 2017 
FORM07. GUIDELINE OF ANTIBIOTICS FOR ACUTE OTITIS MEDIA 
 
 
Initial immediate or delayed antibiotic therapy Antibiotics after 48-72 hours of failure of initial antibiotic therapy 
Recommended first-line 
treatment 
Alternative treatment (if 
penicillin allergy) 
Recommended first-line 
treatment 
Alternative treatment 
Amoxicillin (80-90 mg/kg per day 
in 2 divided doses) 
 
OR 
 
Amoxicillin-clavulanatea (90 
mg/kg per day of amoxicillin, with 
6.4 mg/kg per day clavulanate 
(amoxicillin to clavulanate ration, 
14:1) in 2 divided doses) 
Cefdinir (14 mg/kg per day in 1 or 2 
doses) 
 
Cefuroxime (30 mg/kg per day in 2 
divided doses) 
 
Cefpodoxime (10 mg/kg per day in 
2 divided doses) 
 
Ceftriaxone (50 mg IM or IV per 
day for 1 or 3 days) 
Amoxicillin-clavulanatea (90 
mg/kg per day of amoxicillin, 
with 6.4 mg/kg per day in 2 
divided doses) 
 
OR 
 
Ceftriaxone (50 mg IM or IV per 
day for 3 days) 
Ceftriaxone, 3 days Clindamycin 
(30-40 mg/kg per day in 3 divided 
doses), with or without third-
generation cephalosporin (50 mg 
IM or IV per day for 3 days) 
Failure of second antibiotic 
Clindamycin (30-40 mg/kg per day 
in 3 divided doses) plus third-
generation cephalosporin 
Tympanocentesisb 
Consult specialistb 
a 
may be considered in patients who have received amoxicillin in the previous 3 o days or who have the otitis conjunctivitis syndrome; 
 b Perform tympanocentesis/drainage if skilled in the procedure, or seek a consultation from an otolaryngologist for tympanocentesis/drainage if the 
tympanocentesis reveals multidrug/resistant bacteria, seek an infection disease specialist consultation. 
 
Reference: Lieberthal AS, Carroll AE, Chonmaitree T, et al. Clinical Practice Guideline: The diagnosis and management of acute otitis media. The American Academy of 
Pediatrics. Pediatrics. 2013;131:e964-e99 
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine Unit, Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral Prednisolone for acute otitis media in children: a pilot pragmatic, randomised, open-label, single-blind, controlled study (OPAL Study) 
 
Prednisolone dose for OPAL study. Version.1.0. Date 5 September 2017. 
FORM08 – PREDNISOLONE DOSE FOR OPAL STUDY 
 
 
 
 
 
 
 
Aged two years to up to six 
years old 
20 tablets  of Prednisolone  
for five days 
Dose :  20 mg / day 
(4 tablets per day) 
Aged six months to up to two 
years old 
10 tablets of Prednisolone  
for five days 
Dose : 10 mg / day   
(2 tablets per day) 
Aged six years to 12 years old 
30 tablets of Prednisolone 
for five days 
Dose : 30 mg / day  
(6 tablets per day) 
Lupred® 5 contains 5 mg prednisolone in each tablet 
ORAL PREDNISOLONE FOR ACUTE OTITIS MEDIA IN CHILDREN (OPAL STUDY) 
 
 
 
 
 
 
 
 
 
 
 
 
  
This leaflet has been written for parents and carers about 
how to use this medication in children. This information 
may differ from that provided by the pharmaceutical 
company, because their information is usually aimed at 
adult patients. Please read this leaflet carefully. 
We copied cited and copied the information on the leaflet from: 
Medicine for children – information for parents and carers: prednisolone for asthma. 
http://www.medicinesforchildren.org.uk/prednisolone-asthma 
  Instruction for using Prednisolone  
Name of drug 
Lupred tablet contains of prednisolone. 
When should I give prednisolone? 
Prednisolone is usually given once each day, usually in the 
morning. Give the medicine at about the same time each day 
so that this becomes part of your child’s daily routine, which 
will help you to remember.  
How much should I give?  
Your doctor will work out the amount (the dose) that is right 
for your child. It is important that you follow your doctor’s 
instructions about how much to give. 
How should I give it?  
The pharmacist will prepare the prednisolone tablets by 
crushing the tablets, mixing it with the sweetener, and 
packing them in a daily paper-pack for your child.  
You can mix it with a small amount of soft food such as 
yogurt, honey, or jam, or give a glass of milk or juice. Make 
sure your child swallows it straight away, without chewing. 
When should the medicine start working? 
Prednisolone usually takes 4–6 hours to have its full effect. 
What if my child is sick (vomits)?  
If your child is sick less than 30 minutes after having a dose of 
prednisolone, give them the same dose again. 
If your child is sick more than 30 minutes after having a dose 
of prednisolone, you do not need to give them another dose. 
Wait until the next normal dose. 
If your child is sick again, please contact us.  
What if I forget to give it?   
You can give your child the missed dose as soon as you 
remember on the same day. If you remember after they have 
gone to bed, do not give them the missed dose. Give the next 
dose in the morning as usual. Never give a double dose of 
prednisolone 
 
Are there any possible side-effects? 
We use medicines to make our children better, but sometimes 
they have other effects that we don’t want (side-effects). It is 
unlikely that your child will have side-effects if they only take 
prednisolone for a few days. They are more likely to get side-
effects if they are on a high dose, have extra doses or take 
prednisolone for a long time.  
Side effects that you must do something about 
• If your child has bad stomach pain or repeated 
vomiting (being sick), contact us straight away. This 
may be due to an ulcer or inflammation of the 
pancreas 
• If your child develops a rash or severe/unexplained 
bruising, contact us straight away, as there may be a 
problem with your child’s blood 
• If your child has eye pain or changes in their vision, 
contact us straight away 
What if I give too much? 
It can be dangerous to give too much prednisolone. If you 
think you may have given your child too much prednisolone, 
contact us immediately.  
 ORAL PREDNISOLONE FOR ACUTE OTITIS MEDIA IN CHILDREN (OPAL STUDY) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
WHO TO CONTACT FOR MORE INFORMATION 
OPAL STUDY 24-HOUR CALL CENTRE 
08111 012 185 
 
  Other side effects you need to know about 
• child may have stomach ache, feel sick or be sick 
(vomit) or may have indigestion (heartburn). Giving 
the medicine with some food may help 
• Your child may have an increased appetite and may 
gain weight while taking prednisolone. You can help 
by making sure your child has plenty of physical 
activity, and by offering fruit and vegetables and low-
calorie food, rather than food that is high in calories 
(e.g. cakes, biscuits, sweets) 
• Your child may have trouble sleeping and nightmares 
and may feel depressed, or their behaviour may 
change in other ways. Contact us for advice if you are 
concerned  
Side effects with high doses or long courses 
• Prednisolone can slow growth and affect puberty. It 
can also cause growth of body hair and irregular 
periods in girls 
• Your child may be more at risk of severe infections. 
They should stay away from anyone with an infection 
(such as chicken pox, shingles, measles) if they have 
not had these illnesses or have not been vaccinated 
for measles 
• If your child is unwell and you are worried about an 
infection, contact us straight away 
• Your child’s skin may become thinner, and heal more 
slowly than usual. Acne (spots) may become worse or 
your child may develop mouth ulcers or thrush 
(candidiasis). If you are concerned, contact us 
• Your child may develop problems with their hip 
bones or their bones may become weaker 
(osteoporosis). The muscles around the hips and 
shoulders may also become weaker. If your child has 
any difficulty walking or moving around, contact us 
• Occasionally, prednisolone causes diabetes. If your 
child seems more thirsty than normal, needs to pass 
urine (wee) often, or starts wetting the bed at night, 
contact us 
There may, sometimes, be other side-effects that are not 
listed. above. If you notice anything unusual and are 
concerned, please contact us. 
Can other medicines be given at the same time? 
You can give your child medicines that contain paracetamol or 
ibuprofen, unless your doctor has told you not to. Check with 
us or your doctor before giving any other medicines to your 
child. This includes herbal or complimentary medicines. 
Is there anything else I need to know about 
prednisolone?  
For children who have been taking prednisolone in high doses 
or for longer than 2-3 weeks 
• They must not stop taking the medicine suddenly 
because they may get withdrawal symptoms: they 
will feel unwell, dizzy and thirsty and may be sick 
(vomit). If this occurs, you should contact us straight 
away 
• If your doctor decides to stop prednisolone, they will 
reduce the dose gradually before stopping it 
completely. Make sure you follow your doctor’s 
instructions 
• Make sure that you always have enough medicine.  
 
Where should I keep this medicine?  
• Keep the medicine in a cupboard, away from heat 
and direct sunlight. It does not need to be kept in the 
fridge 
• Make sure that children cannot see or reach it. 
• Keep the medicine in the container it came in 
 
 
 
dr. Respati W. Ranakusuma, SpTHT-KL 
Clinical Epidemiology & Evidence-Based Medicine (CEEBM) Unit Dr. Cipto Mangunkusumo Hospital – Faculty of Medicine Universitas Indonesia 
Oral prednisolone for acute otitis media in children: a pilot, pragmatic, randomised, open-label, single-blind study (OPAL Study) 
 
 
Please write ‘Y’ for ‘YES’ and ‘N’ for ‘NO’.  
Study recruitment log book. Versi 2.0. Date 4 September 2017 
Page 1 of 1 
 
 
Study 
registration 
ID 
Patient’s 
name 
 
Date 
screened 
Has your 
child 
experien-
cing ear 
pain in the 
past 48 
hours? 
(YES or 
NO) 
Has your 
child 
been 
tugging 
or 
rubbing 
her/his 
ear(s) 
and been 
more 
irritable 
or fussy 
or crying 
more 
than 
usual 
over the 
past 48 
hours 
(YES or 
NO) 
Has 
your 
child 
been 
experie
ncing 
ear 
discharg
e in the 
past 48 
hours? 
(YES or 
NO) 
Body 
weight 
(kg) 
Body 
height 
(cm) 
Body 
tempe-
rature 
(○C) 
Blood 
pressure 
(mmHg) 
Did 
patient 
go on the 
study? 
(YES or 
NO) 
If YES,  
what is the 
Randomisation 
ID 
 
If NO, please tell us reason not on the 
study below 
Not 
eligible 
(YES or 
NO) 
 
Did not 
give 
consent  
(YES or 
NO) 
Was not 
approached 
(YES or NO). 
Write the 
reason 
               
               
               
               
               
 
FORM01 – STUDY RECRUITMENT LOG BOOK 
Nurse name/ID : 
 
Study title :  
Oral prednisolone for acute otitis media in children:  a pilot, pragmatic, 
randomised, open-label, single-blind, controlled study (OPAL study) 
Hospital ID : 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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This book belongs to: 
 
____________________________ 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
Page 2 of 43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
http://tinyurl.com/thankswithflower
Hello Uncle / Aunty!! 
 
My name is_____________________ 
I was born in________________  
On date _____ month ________ year ___________ 
 
If you find this Diary, I would be very grateful if you can 
return it to my Dad (mobile no. _______________) or  
my Mom (mobile no. _______________).   
 
 
                                                        
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
Page 3 of 43 
 
Day-0 (your first visit) : |___|___| – |___|___| – 20 |___|___|                                
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
           
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
Medicines given (please write the name, dose, and frequency) 
Medicines have 
been given to your 
child before going 
to the hospital 
(from other 
doctor or chemist 
store) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Thank you for filling the diary today.  
Now please give your child the study medicine. 
 
Notes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Day – 1* : |___|___| – |___|___| – 20 |___|___|           
*On the morning after your first visit to the hospital or doctor 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No      7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________
________________________________ 
 Medicine prescribed: ________________________________
________________________________ 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
 
Thank you for filling the diary today.  
Now please give your child the study medicine. 
 
Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Day-2 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
           
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
Medicines given (please write the name, dose, and frequency) 
Medicines have 
been given to your 
child before going 
to the hospital 
(from other 
doctor or chemist 
store) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
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                         For each question, please tick () your answer on O or write you answer on ______ 
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 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
Medicines given (please write the name, dose, and frequency) 
Medicines have 
been given to your 
child before going 
to the hospital 
(from other 
doctor or chemist 
store) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
 
Thank you for filling the diary today.  
Now please give your child the study medicine. 
 
Notes:  
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Day – 3 (1st Follow-up Visit): |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
 
Thank you for filling the diary today.  
Now please give your child the study medicine. 
 
Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for completing the first Diary. 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Additional Visit : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
Page 12 of 43 
 
Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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http://tinyurl.com/thankswithflower
Hello Uncle / Aunty!! 
 
My name is_____________________ 
I was born in________________  
On date _____ month ________ year ___________ 
 
If you find this Diary, I would be very grateful if you can 
return it to my Dad (mobile no. _______________) or  
my Mom (mobile no. _______________).   
 
 
                                                        
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
Page 16 of 43 
 
Day-4 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
 
Thank you for filling the diary today.  
Now please give your child the study medicine. 
 
Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Day – 5 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
 
Thank you for filling the diary today.  
Now please give your child the study medicine. 
 
Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Day-6 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Day – 7 (2nd Follow-up Visit): |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for completing the first Diary. 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Additional Visit : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for completing the second Diary. 
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http://tinyurl.com/thankswithflower
Hello Uncle / Aunty!! 
 
My name is_____________________ 
I was born in________________  
On date _____ month ________ year ___________ 
 
If you find this Diary, I would be very grateful if you can 
return it to my Dad (mobile no. _______________) or  
my Mom (mobile no. _______________).   
 
 
                                                        
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Day – 8  : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
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Day – 9 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
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Day – 9 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
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Day – 11 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
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Day – 12 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
                                                                                               Registration ID 
                         For each question, please tick () your answer on O or write you answer on ______ 
                    Patient Symptom Diary. Version 1.1.0 Date 16 October 2017 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
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Day – 13 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
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Day – 14 : |___|___| – |___|___| – 20 |___|___| 
1. Please place a vertical line across the available horizontal line that best describes your or your child’s pain during the past  
      12 hours? Please write the time accordingly ……. (am/ pm) 
 
 
 
 
          
2.  We are interest finding out how your child has been doing. For each question, please place a check mark in O 
       corresponding to your child’s symptoms. Please answer all questions. Please write the time accordingly ……. (am/ pm) 
2.1  Over the past 12 h, has your child been tugging, rubbing, or holding the ear(s) more than   
       usual? 
O No     O A little     O A lot    
2.2  Over the past 12 h, has your child been crying more than usual? O No     O A little     O A lot    
2.3  Over the past 12 h, has your child been more irritable or fussy than usual? O No     O A little     O A lot    
2.4  Over the past 12 h, has your child been having more difficulty sleeping than usual? O No     O A little     O A lot    
2.5  Over the past 12 h, has your child been less playful or active than usual? O No     O A little     O A lot    
2.6  Over the past 12 h, has your child been eating less than usual? O No     O A little     O A lot    
2.7  Over the past 12 h, has your child been having fever or feeling warm to touch? O No     O A little     O A lot    
Other symptoms 
3 Does your child experience discharge from the ear(s)?  O Yes       O No 
4 Does your child experience intense ear pain and pain behind the ear?  O Yes       O No 
5 Does your child experience swelling/bulging, redness, tenderness, or dropping behind or of the 
ear(s)  
 O Yes       O No 
6 Does your child experience facial asymmetry (e.g. when the child smiles, cries)?  O Yes       O No 
7 Side effects   
 Does your child have these complaints after taking the medicine 
 7.1  Increased appetite O Yes       O No       7.8   Drowsiness O Yes       O No       
 7.2  Increased urine amount O Yes       O No       7.9   Anxiety/distractibility/mood swing O Yes       O No       
 7.3  Weight gain O Yes       O No       7.10  Headache O Yes       O No       
 7.4   Gastritis/abdominal pain O Yes       O No       7.11  Skin rash or diaper rash O Yes       O No       
 7.5   Nausea O Yes       O No       7.12  Candidiasis O Yes       O No       
 7.6   Vomiting O Yes       O No       7.13  Dry mouth / throat irritation O Yes       O No       
 7.7   Diarrhea O Yes       O No       7.14  Sleep disturbance O Yes       O No       
 Others _______________________________________________________________________ 
 Did you bring your child to 
doctor (clinic or outpatient)? 
O Yes       O No       
       
Reason: ________________________________
________________________________ 
Medicine prescribed: ________________________________
________________________________ 
 Has your child has been 
admitted to hospital?  
O Yes       O No          
       
Reason: ________________________________ 
Medicine prescribed: ________________________________
________________________________ 
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                         For each question, please tick () your answer on O or write you answer on ______ 
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Medicines given (please write the name, dose, and frequency) 
Additional 
medicine from the 
chemist store or 
other (not 
precribed by your 
doctor) 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
_________________________    Dose    :  _____ mg / body weight kg          Frequency   :    ______ / day 
Please list all medicines you give to your child today by marking the circle based on the frequency and the time 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
_______________________________ O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm O ____ am/pm 
Notes: 
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Lupred ® 5 
Prednisolone 5 mg 
TABLET 
 
COMPOSITION 
Each tablet contains: 
Prednisolone 5 mg 
 
PHARMACOLOGY 
Prednisolone is a systemic corticosteroid with glucocorticoid and anti-inflammatory potencies. The mechanism of 
action of corticosteroids is thought to be by control of protein synthesis. Corticosteroids react with receptor 
proteins in the cytoplasm of sensitive cells in many tissues to form a steroid-receptor complex. 
 
INDICATION 
Allergic reaction, inflammation and other diseases that require glucocorticoid treatment, such as rheumatoid 
arthritis, collagen diseases, and dermatology disorders. 
 
DOSAGE AND INSTRUCTION 
Adults: 1 – 4 tablets per day or according to the doctor’s instruction. 
The dosage reduces gradually until reach the lowest effective dose. 
 
PRECAUTION 
• Avoid the abrupt discontinuation in a long-term use  
• Use with caution in paediatric patients who are still in the growing process 
• Not recommended for pregnant and breast-feeding women 
• Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible 
damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi 
or viruses 
• Risk of secondary adrenocortical insufficiency could be reduced by gradual reduction of dosage 
• Use with caution in patients with diabetes mellitus because it can increase the gluconeogenesis and reduce 
the sensitivity to insulin 
• Use with caution in patients with hypothyroidism because it can enhance the effect of corticosteroids 
• Use with caution in patients with heart failure, infection diseases, chronic renal failure, and elderly 
 
ADVERSE EFFECTS 
• Water balance and electrolytes disturbance: Natrium retention, excretion of potassium, hypokalaemic 
alkalosis, hypertension, and congestive heart failure 
• Musculoskeletal: Muscle weakness, steroid-induced myopathy, osteoporosis, vertebral compression 
fractures and pathologic fractures of long bones 
• Gastrointestinal: Peptic ulceration with haemorrhage and perforation, pancreatitis, abdominal distension 
and ulcerative esophagitis 
• Dermatological: Impaired wound healing, thinning of the skin, facial plethora, increased sweating 
• Neurological:  seizures, intracranial hypertension with papilloedema (cerebral pseudotumour), vertigo, 
headache 
 I001404-PG-1043 
• Endocrine: Disorders of menstruation, suppression of growth in children, secondary adrenocorticoid and 
non-responsive pituitary (particularly in stress, trauma, surgery or illness), metabolic effects, primarily 
involving the carbohydrates 
• Ophthalmological: Posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and 
exophthalmos 
• Metabolic: Nitrogen depletion due to protein catabolism 
• Hypersensitivity: anaphylactic reaction 
 
CONTRAINDICATION 
• Patients who are known hypersensitivity to prednisone or prednisolone  
• Peptic ulceration, active tuberculosis, osteoporosis, neurological disorders, renal and heart disorders 
• Systemic fungal infections and ocular herpes simplex 
 
INTERACTION WITH OTHER MEDICINES 
• The use of aspirin and corticosteroid is not recommended in patients with non-specific ulcerative colitis 
• Rifampicin, phenytoin, phenobarbital can increase the metabolism of corticosteroids 
• Vaccination with live vaccine must be avoided 
 
OVERDOSAGE 
There is no specific antidot. Treatment is symptomatic with the dosage being reduced or the drug withdrawn. 
 
STORAGE CONDITION 
Store below 30°C.  
 
DOCTOR’s PRESCRIPTION IS A MUST 
 
Manufactured by: 
PT. PRATAPA NIRMALA 
Tangerang – Indonesia  
 
 
